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Influenza causes a large number of hospitalisations and deaths each year. This 
thesis is the first study to use modelling in a single country to estimate the health 
burden of influenza across demographic characteristics (age, sex, and ethnicity) 
and socioeconomic status; the proportion of influenza deaths occurring inside and 
outside hospital; the proportions with respiratory causes compared with 
cardiovascular disease and other medical illnesses; and to validate modelled 
estimates using observations of influenza incidence and distribution. 
 
Aims 
This thesis aims to 
1. Estimate the contribution of seasonal influenza to hospitalisations in New 
Zealand and its sociodemographic distribution. 
2. Estimate the contribution of seasonal influenza to mortality in New 
Zealand and its sociodemographic distribution.  
3. Validate modelled estimates of influenza incidence and distribution using 
observed influenza hospitalisation data. 
4. Investigate how and where influenza kills people by major health settings 





The main analyses used a total of over 200 quasi-Poisson and negative binomial 
regression models with weekly counts of hospitalisations, deaths or isolates of 
influenza A, B and respiratory syncytial virus. It focused on the period 1994-
2008, except for the validation Chapter, in which the study period was extended to 
2015 to match the observational data.  The virus’ contribution to hospitalisations 
and deaths coded as pneumonia and influenza (P&I), respiratory, circulatory, 
medical illness, and all causes were modelled. 
 
Results 
The contribution of influenza to total hospitalisations and mortality was about 9 
and 23 times, respectively, larger than indicated by routine coded data. 
Respiratory illness was the major contributor (77%) to hospitalisations attributed 
to influenza whereas circulatory illness made a negligible contribution. By 
contrast, influenza mortality included a large (37%) contribution from circulatory 
illness. 
 
The elderly (80 years of age and older) had the highest influenza-attributable 
hospitalisation rate (327.8 per 100,000) and mortality (214.0 per 100,000). Infants 
also had high rates of influenza hospitalisation (245.5 per 100,000). Influenza 





Direct measurement and modelling produced similar rates of influenza-associated 
respiratory hospitalisation across sex, ethnicity and deprivation. However, 
modelling found the highest rates of influenza hospitalisation in the elderly (538.2 
per 100,000 in those aged 80 years plus) whereas directly measured rates were 
highest in children 1 to 4 years of age (262.9 per 100,000). 
 
Overall 58.1% of influenza-associated deaths occurred in hospital. The majority 
of these influenza-associated deaths (66.4%) were associated with respiratory 
illness. By contrast, circulatory illness predominated in those dying in other places 
(57%). Using modelled mortality (numerator) and modelled hospitalisations 
(denominator) data, the case fatality risk (CFR) of influenza in hospital was 
12.0%. CFR varied markedly by age, ranging from 3.8% for those 20-64 years of 
age to 41.3% for those aged 80 years and above.  
 
Conclusions 
These results provide strong evidence for applying modelling techniques to 
estimate the health burden of influenza. The marked inequalities of influenza 
deaths and hospitalisations by sociodemographic characteristics, illness categories 
and health setting support prioritised interventions (notably vaccination) for these 
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Chapter One: Introduction 
 
1.1 Chapter goal 
This chapter summarises key definitions and perspectives on influenza and 
modelling techniques. It describes the health impacts of influenza both globally 
and in New Zealand. It then briefly outlines challenges in estimating the true 
burden of influenza and how these gaps are addressed by applying statistical 
modelling methods. This chapter includes a summary of the thesis structure. 
 
1.2 Terminology 
In this project, the terms “influenza-related”, “influenza-attributable” and 
“influenza-associated” refer to influenza cases (including deaths or 
hospitalisations) that are estimated from modelling techniques.  
 
The burden of influenza, described in detail in Chapter Two, is built up based on 
the disease pyramid with multiple tiers including deaths, intensive care unit (ICU) 
admissions, hospitalisations, medically attended illnesses, non-medically attended 
illnesses, and asymptomatic infections (Pelat et al., 2014). 
 
1.3 What is influenza? 
The World Health Organization (WHO) states that “Influenza is a viral infection 
that affects mainly the nose, throat, bronchi and, occasionally, lungs. Infection 
usually lasts for about a week, and is characterized by sudden onset of high fever, 
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aching muscles, headache and severe malaise, non-productive cough, sore throat 
and rhinitis”. The virus can be transmitted from an infected individual through 
airborne droplets, by direct contact with infected people, and through contact with 
surfaces and objects contaminated by infected people. Normally, people with 
influenza recover after 7 to 14 days without treatment. However, in some 
vulnerable groups such as the elderly, children or people with underlying illness, 
influenza can have severe and occasionally fatal consequences (WHO, 1999). 
 
The WHO has developed case definitions for influenza surveillance that are used 
worldwide. Influenza-like illness (ILI) is an acute respiratory illness with a history 
of fever or measured fever of ≥38°C, and cough, and onset within the last 10 days. 
Severe acute respiratory infections (SARI) are similar to ILI but require hospital 
admission (WHO, 2013). 
 
Influenza virus is categorised into three types: influenza A, influenza B, and 
influenza C, based on its nucleoprotein antigen structure (Baron, 1996). Influenza 
A and influenza B are responsible for annual epidemics of influenza. Influenza C 
is uncommon and leads to mild illness. Influenza A is considered the biggest 
concern to public health (WHO, 2016). This thesis focuses on influenza caused by 
influenza A and influenza B viruses only.  
 
Influenza A viruses are divided into subtypes based on their two surface proteins: 
haemagglutinin (H1-H18) and neuraminidase (N1-N11) (CDC, 2017a).  The 
current subtypes causing human disease are A (H1N1) and A (H3N2) viruses. 
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They can be further divided into different virus strains. Current influenza B 
viruses are classified into two lineages: B/Yamagata and B/Victoria (CDC, 
2017a).  Influenza A and influenza B  cause seasonal influenza, with the exact 
strains changing from year to year through antigenic drift (Global Security, 2011).  
Influenza virus hosts include domestic birds, wild birds, domestic pigs and 
humans. The natural hosts for influenza B viruses are restricted to humans 
(Nicholson, 2003).  Influenza A may occasionally undergo  antigenic shift which 
results in a change in influenza subtype or a major change in strain, often within 
animal and bird populations.  These new subtypes or strains can cause pandemic 
influenza if they become easily transmitted between people (CDC, 2017b). 
 
1.4 What is influenza burden? 
Globally, influenza causes a substantial burden of morbidity and mortality. The 
annual incidence rate of influenza worldwide is 5-10% in adults and 20-30% in 
children. Influenza kills approximately 250,000-500,000 people each year. It can 
lead to severe illness and a large number of hospitalisations (WHO, 2016).  
 
In the USA, influenza and pneumonia were ranked the 8
th
 leading cause of death 
in 2014. Influenza and pneumonia caused 55,221 deaths, which accounted for 
2.1% of total deaths in the US in that year (Heron, 2016). According to the 
Australian Lung Foundation, in 2002, there were 3,084 Australians who died from 
pneumonia and influenza. This number corresponded to 2.3% of total deaths in 
the country. Respiratory infections (including influenza) were the 6
th
 leading 
cause of death in Australia (The Australian Lung Foundation, 2007). Pneumonia 
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and influenza were amongst the four leading causes of deaths from respiratory 
illness in European children and the elderly (WHO, 2012).  
 
In the USA there were an estimated 334,000 to 1,973,000 years of life lost (YLL) 
from the 2009 influenza pandemic (Viboud et al., 2010). During the 2009 
influenza pandemic, the Netherlands lost 5,800 Disability Adjusted Life Years 
(DALY), equivalent to 35 DALY per 100,000 populations. It was estimated that 
influenza contributed to 0.13% of the total annual DALY lost in the Netherlands 
(Wielders et al., 2012). In Spain, for the seasons dominated by influenza A 
(H3N2), the YLL was calculated as 5,297 corresponding to an average of 1,348 
excess deaths from pneumonia and influenza. In seasons with influenza A (H1N1) 
or influenza B, the mean pneumonia and influenza associated deaths and YLL 
were 648 and 2,885, respectively, half of those seen in A (H3N2) dominant years 
(Simon Mendez et al., 2012). 
 
In New Zealand, influenza and acute respiratory illness are common in the 
population. 38.5% of acute infectious disease hospitalisations and 9.5% of all 
acute admissions over the 1989-2008 period were from respiratory illness 
(including influenza) (Baker et al., 2012). In 2014 there were 1966 consultations 
for influenza-like illness (ILI) which made a cumulative rate of ILI consultations 
of 660 per 100,000 patients. The incidence rate of ILI in the Auckland District 
Health Board (ADHB) and Counties Manukau District Health Board (CMDHB) 
(based on community based surveillance) was 465.6 per 100,000 patients. The 
hospital based surveillance reported a cumulative rate of influenza for this region 
of 39.0 per 100,000 patients. Infants under 1 year, Pacific peoples and those living 
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in the most deprived areas (New Zealand Deprivation 9&10) were the most 
vulnerable groups (ESR, 2014). The annual average influenza hospitalisation rate 
(per 100,000) during the period 1997-2006 in New Zealand was 10.4 (Huang et 
al., 2008). During the first wave of the 2009 influenza pandemic, 16 influenza 
deaths out of 3,000 cases were reported in the country (Baker et al., 2009).  
 
Influenza causes a huge economic burden. In Norway, the average costs for 
seasonal influenza in 2005 were approximately $253 million. These costs included 
tangible costs of $22 million (which accounted for 8.7% of the total economic 
burden) and intangible costs amounting to $231 million (91.3% of the total 
monetary impact which was mainly caused by employee’s own sickness) (Xue et 
al., 2010). In the USA the estimated total monetised impact of influenza was 
$87.1 billion in 2003 (Molinari et al., 2007). The total annual estimated tangible 
costs for seasonal influenza were approximately 844 million Euros in the 
Netherlands. Of that total, 67% of the health burden was in adults, followed by the 
elderly with 25.3% and children aged 19 years and below with 7.3% (Hak et al., 
2006). In New Zealand, the total costs for ICU and non-ICU admission in the 
2009 influenza pandemic were NZ$9.9 million and NZ$20.6 million, respectively 
(Wilson et al., 2012b). 
 
1.5 The difficulties in measuring influenza and its burden 
Despite its high measured impact on population health, a large proportion of 
influenza cases are still not diagnosed and reported. Many cases are not 
ascertained because of lack of laboratory results, indicative signs or ambiguous 
aetiology (Zambon, 2011, Shubin et al., 2013, Galante et al., 2012, Yang et al., 
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2012b). The health system routinely underestimates actual influenza impact 
(Thompson et al., 2003). Much of the disease burden from influenza is thought to 
come from triggering respiratory illness (Pitman et al., 2007), circulatory illness 
(Warren-Gash et al., 2009, Fleming et al., 2005a) or central nervous system 
impairment (Toovey, 2008). Less than 4% of cardiovascular diseases (myocardial 
infarction) hospitalisations associated with influenza were identified in Hong 
Kong, and England and Wales (Warren-Gash et al., 2011). In the USA, 50% of 
influenza-associated hospitalisations in adults were missed if the influenza 
surveillance system was restricted to pneumonia only (Ortiz et al., 2014a). 
 
Measured deaths from influenza are rare. Death certificates with influenza as the 
underlying cause of death are a large underestimate of the real number of deaths 
from influenza (Ortiz et al., 2014b, Wong et al., 2015b). In England it was 
estimated that only 39% of deaths with positive pandemic A/H1N1 results were 
registered as influenza in death certificates of the deceased (Donaldson et al., 
2009). Modelling is a potential method to capture influenza deaths. 
 
In New Zealand, in the 13 year period from 1988-1992, modelling suggested there 
were an average of 434 deaths attributed to influenza each year, while only 6 
deaths were confirmed as attributed to influenza. This difference means that for 
each recorded influenza death, there were 72.3 deaths associated with influenza 
but without laboratory confirmation (Public Health Commission, 1996). For the 
more recent 19 year period from 1990-2008 modelling suggests that total New 
Zealand mortality for influenza was 401 medical deaths a year, with 306 of these 
for respiratory and circulatory conditions. This total is almost 20 times higher than 
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the average number of coded influenza deaths in New Zealand over that same 
period (average of 23 per annum) (Kessaram et al., 2014). In the USA, the annual 
average number of modelled influenza-associated deaths for all causes was about 
9 times higher than observed pneumonia and influenza deaths reported by routine 
surveillance (Thompson et al., 2003). 
 
Direct measurement from the Southern Hemisphere Influenza and Vaccine 
Effectiveness Research and Surveillance (SHIVERS) from 29 April-29 September 
2013 identified only one influenza death out of a total of 539 hospital deaths in 
Auckland and Manukau (internal circulation paper). 
 
Preliminary analysis of the annual number of deaths from 2000-2010 (from 
Ministry of Health mortality data) in ADHB and CMDHB shows that there was 
an average of only 2.1 deaths coded as influenza per year from these two DHBs. 
Influenza and Pneumonia accounted for 1.3% of total deaths (59.5 fatalities). A 
large proportion of deaths were coded as respiratory and circulatory diseases 
(2113 deaths corresponding to 45.8% of total mortality). Among these, respiratory 
deaths amounted to 372 (8.1% of total deaths). As the population of ADHB and 
CMDHB is about 19.6 % of the New Zealand population (Statistics New Zealand, 
2017) and based on the regression model applied for the period 1990-2008 
(Kessaram et al., 2014), it is extrapolated that the actual number should be about 
80 influenza deaths a year in this population and 60 influenza deaths coded as 





Moreover, influenza is not systematically tested for when patients are 
hospitalised, even for respiratory illnesses. Influenza is sometimes a consequence 
or secondary infection in a person with a long-term disease (Pitman et al., 2007). 
People with cardiovascular and chronic liver diseases were at a 5-50 times higher 
risk of influenza compared with those without a co-morbidity (The Australian 
Lung Foundation, 2007). About 1% of employees with influenza in Norway had 
at least an underlying medical illness (de Blasio et al., 2012). Hospital discharge 
diagnoses do not provide a fully accurate number of influenza hospitalisations 
(Williamson et al., 2012). In the Netherlands, for every detected influenza case 
there were 2.6 influenza cases which were coded under another illness (Sprenger 
et al., 1993). In the USA, the contribution of influenza to total hospitalisations 
was about 4.7 times larger than indicated by routine coding (63.5 per 100,000 for 
modelling compared with 13.5 per 100,000 for recorded system) (Zhou et al., 
2012). 
 
1.6 Using statistical modelling techniques to estimate the burden of 
influenza 
The disease burden of influenza is markedly greater than that reported from 
routine coded data. Shubin et al. described how influenza was only the “tip of the 
iceberg” and there were a large undetected number of influenza cases beneath the 




Figure 1.  The iceberg pyramid of influenza (Shubin et al., 2013) 
IC: Intensive care  
 
In infectious disease surveillance, observational studies do not capture the real 
number of cases because of a lack of homogeneity of data reporting systems, 
diagnostic method, and case definition (Nicoll et al., 2012, Taylor et al., 2016b). 
In contrast, statistical approaches overcome these obstacles by using mathematical 
models and population-based datasets to estimate morbidity and mortality from a 
disease (Nicoll et al., 2012). 
 
Regression models are plausible methods to measure numbers of influenza cases 
and deaths (Nicoll et al., 2012). There are four common modelling approaches: (i) 
rate-difference models; (ii) Serfling least squares cyclical regression models; (iii) 
Serfling–Poisson regression models; and (iv) autoregressive integrated moving 
average models (Thompson et al., 2009). Each method has its strengths and 
weaknesses (Nicoll et al., 2012) but requires various input data such as count data 
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of hospitalisations or deaths (Thompson et al., 2009), and/or virology data 
(influenza A, influenza B and/or respiratory syncytial virus (RSV) (Nicoll et al., 
2012). 
  
Various types of regression models have been applied in many countries to 
estimate the true burden of influenza. Influenza mortality and hospitalisation rates 
vary by population, year of study and applied modelling approaches. With 
Poisson regression models, the annual average rates (per 100,000) of influenza-
associated deaths were 19.6, 13.1 and 10.6 in the USA, Canada and New Zealand, 
respectively (Kessaram et al., 2014, Schanzer et al., 2007a, Thompson et al., 
2003). Multiple linear regression models provided a similar annual mean rate (per 
100,000) of influenza-attributable deaths of approximately 11.0 in both the USA 
and Hong Kong for the same study period (Quandelacy et al., 2014, Wu et al., 
2012). The annual average rates (per 100,000) of influenza-associated 
hospitalisation varied markedly, from 11.5 in Finland (Jacks et al., 2012) to 94.2 
in Australia, although they applied similar negative binomial regression models 
(Newall and Scuffham, 2008). 
 
Modelling approaches can provide evidence of the contribution of a single 
outcome (pneumonia and influenza, respiratory illness, circulatory illness, all 
medical illness and all causes) to influenza deaths and hospitalisations by broad 
demographic and socio economic groups, such as age or sex (Jansen et al., 2007, 
Newall and Scuffham, 2008, Wong et al., 2004, Wong et al., 2006, Wu et al., 




1.7 Thesis chapters 
The goal of this thesis was to improve the evidence base on the health impacts for 
influenza in New Zealand, to inform policies and practices to lower this burden. 
 
Specific aims of this thesis were to:  
(i) Review the major population health impacts of influenza; 
(ii) Estimate the contribution of influenza to hospitalisations for all age and 
ethnic groups in New Zealand; 
(iii) Assess the distribution of seasonal influenza-attributable mortality in New 
Zealand according to a broad set of sociodemographic characteristics 
including age, sex, ethnicity and socioeconomic status; 
(iv) Use direct measurement of hospitalised influenza to validate modelled 
estimates of influenza incidence and distribution; 
(v) Estimate the proportion of influenza deaths occurring inside and outside 
hospital, and the proportions with respiratory causes compared with 
cardiovascular disease and other medical illnesses. 
 
The thesis consists of nine chapters. Chapter One briefly describes the main 
concepts of influenza and the methods used to estimate its disease burden. The 
chapter describes the thesis goal, aims and structure. 
 
Chapter Two is a systematic review of the major population health impacts of 
influenza. The purpose of this chapter is to summarise evidence regarding the 
major health impacts of influenza, being hospitalisations and deaths. These are 
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two of the five tiers of the influenza disease pyramid: death, ICU admission, 
hospitalisation, medically attended illness and non-medically attended illness/non-
symptomatic infections; and describe the main methods for measuring influenza 
outcomes. PRISMA (preferred reporting items for systematic reviews and meta-
analyses) guidelines were used in this review chapter. This literature review listed 
selected studies in tables and extracted standard information from each: author, 
country, study population, period of study, method used, data source and key 
findings (influenza rate per 100,000 with 95% confidence interval (CI), if 
available) by illness categories (pneumonia and influenza, respiratory illness, 
circulatory illness, cardiopulmonary illness and all causes). Pooled estimates of 
influenza-attributable rates per 100,000 are generated in this chapter. In the 
literature review, the pooled rate of influenza-associated mortality was 13.9 per 
100,000 for seasonal influenza and 12.1 per 100,000 for pandemic influenza. 
 
Chapter Three describes some of the methodological issues involved in influenza 
modelling, with a particular focus on hospitalisations. It introduces a procedure to 
select 50 weeks of data instead of 52 weeks (the average number of weeks per 
annum) from the National Minimum Dataset of New Zealand for the models’ 
input. This chapter also explains reasons to apply negative binomial regression 
models to estimate influenza hospitalisations compared with Poisson models used 
in estimating influenza mortality. 
 
Chapter Four describes the modelled estimates of the contribution of influenza to 
hospitalisations in New Zealand for the period 1994-2008 by major illness 
categories (pneumonia and influenza, respiratory, circulatory, all medical, and all 
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causes), age grouping (all ages; under 1; 1-4; 5-19; 20-34; 35-49; 50-64; 65-79; 80 
years of age and older) and ethnic grouping (Māori, Pacific, European/Others). 
The chapter shows that the contribution of influenza to hospitalisation was nine 
times higher than reported in the routine discharge system. A version of this 
chapter has been published in Vaccine.  
 
Chapter Five describes modelled estimates of the contribution of influenza to 
mortality in New Zealand for the period 1994-2008, by major illness categories 
(pneumonia and influenza, respiratory, circulatory, all medical, and all causes), 
age grouping (under 20; 20-64; 65-79; 80 years of age and older), sex (male, 
female), socioeconomic status (New Zealand Deprivation (NZDep) 1&2, NZDep 
3&4, NZDep 5&6, NZDep 7&8, and NZDep 9&10) and ethnic grouping (Māori, 
Pacific, European/Others). This chapter uses similar statistical approaches as in 
the analysis for hospitalisations in Chapter Four. The chapter shows that the 
contribution of influenza to mortality was 23 times higher than indicated in the 
routine mortality system. The manuscript of this chapter has been accepted for 
publication in the Journal of Infection. 
 
Chapter Six describes the approach taken to validate the statistical modelling 
techniques by comparing modelled results with those obtained by direct 
measurement, with data from the SHIVERS study population (Auckland and 
Manukau) during influenza seasons (from week 18 to week 39) over four years 
from 2012-2015. In this chapter, negative binomial regression models were used 
to estimate influenza associated respiratory hospitalisations and compare results 
with measured SARI influenza and measured respiratory influenza obtained from 
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SHIVERS by major sociodemographic characteristics (time, age, sex, ethnicity, 
socioeconomic status and registered hospital). This chapter shows modelling 
methods can be used to provide valid estimates of the influenza burden, especially 
in children and the elderly.  
 
Chapter Seven is a novel study that aims to partition the large number of influenza 
deaths that occur each year into more meaningful, and potentially preventable, 
categories defined by setting and major cause. Although influenza is responsible 
for a large number of deaths every year, little has been published about where and 
how these deaths occur. This chapter aimed to estimate the proportion of influenza 
deaths by place of death, and the proportion with respiratory causes compared 
with circulatory disease and other medical illnesses. Such information could help 
to identify and prioritise broad prevention strategies. A total of 75 quasi Poisson 
and negative binomial regression models were applied to estimate influenza 
deaths by major outcomes (pneumonia and influenza, respiratory illness, 
circulatory illness, all medical illness and all causes) occurring in and outside 
hospital. In addition to the number and rate of influenza deaths by health settings 
and illness categories, the case fatality risk (CFR) for people hospitalised with 
influenza using modelled mortality and hospitalisations is calculated. Findings 
from Chapters Four and Five on modelled mortality and hospitalisations were 
used in this chapter for comparison and calculation of case fatality risk by age 
group and illness category for people hospitalised with influenza. The method 
using observational data to validate modelled CFR (that is used in Chapter Six) is 
also repeated in this chapter. Findings from this chapter, for the first time, 
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partition estimated influenza mortality into major facility settings and illness 
categories.  
 
Chapter Eight is a general discussion of the thesis. This chapter presents the 
author’s assessment of the entire burden of influenza by drawing on the discussion 
sections in previous chapters. It then describes the project’s strengths and 
limitations, and compares the key findings of the thesis with what is known from 
the international literature.  
 
The final chapter of the thesis, Chapter Nine, presents the overall conclusions of 
the thesis, its implications for reducing the burden of influenza, and future studies 




Chapter Two: The major population 
health impacts of influenza: A 
systematic review 
 
2.1 Chapter goal 
The goal of this chapter is to summarise the major influenza health impacts and 
how they are estimated and measured. The main focus was therefore on influenza 
mortality and hospitalisations. A systematic review of the impact of influenza on 
population health in all countries without restriction of language, income and 
geography was conducted. Original studies published from 1 January 1994 - 31 
May 2015 that covered the outcomes mortality, and hospitalisations were 
included.  
 
A total of 83 papers were eligible for review. Most reported influenza-associated 
respiratory diseases, pneumonia and influenza and all causes. This review 
estimated that the overall rate of seasonal influenza- attributable mortality for all 
ages and all causes was 13.9 per 100,000, which was slightly higher than that 
estimated for pandemic (pH1N1) 2009 influenza at 12.1 per 100,000. The 
influenza-associated hospitalisation rate (per 100,000) for all causes varied widely 
from 11.5 to 94.2 per 100,000. Direct measurements of the impact of influenza 
produced consistently lower rates. An important observation explored in Chapter 
Seven is that influenza makes an important contribution to circulatory disease 





Globally, every year an average of 250,000-500,000 people die from influenza 
and another 3-5 million people suffer severe illness (WHO, 2016). Influenza and 
acute respiratory illness (ARI) are also common causes of illness and death in 
children under five years old. Annually, there are 2 million ARI (including 
influenza) related deaths in infants and young children worldwide (WHO, 2004, 
Williams et al., 2002, Chadha et al., 2013).  
 
In New Zealand, respiratory infections (including influenza) are the largest 
component of infectious disease hospitalisations (Kool et al., 2013, Huang et al., 
2007), and have made a large contribution to the rise in hospitalisations over the 
20 year period 1989-2008 (Baker et al., 2012b). According to Ministry of Health 
reporting, the average mortality rate of both pandemic and seasonal influenza in 
the country was 0.57 per 100,000 people in the 2000s. 86% of people who died of 
influenza in 2009 also suffered from co-morbidities or underlying medical 
conditions such as respiratory illness, drug abuse or obesity (MOH, 2010). 
 
Assessing the impact of infectious diseases (including ARI and influenza) on a 
population is difficult. Many cases are not identified because of a lack of 
laboratory results, indicative signs or supporting symptoms, non-medical 
attendance, or ambiguous aetiology (Zambon, 2011) (Galante et al., 2012) 
(Shubin et al., 2013). In many developed countries, influenza impacts are assessed 
using the “influenza pyramid” which categorises these impacts into deaths, 
hospitalisations, medically attended respiratory illness (MARI) and non-medically 
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attended respiratory illness (NMARI) (Molinari et al., 2007) (Shubin et al., 2013) 
(Zambon, 2011). Previous studies describe a strong association among influenza 
outcomes. For instance, data from general practitioners (GP) has been used to 
estimate excess deaths and hospital admissions (van den Wijngaard et al., 2010). 
Increase in intensive care unit (ICU) admission can be a good indicator of an 
influenza epidemic (Koetsier et al., 2013). The probability of influenza deaths, 
hospitalisation and GP consultations has been used to calculate the probability of 
non-medically attended influenza (Molinari et al., 2007). The influenza pyramid 
provides a basis for measuring the health, economic and societal burden of disease 
(Ambrose and Antonova, 2013) (Shubin et al., 2013) (Xue et al., 2010).  
 
Previous reviews have summarised the literature on specific influenza events such 
as the 2009 pandemic (Wong et al., 2015a) (Khandaker et al., 2011) (Van 
Kerkhove et al., 2013) or the population impact of influenza B (Paul Glezen et al., 
2013); specific outcomes such as the contribution of cardiovascular diseases to 
influenza mortality (Warren-Gash et al., 2009) or the association of influenza with 
other medical illness (Toovey, 2008); specific populations such as children (Nair 
et al., 2011) (Antonova et al., 2012) or pregnant women (Meijer et al., 2015) or 
the most vulnerable (Mauskopf et al., 2013); or specific geographic areas such as 
in Kenya (Emukule et al., 2015) or East and South East Asia (Simmerman and 
Uyeki, 2008) or Latin America and the Caribbean region (Savy et al., 2013). Few 
reviews have attempted to develop an integrated picture of the impact of influenza 
at multiple levels of the disease pyramid. This review aims to achieve that for 




The purpose of this review was to:  
(1) summarise the reported effects of influenza hospitalisation and deaths on 
population health;  
(2) summarise how these influenza outcomes were measured or estimated, 
including the scope of clinical syndromes included (eg respiratory, circulatory, 
other); and 
(3) broadly partition these impacts according to major age bands. The review will 
provide a base to determine which method and data source would be the best for 
estimating the impact of influenza on health in New Zealand. 
 
2.3 Method 
This review followed the PRISMA (preferred reporting items for systematic 
reviews and meta-analyses) guidelines (Liberati et al., 2009). 
 
2.3.1 Search strategy 
The literature review was conducted using the Ovid MEDLINE, EMBASE, 
Cochrane and PUBMED databases. The search was limited to publications 
published from 1 January 1994-31 May 2016. 
 
Searches used various keywords (exploded to include their respective 
subheadings): influenza or flu (seasonal or pandemic), influenza related, influenza 
like illness, influenza associated, influenza attributable, respiratory infections, 
hospitalisations (hospitalizations) or hospital admission, mortality or death or 
fatality, and burden or impact or magnitude or rationale or effect. Bibliographies 
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of relevant articles were scanned for additional references. Google Translate was 
used for articles not written in English. 
 
2.3.2 Selection criteria 
Original studies that covered the outcomes mortality or morbidity from influenza 
and hospitalisations due to influenza were included without language restrictions. 
Studies covered the entire population of a country or a specific geographic area or 
an age band or specific group such as pregnant women, children or the elderly. 
Both seasonal influenza and pandemic (pH1N1) 2009 influenza were included. 
Studies in high, middle and low income countries were eligible for review. These 
studies were limited to publication date as mentioned in the search strategy.  
 
Reports with any of the following were excluded:  
 Published before 1994; 
 Not based on original research (review articles, editorials, 
comments, clinical guidelines and letters); 
 Repeat analysis of same data; 
 Insufficient information on methodology to understand and 
categorise; and/or 





2.3.3 Definitions and categorisation of studies 
In this review, studies were categorised according to their main outcomes covered 
and major methods. 
 
The influenza literature includes a range of outcomes. Most are deaths/mortality 
and hospitalisation (including ICU admission). However, these outcomes are only 
the top of the disease pyramid and do not reflect the full influenza impact on 
population health (Shubin, et al., 2013). The health impact pyramid has been used 
as a tool to assess the range of disease outcomes affecting population health. The 
US Center for Disease Control and Prevention (CDC) designed the “burden of 
illness pyramid” to estimate the impact of food related diseases. The “burden of 
illness pyramid” allows researchers to evaluate each layer of impact and identify 
relationships (if any) between the outcomes. The pyramid is considered useful for 
presenting surveillance data for any infectious disease (Allos et al., 2004, Pelat et 
al., 2014). Figure 2 describes the influenza outcomes in general. This literature 
review only concentrated on estimating the health burden of influenza deaths and 
hospitalisations. 
 
Studies were divided according to whether they used direct measurements or 
modelled estimates of influenza impact. 
 
The disease burden was also divided according to clinical syndrome (pneumonia 
and influenza, respiratory illness, circulatory illness, cardiopulmonary (both 
respiratory and circulatory) illness, and all causes. Outcomes were also stratified 





Figure 2. Burden of illness pyramid for the impacts of influenza on 
population health 
 
2.3.4 Data extraction and statistical analysis 
From each study, this literature review extracted the following information: 
author, country, study population, period of study, method used, data source and 
key findings (influenza rate per 100,000 with 95% confidence interval (CI), if 
available) by illness categories (pneumonia and influenza, respiratory illness, 
circulatory illness, cardiopulmonary illness and all causes). Data by age group (if 
available) were extracted. 
 
The pooled estimates of the influenza-attributable rate per 100,000 by region and 
overall, were generated using random-effects analysis. Analysis was conducted 







GP visits/Medically attended respiratory 
illnesses 





2.4.1 Study selection 
The search yielded 4,905 articles from four databases Ovid Medline, EMBASE, 
PubMed and Cochrane. 3,540 relevant articles were retrieved after title review. 
227 relevant articles were included after abstract review. 77 relevant articles were 
retrieved after full text review. An additional six studies were found after scanning 
reference lists of eligible articles. In total 83 papers published from 1 January 
1994 - 31 May 2016 were included in this review (Figure 3).  
 
These analyses were based on articles from 32 countries and regions (Table 1).  
 
Table 1. List of countries included in the review 
 
High income countries Middle and low income countries 
The USA (15); Canada (5);  Mexico (1); South Korea (2); 
Singapore (3); Japan (1); Israel (1); France (2); Finland (1); 
Switzerland (1); Germany (3); England or England and 
Wales or the United Kingdom (3); the Netherlands (2); 
Austria (2); Portugal (1); Denmark (2); Spain (2); South 
Africa (2); Australia (5) and New Zealand (2). 
Argentina (3); Costa Rica (1); Chile (1); Guatemala (1); 
Brazil (1); India (2); the Philippines (1); Thailand (3); 
Kenya (2); China (2); and Bangladesh (1); 
 
By classifying studies based on outcomes of influenza, 37 articles summarised 
influenza related deaths, 29 papers included influenza related hospitalisations and 





























Figure 3. Flow chart of selection of 83 articles for the review 
  
4,905 relevant articles found from literature searches: 
- 2,606 from PubMed  
- 1,459 from EMBASE  
- 571 from Medline 
- 269 from Cochrane 
 
3,540 relevant articles retrieved 
after title review 
 
3,325 articles excluded because 
did not meet criteria: 
- 3,274 not relevant to the topic 
- 51 comments, editorial, 
letters, guidelines, reviews 
 
83 articles retrieved for data and 
information extraction 
6 additional articles 
obtained after scanning 
reference lists of 
eligible studies 
 
1,365 duplicates removed 
 
215 relevant articles retrieved after 
abstract review 
 
77 articles retrieved after full text 
review 
 
138 articles excluded because did not meet 
criteria: 
- 69 duplicates and with non-useful 
information 
- 10 repeat analyses 
- 26 insufficiently described method 





Identifying influenza deaths or hospitalisations is difficult so carefully designed 
methods are needed to measure and estimate the number of influenza related 
deaths or hospitalisations (Dushoff et al., 2006). 
 
Various models have been used to estimate influenza mortality and 
hospitalisation. Overall, there are four common models: (i) rate-difference models 
(used to estimate influenza associated hospitalisations and deaths); (ii) Serfling 
least squares cyclical regression models (used to estimate the number of influenza 
associated deaths); (iii) Serfling-Poisson regression models (used to estimate age 
specific mortality and hospitalisation from influenza); and (iv) autoregressive 
integrated moving average models (Thompson et al., 2009).  
 
2.4.2 Deaths attributable to influenza 
The search identified 47 articles that described influenza-attributable deaths (35 
studies for seasonal influenza, eight studies for pandemic influenza and four 
studies for both seasonal and pandemic influenza). Seasonal influenza mortality 
was estimated by modelling techniques in 33 papers and by direct measurement in 
five papers. Among eight articles on pandemic influenza, five papers used 
modelling techniques and three papers used population-based surveillance. All 
four studies for both seasonal and pandemic influenza applied regression models 









Period Method  Data source Age group 
Findings (95% CI, if available) (Influenza- associated mortality rate per 100,000) 




1. DIRECT MEASUREMENT           
Seasonal influenza           
(Bhat et al., 
2005) 
USA Children under 
18 years old in 
40 state health 
departments 


























    











All 3.1     
            
(Fleming et al., 
2005b) 
England Children under 
15 years old 
1989-2000 Retrospective 
study 












            















    
            
(Feikin et al., 
2012) 
Kenya Rural western 
Kenya 










    7.6 (2.1, 13.2) 
0.2 (0.0, 0.6) 
1.5 (0.5, 2.5) 





     






Period Method  Data source Age group 
Findings (95% CI, if available) (Influenza- associated mortality rate per 100,000) 






           
(Wilking et al., 
2010)  











    44 (16, 95) 
19 (5, 49) 
25 (15, 39) 
22 (16, 30) 
42 (35, 50) 
24 (18, 32) 
31 (21, 35) 
            
(Homaira et al., 
2012) 



















Argentina 3 sites covering 
2,512,370 
population 







    1.8 (1.8,1.8) 
1.5(1.5, 1.7) 
4.1 (3.8, 4.4) 
5.6 (5.6, 5.6) 
2.7 (2.4, 3.0) 
            
            
            
2. MODELLING           
Seasonal 
pandemic 
           
(Thompson et 
al., 2003) 
USA National 1990-1999 Poisson regression 
model  






























Period Method  Data source Age group 
Findings (95% CI, if available) (Influenza- associated mortality rate per 100,000) 




(Matias et al., 
2014) 
USA National 1997-2009 Multiple linear 
regression model 
































USA National 1997-2007 Multiple linear 
regression model 






    0.4 (0.2,0.6) 
1.0 (0.6, 1.5) 
7.2 (5.9, 8.4) 
26.41 (22.1, 30.5) 
141.2 (118.3, 163.8) 
11.8 (10.3, 13.2) 
            
(Thompson et 
al., 2009) 
USA National 1976-2003 Poisson regression  Weekly deaths <65 
≥65 
All ages 




    Rate-difference   <65 
 ≥65 
All ages 




            
(Schanzer et al., 
2013b) 
Canada National 1992-2009 Poisson regression 
model 
Weekly deaths All ages     11.3 (10.5,  12.1) 
            








Rate – difference 
model  
Monthly deaths <65 
≥65 
0 
139 (105 – 173) 
0 
82 (50 – 115) 
   






Period Method  Data source Age group 
Findings (95% CI, if available) (Influenza- associated mortality rate per 100,000) 




(Schanzer et al., 
2008) 
Canada National 1994-2000 Poisson regression 
model 
























            
(Schanzer et al., 
2007b) 
Canada National 1990-1999 Poisson regression 
model 














            
(Wu et al., 
2012) 
Hongkong National 1998-2009 Multiple linear 
regression model 











2.99 (1.81, 4.16) 
−0.06 (−0.91,0 .78) 
0.11(-0.13,0.33) 
−0.20 (−0.48,0 .14) 
1.77 (.90, 2.65) 
49.64 (37.06, 61.03) 
5.83 (4.09, 7.29) 
0.28 (−65, 1.27) 
0.03 (−19,0.28) 
0.09 (−17,0.4) 
0.85 (−56, 2.35) 
18.96 (9.61, 31.18) 
2.04 (63, 3.58) 
 −0.68 (−3.74, 2.37) 
−0.24 (−0.96,0.48) 
1.26 (0.41, 2.34) 
3.31 (0.13, 6.08) 
89.68 (61.9, 114.7) 
11.08 (7.18, 14.63) 
            
(Wong et al., 
2004) 
Hong Kong National 1996-1999 Poisson regression 
model 
Weekly deaths 40-64 
≥65 
All ages 
0.8 (1.0, 2.6) 
39.3 (21.4, 57.3) 
4.1 (2.1, 6.2) 
1.7 (0.3, 3.2) 
24.6 (11.6, 37.9) 
3.1 (1.6, 4.6) 
(for COPD) 
3.3 (1.1, 5.4) 
21.5 (4.9, 37.7) 
3.0 (1.2, 4.9) 
(for IHD) 
7.3 (3.1, 11.4) 
102.0 (61.2, 142.7) 
12.4 (7.7, 17.1) 
11.8 (3.8, 20.1)  
136.1 (83.7, 188.4) 
16.4 (9.4, 23.3) 
            
(Park et al., 
2016) 
South Korea National 2003-2013 Generalised linear 
regression model 
 






0.08 (0.00, 0.18) 
0.00 (-0.01, 0.02) 
0.05 (0.03, 0.07) 
0.22 (0.17, 0.30) 
5.49 (5.05, 7.14) 
0.68 (0.63, 0.96) 
0.17 (0.03, 0.34) 
0.02 (0.00, 0.05) 
0.05 (0.03, 0.08) 
0.37 (0.30, 0.55) 
11.45 (10.05, 14.28) 
1.34 (1.21, 1.66) 
-0.02 (-0.13, 0.09) 
0.02 (-0.02, 0.06) 
0.12 (0.04, 0.21) 
0.83 (0.44, 1.22) 
10.60 (8.09, 13.86) 
1.41 (1.14, 1.80) 
 0.32 (-0.41, 0.96) 
0.23 (-0.09, 0.50) 
0.44 (-0.03, 0.94) 
2.73 (1.58, 3.87) 
46.98 (38.32, 58.94) 
5.97 (4.96, 7.59) 






Period Method  Data source Age group 
Findings (95% CI, if available) (Influenza- associated mortality rate per 100,000) 






Japan National 1975-1999 Generalised linear 
regression model 
 





            
(Chow et al., 
2006) 
Singapore National 1996-2003 Negative binomial 
regression model 
Monthly deaths 20-64 
≥65 
All ages 
0.8 (0.2, 1.4) 
40.9 (20.3, 70.6) 
2.9 (1.0, 5.0) 
  3.2 (1.7, 4.8) 
155.4 (108.8, 203.0) 
11.9 (8.3, 15.7) 
4.2 (1.6,6.8) 
167.8 (107.0, 229.5) 
14.8 (9.8, 19.8) 
            
(Nielsen et al., 
2011)** 
Denmark National 1994-2010 Multiple linear 
regression model 











Cuadrado et al., 
2012) 



























            
(Kessaram et 
al., 2014) 
New Zealand National 1990-2008 Poisson regression 
model 
Weekly deaths <65 
≥65 
All ages 






            
(Gran et al., 
2010) 
Norway National 1975-2004 Poisson regression 
model 










            
(Newall et al., 
2008) 
Australia National 1997-2004 Negative binomial 
and Poisson 
regression  
Monthly deaths 50-64 
≥65 
0.6 (0.3, 1.0)  
17.6 (12.9, 22.3) 
2.1 (1.2, 3.0) 
24.4 (18.8, 30.0) 
1.4 (−0.6, 3.4)  
49.3 (27.0, 71.6) 
 
 
6.4  (2.6, 10.2) 
116.4  (71.3,161.5) 






Period Method  Data source Age group 
Findings (95% CI, if available) (Influenza- associated mortality rate per 100,000) 




(Nunes et al., 
2011) 
Portugal National 1980-2004 Serfling cyclical 
regression  




















































































            
(Kuo et al.) Austria National 2001-2009 Cycle regression 
model 
Weekly deaths All ages     13.5 
            
(Redlberger-
Fritz et al., 
2012) 
Austria National 1999-2010 Poisson regression 
model 




















            
(Comas-Garcia 
et al., 2011) 















            
(Thiberville et 
al., 2015) 
France South Eastern 1999-2010 Generalised linear 
regression model 
 
Weekly deaths All ages  91.5 (41.6, 154.1) 36.8 (-67.1, 178.8)   
            
(Zucs et al., 
2005) 
Germany National 1985-2001 Cyclical 
regression model 
Monthly deaths All ages     17.4  
 
            
(Jansen et al., 
2007) 





     - 
0.3 (0.1, 0.7) 
0.4 (-0.1, 0.9) 
3.8 (1.8, 5.7) 






Period Method  Data source Age group 
Findings (95% CI, if available) (Influenza- associated mortality rate per 100,000) 




            
(Freitas et al., 
2013) 
Brazil Southern Brazil 1980-2008 Serfling regression 
model 




  86.6 
9.2 
 
            
(Wang et al.) China Guangzhou, 
Southern China 
2010-2012 Negative binomial 
regression model 









 (for COPD) 
0.3(0.2,0.4) 
29.3(23.2, 35.4) 








            
(Cohen et al., 
2010) 
South Africa Those aged 65 
years and above 
1998-2005 Serfling regression 
model 




10 (2, 18) 
30 (15, 45) 
32 (0,64) 
175 (88,262) 
30 (13, 47) 
54 (22, 86) 
104 (36,172) 





 156 (107,205) 
243 (144, 342) 
429 (236,622) 
1326(888,1754) 
      ≥65 42(21, 63) 87(42, 132) 40(26,54)  340 (197, 483) 
            
(Imaz et al., 
2006) 
Argentina National 1992-2002 ARIMA model Monthly deaths All ages 1.0     8.0 




Argentina National 2002-2009 Generalised linear 
regression model 
Monthly deaths All ages 6.0 (4.1, 8.0)   21.4 (11.9, 30.8)  
            
(Aungkulanon 
et al., 2015) 
Thailand National 2006-2011 Negative binomial 
regression model 




21 (-64.7, 106) 
2.2 (-7.0, 11.0) 
1.1 (-0.3, 5.3) 
42 (-93, 178) 
4.3 (-10.1, 19.0) 
0.0 (-5.8, 5.3) 
11.0 (-120.0,138) 
0.8 (-14.7, 16) 
 0.7 (-8.0, 10) 
46 (-128,215) 
4.3 (-17, 26) 
            
(Cooper et al., 
2015)  
Thailand National 2005-2009 Bayesian 
regression model 





1.1 (-1.7, 4.0) 
68.0 (27.2, 108.1) 
6.1 (0.5, 12.4) 
(for influenza A and B) 
    
            
(Cheng et al., 
2015) 
PAHO region 
( 35 countries)  








    2.1 (0.7, 4.3) 
31.9 (13.0, 65.7) 
161.8 (87.2, 288.3) 











Period Method  Data source Age group 
Findings (95% CI, if available) (Influenza- associated mortality rate per 100,000) 






           
(Lemaitre et al., 
2012) 
France National 1997-2010 Serfling regression 
model 






0.12 (0.02, 0.21) 
0.07 (0.04, 0.09) 
0.15 (0.10, 0.21) 
0.70 (0.54, 0.85) 
1.8 (−0.16, 3.7) 
0.54 (0.22, 0.87) 
0.17 (−0.02, 0.36) 
0.10 (0.05, 0.15) 
0.21 (0.11, 0.31) 
0.75 (0.43, 1.1) 
3.2 (−1.1, 7.8) 
0.82 (0.09, 1.6) 
 0.28 (−0.06,0.61) 
0.13 (0.03, 0.23) 
0.30 (0.01, 0.59) 
0.93 (0.05, 1.8) 
7.4 (−4.6, 19) 
1.6 (−0.41, 3.6) 
0.74 (−1.1, 2.6) 
0.39 (−0.12, 0.90) 
0.74 (−0.20, 1.7) 
2.7 (0.21, 5.2) 
22 (−1.9;,45) 
4.7 (0.66, 8.7) 
 
    Poisson regression 
model 






0.10 (0.04, 0.14) 
0.07 (0.06, 0.08) 
0.15 (0.12, 0.18) 
0.80 (0.71, 0.89) 
3.5 (1.2, 5.6) 
0.86 (0.43, 1.3) 
0.02 (−0.17, 0.15) 
0.13 (0.11, 0.15) 
0.19 (0.13, 0.25) 
0.78 (0.55, 1.0) 
4.1 (−0.94, 8.9) 
0.98 (0.04, 1.9) 
 −0.02 (−0.30, 0.21) 
0.19 (0.14, 0.23) 
0.29 (0.10, 0.48) 
0.43 (−0.31, 1.2) 
−3.1 (−18, 11) 
−0.28 (−3.0, 2.4) 
−0.71 (−2.0, 0.5) 
0.36 (0.04, 0.67) 
0.10 (−0.56, 0.75) 
−0.47 (−2.8, 1.8) 
−6.59 (−41, 27) 
−1.15 (−7.8, 5.4) 
            
(Redlberger-
Fritz et al., 
2012) 
Austria National 1999-2010 Poisson regression 
model 




















            
(Comas-Garcia 
et al., 2011) 















            
(Muscatello et 
al., 2014b) 
Australia National 2003-2009 Generalised 
additive model 
Weekly deaths <65 
≥65 
 
 0.5 (0.3,0.7) 
5.2 (-2.8,13.2) 
 0.6 (0.2,1.1) 
7.9 (-11.6, 27.4) 
0.2 (-0.8,1.1) 
17.6 (-11.8, 47.0) 
            
(Green et al.) England and 
Wales 
National 2006-2012 Generalised linear 
regression model 

















0.4 (0.0, 1.1) 
0.9 (0.1, 1.8) 
8.9 (5.2, 12.7) 
47.3 (22.2,72.2) 
(Wu et al., 
2014) 




Weekly deaths 0-64 
≥65 
All ages 
 0.1 (-0.8, 1.1) 
9.2 (-24,1, 43.3) 
1.2 (-3.2, 5.5) 
  -0.2(-3.2, 2.9) 
18.1 (-57.3, 94.6) 






Period Method  Data source Age group 
Findings (95% CI, if available) (Influenza- associated mortality rate per 100,000) 




            
   1-3/2011   0-64 
≥65 
All ages 
 0.6 (0.1, 1.2) 
21.2 (11.2, 30.3) 
2.9 (1.5, 4.0) 
  0.4 (-1.2, 2.5) 
33.7 (-8.1, 76.9) 
4.7 (-0.7, 10.5) 
            
(Yang et al., 
2012a) 
Hong Kong National 7-12/2009 Poisson regression 
model 




Argentina National 2002-2009 Generalised linear 
regression model 
Monthly deaths All ages 8.4 (6.5, 10.3)   21.9 (11.9, 31.9)  




There were 22 modelling studies with data on seasonal influenza-associated 
deaths for all causes and all ages. Meta-analysis was used to produce a combined 
estimate of mortality rate (Figure 4). Most studies were from high income 
countries in the Americas or the European region. No studies on influenza 
mortality for all causes and all ages were found for Africa. Different models were 
applied in the studies. Eight studies used Poisson regression model. Five studies 
used Serfling/Cyclical regression modelling. Three studies used negative binomial 
regression modelling. The remaining studies used multiple regression modelling; 
generalised linear modelling (GLM); generalised additive modelling; Bayesian 
modelling; ARIMA; and rate-difference.  
 
The pooled estimate of influenza-associated mortality rate (per 100,000) for all 
causes and all ages was 13.9 (95% CI: 13.8,13.9). Rates ranged from 4.3 per 
100,000 to 30.4 per 100,000. The influenza mortality rate varied by modelling 
techniques. For example, in Spain, rates of influenza-attributable mortality were 






   
 
Author, country, year Rate per 100,000  (95% CI) 
Thompson, USA, 2003 19.6*  
Schanzer, Canada, 2013 11.3 (10.5,  12.1) 
Schanzer, Canada, 2008 14 (13.6,14.4) 
Schanzer, Canada, 2007 13.1 (12.7,13.5) 
Wu, Hong Kong, 2012 11.1 (7.2, 14.6) 
Wong, Hong Kong, 2004 16.4 (9.4, 23.3) 
Park, South Korea, 2016 6 (5.0,7.6) 
Chow, Singapore, 2006 14.8 (9.8, 19.8) 
Nielsen, Denmark, 2011 26.4 (25.0,27.8) 
Lopez-Cuadrado, Spain, 2012 (GLM) 11 (10.9,11.1) 
Lopez-Cuadrado, Spain, 2012 (Serfling) 30.4 (30.2,30.6) 
Kessaram, New Zealand, 2014 10.6 (9.6,11.6) 
Gran, Norway, 2010 21.3 (19.9,22.7) 
Nunes, Portugal, 2011 13 (12.5,13.5) 
Kuo, Austria, 2010 13.5 (12.4,14.6)  
Redlberger-Fritz, Austria, 2010 19.1 (17.0,21.2) 
Zucs, Germany, 2005 12 (11.8,12.2) 
Wang, China, 2013 14.7 (12.1, 17.3) 
Imaz, Argentina, 2006 8 (7.7,8.3) 
Comas-Garcia, Mexico,2011 17.6 (17.3,17.9) 
Aungkulanon. Thailand, 2015 4.3 (-17, 26) 
Cheng, PAHO countries, 2015 9.6*  
Overall 13.9 (13.8, 13.9) 
Figure 4. Modelled estimates of influenza-attributable mortality rates (per 100,000) for seasonal influenza, all causes, all 
ages  
Note: Diamonds represent estimated rate (per 100,000) of influenza-attributable mortality for all causes by country. Dot represents overall meta - analysis of influenza-associated mortality rate per 100,000 using random-
effects analysis 
95% CI: 95% confidence interval. All CI values (except for overall rate) were from original papers. (*): original paper did not report CI. 
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As with seasonal influenza, meta-analysis was applied to eight studies on 
pandemic influenza-associated deaths for all causes and all ages. The pooled 
estimate of pandemic influenza-associated mortality rates (per 100,000) for all 
causes and all ages was 12.1 (95% CI: 12.0, 12.2). Pandemic influenza deaths 




   
 
Author, country, year Rate per 100,000 (95% CI) 
Wiking, Germany, 2010 31  (21,35) 
Lemaitre, France, 2012 (Serfling) 4.7 (0.7,8.7) 
Lematire, France, 2012 (Poisson) -1.2 (-7.8,5.4) 
Redlberger-Fritz, Austria,2012 15.6*  
Wu, Hong Kong, 2014 (4/ 2009-5/2010) 2.1 (-8.1,11.8) 
Wu, Hong Kong, 2014 (1-3/2011) 4.7 (-0.7,10.5) 
Yang, Hong Kong, 2012 1.8 (-0.1,3.7) 
Comas Garcia, Mexico, 2011 16.1*  
Homaira, Bangladesh,2012 4.0*  
Azzir-Baumgartner, Argentina, 2012 2.7 (2.4,3.0) 
Overall 12.1 (12.0, 12.2) 
Figure 5. Modelled estimates of influenza-attributable mortality rates (per 100,000) for pandemic influenza, all causes, 
all ages  
Note: Diamonds represent estimated rate (per 100,000) of influenza-attributable mortality for all causes by country. Dot represents overall meta - analysis of influenza-associated mortality rate per 100,000 using 
random-effects analysis 
95% CI: 95% confidence interval. All CI values (except for overall rate) were from original papers. (*): original paper did not report CI. 
Eight studies were included in this meta-analysis 














-5 0 5 10 15 20 25 30 35 40
39 
 
Figure 6 below shows a comparison between seasonal and pandemic (H1N1) 
2009 influenza-attributable mortality rates per 100,000 for all causes and all ages 
by regions, 1994-2016. The pooled estimate of the seasonal influenza mortality 
rate was 13.9 per 100,000. Europe had the highest rate of seasonal influenza-
associated mortality (19.0 per 100,000), followed by America (12.1 per 100,000), 
New Zealand (10.6 per 100,000) and Asia (7.0 per 100,000). 
 
As with the seasonal influenza trend, Europe had the highest rate of modelled 
pandemic influenza deaths (13.1 per 100,000), followed by America with 9.9 per 
100,000. Asia had the lowest mortality rate for pandemic influenza with 2.9 per 
100,000. 
 
Figure 6. Comparison between modelled seasonal and pandemic 
(H1N1) 2009 influenza-attributable mortality rate (per 100,000) for 
all causes and all ages by regions (from 30 studies), 1994 -2016 
Note:  
-For seasonal influenza (from 22 papers): *USA, Canada, Argentina, Mexico and PAHO countries; **Spain, Denmark, 
Austria, Norway, Germany, Portugal; ***Hong Kong, Singapore, South Korea, Thailand, China 
Seasonal influenza rate was estimated by modelling  
-For pandemic influenza (from 8 papers): *Mexico, Argentina; ** Germany, Austria, France; *** Hong Kong, Bangladesh 





























Influenza deaths varied by type of influenza (seasonal or pandemic), age group, 
illness category and country. Across all illness categories the majority of seasonal 
influenza-associated deaths were in those aged 65 and older. This age group 
contributed annually between 89.7 deaths per 100,000 (Wu et al., 2012) and 167.8 
deaths per 100,000 (Chow et al., 2006). In contrast, the yearly average influenza 
associated mortality rates for all causes were negligible in children (less than 3 per 
100,000) across all countries (see Table 2).  
 
The pattern was more mixed for modelled pandemic (pH1N1) 2009 influenza 
deaths. The mortality rate was significantly higher for the elderly aged 65 years 
and above across all countries, except Germany and France where pandemic 
influenza deaths were predominant in young people (see Table 2). 
 
Influenza-attributable deaths included a large contribution from respiratory and 
circulatory illness. The influenza-associated mortality rate for cardiopulmonary 
illness was reported highest in Argentina with 21.4 per 100,000 (Azziz-
Baumgartner et al.) and lowest in New Zealand with 8.1 per 100,000 (Kessaram et 
al., 2014).  
 
There were few studies that specifically attempted to measure influenza mortality 
directly (over and above simply reporting the numbers of coded influenza deaths 
based on death certificates and coronial data). Impacts of seasonal influenza on 
death were measured directly by 5 retrospective studies in this review (Table 2). 
The rate of influenza-related pneumonia per 100,000 people varied by age group 
and vulnerable population (pregnant women, the elderly or children), but was 
41 
 
much lower than that estimated by modelling techniques. Rates range from 0.2 to 
8.0 per 100,000 (Bhat et al., 2005, Callaghan et al., 2010, Fleming et al., 2005b, 
Gil et al., 2006). 
 
2.4.3 Hospitalisations attributable to influenza 
36 studies of influenza hospitalisations were included in this review (Table 3). 
Among these, 27 articles (17 studies with modelling techniques and 10 studies 
with direct measurements) described the impact of seasonal influenza on 
hospitalisations. Nine studies (two with modelling and seven with population 
based surveillance) showed the contribution of pandemic (pH1N1) 2009 influenza 
to hospitalisations. One paper analysed the impact of both seasonal influenza and 
pandemic (pH1N1) 2009 influenza on hospitalisation. As with influenza 
mortality, most of these papers used modelling techniques to estimate the 
contribution of influenza to hospitalisations, especially those conducted in high 
income countries.  
 
Influenza-associated hospitalisation rates (per 100,000) for all causes were only 
estimated using modelling techniques in three papers with the highest rate in 
Australia (94.2 per 100,000), followed by the USA (63.5 per 100,000) and 
Finland (11.5 per 100,000) (Table 3 below). 
 
Various regression models (Poisson regression, negative binomial regression and 
generalised linear modelling) were applied to estimate seasonal influenza-
attributable hospitalisation rates (per 100,000) for P&I, respiratory illness and 
circulatory illness from six countries the USA, Australia, Hong Kong, Singapore, 
42 
 
Argentina and South Africa. The rate of influenza hospitalisation ranged from 
20.0 to 52.0 per 100,000 for P&I, from 60.6 to 94.2 for respiratory illness, from 
3.0 to 3.5 per 100,000 for circulatory illness and from 57.0 to 114.8 for both 










Period Method  Data source Age group 
Findings (95% CI, if available) (Influenza- associated hospitalisations rate per 100,000) 




1. DIRECT MEASUREMENT             
Seasonal influenza             



















     
 
























     
 
              
(Dawood et al., 
2010) 
USA 10 states 
covering 5.3 
million children 
under 18 years 




















     
 
              
(Tam et al., 
2014) 
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Findings (95% CI, if available) (Influenza- associated hospitalisations rate per 100,000) 




(Kim et al., 
2011) 





















    
 
 
              
(Tallo et al., 
2014) 


























(for 2009 only) 
 
   
 











All ages   40 (30, 40)    
 
(Hirve et al., 
2015) 

















































    0 (0,189) 
43 (12, 111) 
0 (0, 19) 
16 (7, 34) 
27 (6, 82) 
0 (0, 52) 
15 (9, 25) 
(for seasonal  
influenza A only) 
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Findings (95% CI, if available) (Influenza- associated hospitalisations rate per 100,000) 




(Feikin et al., 
2012) 

















    143.7 (119.6, 167.8) 
18.8(13.1, 24.4) 
55.2(41.2, 69.2) 
65.1 (44.9, 85.3) 
57.3 (38.6, 76.0) 
               
Pandemic 
influenza 
     
     
  
  



















      
 
89 (72, 149) 
62 (42, 111) 
178 (99, 363) 
76 (50, 176) 
92 (71, 143) 


































               
(Orsted et al., 
2013) 


























               
               
               
(Stein et al., 
2010) 
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Findings (95% CI, if available) (Influenza- associated hospitalisations rate per 100,000) 




               
               
(Van Kerkhove 




















     26.1      
 
 
 Chile      10.8        
 Argentina      34.1        
               
               




















      
 
0 
296 (191, 443) 
301 (224, 393) 
317 (262, 384) 
94 (59, 148) 
61 (23, 136) 
23 (0, 87) 
215 (188, 247) 
               
(Baggett et al., 
2012) 
Thailand 20 hopitals in 














All ages       
 
136 (127, 144) 
              
(Reyes et al., 
2010) 












All ages        7.1-8.8 
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2.MODELLING              













































































    
  151.0 (105.3, 659,6) 
38.8 (24.1, 213.2) 
16.8 ( 9.8, 58.4) 
65.6 (35.0, 270.0) 
309.1 (186.0, 1103.7) 
63.5 (37.5, 236.6) 
               
(Mullooly et 
al., 2007) 


















































≥65 2 553 (H1N1) 
39 247 (H3N2) 
11 312 (B) 
53 112 (Influenza total) 
    
            
(Goldstein et 
al., 2015) 













114.0 (93.2, 135) 
22.9 (12.8, 33.4) 
8.6 (6.1, 11.1) 
11.4 (10, 12.9) 
26.4 (21.6, 31.4) 
54.9 (44.7, 65.2) 
140.8 (115, 167) 
129.0 (79.2, 179) 
36.4 (21.6, 51.4) 
10.6 (7.5, 13.7) 
25.6 (21.3, 29.8) 
65.5 (54, 76.9) 
125.8 (105, 147) 
288.3 (244, 331) 
8.0 (-7.2, 22.9)  
-1.1 (-6.1, 4.0) 
0 (-1.3, 1.2) 
-2.9 (-6.1, 0.2) 
-19.9 (-36.1,-3.5) 
-40.2 (-81.2, 0.04) 
15.9 (-38.3, 71.3) 
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Findings (95% CI, if available) (Influenza- associated hospitalisations rate per 100,000) 








































             














34.2 (26.6, 41.7) 
30.1 (24.8, 35.5) 
5.5 (4.1, 7.0) 
0.7 (0.0, 1.3) 
2.1 (1.2,3.0) 
6.7 (5.9, 7.5) 
 
LTRis and PDs 
13.0(4.9, 20.9) 
3.8 (0.2, 7.5) 
- 
6.8 (2.7, 10.9) 







4.3 (1.0, 7.6) 
10.8 (4.6, 16.9) 
32.5 (26.6, 38.2) 
 
 
31.9 (26.2, 37.6) 
16.0 (13.1, 18.9) 
2.5 (1.9, 3.1) 
0.9 (0.1,1.8) 
2.1 (0.8,3.2) 
2.7 (1.5, 3.8) 
            
            
(Menec et al., 
2003) 































              
(Scuffham, 
2004) 

















            
(Beard et al., 
2006) 
Australia Children under 













 489 (473, 504) 
377 (363, 391) 
184 (165, 203) 
54 (37, 72) 
18 (1, 35) 
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Findings (95% CI, if available) (Influenza- associated hospitalisations rate per 100,000) 















































            














    15.2(15.0, 15.4) 
2.3 (2.3, 2.4) 
5.1 (5.0, 5.1) 
47.3 (47.1, 47.5) 
11.5 (11.5, 11.5) 
            
            
(Nguyen-Van-
Tam et al., 
2001) 
England People age 65 











175.8     
            
            
            
            
(Wong et al., 
2006) 













70.4 (56.5, 83.3) 
2.9 (1.7, 4.0) 
6.8 (3.9, 9.4) 
58.7 (43.3, 73.7) 
176.3 (119.2, 231.0) 
29.3 (25.8, 32.6) 
163.3(135.2, 189.7) 
6.0 (2.7, 8.9) 
14.9 (10.7, 18.8) 
83.8 (61.2, 104.2) 
266.0 (198.7, 330.2) 
60.6 (52.8, 67.2) 
(for acute respiratory illness) 
     1.6(-1.6, 4.7) 
16.2(0.0, 33.6) 
55.4 (23.1, 87.8) 
3.5 (1.4, 5.8) 
(for CBD) 
5.3(0.5, 9.5) 
10.1 (-10.1, 30.2) 
56.4 (21.1, 93.4)  
4.2 (1.2, 7.0) 
(for IHD) 
  






Period Method  Data source Age group 
Findings (95% CI, if available) (Influenza- associated hospitalisations rate per 100,000) 
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All ages 20 (7, 32)   57 (29, 85)  
            
(Feng et al., 
2014) 













All ages (0-14) 128 (29, 484) 218(61,679)    
(Kyeyagalire et 
al., 2014) 















241 (136, 340) 
78 (46, 108) 
27 (12, 42) 
20 (10, 30) 
40 (23, 56) 
85 (49, 115) 
255 (143, 358) 
205 (121, 282) 
55 (25, 84) 
37 (18, 55) 
70 (40, 98) 













Period Method  Data source Age group 
Findings (95% CI, if available) (Influenza- associated hospitalisations rate per 100,000) 




      ≥75 
All ages 
256 (153, 341) 
41 (22, 59) 
380 (227, 506) 
75 (41, 108) 
107 (51, 154) 
3 (2,5) 
  
            
Pandemic influenza           
          














    16.6 (14.6, 16.5) 
3.5 (3.4, 3.7) 
6.7 (6.6, 6.9) 
46.5 (45.8, 47.2) 
13.4 (13.2, 13.5) 
URTI: upper respiratory tract infection; LRTI: lower respiratory tract infection; PD: pulmonary disease; RD: Respiratory Disease 
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The pooled rate (per 100,000) of seasonal influenza-associated hospitalisation was 
46.5 (95% CI: 44.7, 48.3) for P&I; 84.9 (95% CI: 82.1, 87.7) for respiratory 
illness; 3.4 (95%CI: 1.9, 4.9) for circulatory illness; and 114.4 (95%CI: 110.6, 
118.2) both respiratory and circulatory illness combined (Figure 7). 
 
 
Figure 7. Pooled estimated rate of seasonal influenza-attributable 
hospitalisations for all ages by illness category, 1994 -2016  
Note: P&I: Pneumonia and Influenza 
        Error bar represents for one standard error above and below estimate. 
 
12 papers used modelling to estimate influenza hospitalisation by age group. As 
with mortality, there was a marked difference in seasonal influenza hospitalisation 
by age groups and illness categories. Elderly aged 65 years and above (especially 
those aged 75 years and over) had the highest rate of influenza-associated 
hospitalisations across all diseases (up to 309 per 100,000), followed by children 
under 5 years old. In contrast to mortality, seasonal influenza hospitalisation 



















































In 10 studies with population-based surveillance (direct measurement), the annual 
average rate of P&I hospitalisations attributable to influenza ranged from 138 per 
100,000 in Spain to 520 per 100,000 in South Korea. Influenza-associated 
hospitalisation for all causes was analysed in three sites in India (presented in two 
papers) with rates from 15 to 329 per 100,000 populations. Consistent with 
modelling estimates, direct measurements also found that older people and young 
children were the most vulnerable groups for influenza hospitalisation (Table 3). 
 
10 articles (eight papers with direct measurements and two papers using 
modelling) in this review analysed the contribution of pandemic (pH1N1) 2009 
influenza to hospitalisation by illness category. The pandemic influenza-
associated hospitalisation rates ranged from 10.8 to 102.6 per 100,000 for P&I 
and from 8.8 to 215 per 100,000 for all causes. Only one study, from Hong Kong, 
analysed the contribution of pandemic (pH1N1) 2009 influenza to hospitalisations 
for respiratory illness and circulatory illness with rates per 100,000 of 133.3 and 
17.0, respectively (Yang et al., 2012b). Unlike seasonal influenza, young people 
(especially children under 5 years old) had the highest rate of pandemic (pH1N1) 
2009 influenza-related hospitalisations (from 16.6 to 297 per 100,000). 
 
2.5 Discussion 
This review is the first to summarise estimates of the impact of influenza (both 
seasonal and pandemic) on deaths and hospitalisations. Several health outcomes 
(P&I, respiratory illness, circulatory illness, cardiopulmonary illness and all 





2.5.1 Main findings 
87% of articles included in this review were from high income countries, only 
13% of papers were from low and middle income countries. A small proportion 
(less than 25%) of studies on influenza burden covered Asia and Africa. Over 
70% of papers in this review described the impact of influenza-associated P&I, 
respiratory illness and all causes. The contribution of either circulatory illness or 
cardiopulmonary illness to influenza was analysed in about 30% of articles.  
 
The burden of influenza was substantial with high rates of mortality and 
hospitalisations. This review estimated the overall rate of seasonal influenza- 
attributable mortality for all ages and all causes to be 13.9 per 100,000, which was 
slightly higher than that estimated for pandemic (pH1N1) 2009 influenza at 12.1 
per 100,000. Studies for a single country in different regions found similar results 
(Muscatello et al., 2014b) (Lemaitre et al., 2012, Azziz-Baumgartner et al.). 
Estimated influenza mortality rates were variable among regions, data sources or 
methods used and geographical characteristics. Europe experienced the highest 
influenza mortality rate, followed by the Americas, New Zealand and Asia. 
Limited numbers of published studies from Asia (Simmerman and Uyeki, 2008) 
may have resulted in a lower pooled rate of influenza mortality in this region.  
 
In this review, the influenza-associated hospitalisation rate (per 100,000) for all 
causes ranged from 11.5 to 94.2 per 100,000. The pooled rate (per 100,000) of 
seasonal influenza-associated hospitalisation was 46.5 (95% CI: 44.7, 48.3) for 
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P&I, 84.9 (95% CI: 82.1, 87.7) for respiratory illness, 3.4 (95%CI: 1.9, 4.9) for 
circulatory illness and 114.4 (95%CI: 110.6, 118.2) for cardiopulmonary illness. 
 
This review found that circulatory illness made a marked contribution to influenza 
mortality with a rate up to 36.8 per 100,000. The burden of influenza in the 
elderly aged 65 years and over in this review was large and similar to the rate 
found for Latin America and the Caribbean (Savy et al., 2013).  
 
2.5.2 Methodological approaches: Modelling techniques (indirect 
measurements) or direct measurements? 
Studies included in this review used two methodological approaches: direct 
measurements (data based on clinical case definition usually with laboratory 
confirmation) and indirect measurements (applying modelling techniques to 
estimate the number of influenza-associated health outcomes across particular 
levels of the disease pyramid). 
 
Direct measurement used data from laboratory-confirmed cases. This basic 
detection method has high specificity but low sensitivity because it may not 
capture influenza cases in people across all conditions (e.g. circulatory illness) 
(Nicoll et al., 2012). This review found that the number of influenza cases 
reported in papers with direct measurement was markedly lower than in those 
using indirect measurement. For example, total New Zealand deaths from 
influenza-associated all medical illness over a 19-year period from 1990-2008 was 
modelled at 401per year. This total was almost 20 times higher than the average 
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number of coded influenza deaths in NZ over that same period (average 23 per 
year) (Kessaram et al., 2014). In Canada, the number of influenza attributable 
hospitalisations for respiratory illness from 2003-2009 was 6.4 times higher than 
indicated by routine coded data (J10 for influenza defined in ICD 10) (Schanzer et 
al., 2013a).  
 
Direct measurement is more practical to carry out in small areas/regions or in 
specific populations. In this review, target populations in papers using direct 
measurements were pregnant women (Callaghan et al., 2010); children (Dawood 
et al., 2010, Fleming et al., 2005b, Rebolledo et al., 2014); or the elderly (Gil et 
al., 2006). Some papers which included direct measurement were conducted in 
sub-national regions such as Ballabgarh and Vadu in India (Hirve et al., 2015, 
Chadha et al., 2013); rural Western Kenya (Feikin et al., 2012); New Haven 
County in the USA (Tam et al., 2014); or urban cities of the Philippines (Tallo et 
al., 2014). 
 
Statistical modelling techniques have been used to estimate the influenza burden 
(Nicoll et al., 2012) (Thompson et al., 2009). These methods can capture all 
influenza-attributable health outcomes (P&I, respiratory illness, circulatory 
illness, cardiopulmonary illness and all causes) (Nicoll et al., 2012). This review 
found that various models were used to estimate the burden of influenza such as 
Poisson regression modelling; negative binomial regression modelling; multiple 
linear modelling; generalised linear modelling; rate-difference; Serfling regression 
modelling; and autoregressive integrated moving average modelling (ARIMA). 
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Each model has its advantages and disadvantages. Model input data were weekly 
or monthly deaths, hospitalisations, and isolate virus counts. In this review, 
modelling techniques provided a pool rate of seasonal influenza-attributable all-
cause mortality of 13.9 per 100,000. Although modelling is generalisable, it still 
has limitations. Models may overestimate the numbers or rates of influenza 
(Nicoll et al., 2012). For example, many papers in this review did not include in 
model inputs respiratory syncytial virus (RSV) or other viruses such as rhinovirus 
or adenovirus, which can result in respiratory infection (Newall and Scuffham, 
2008, Muscatello et al., 2014a). Some confounders (for example, humidity and 
ambient temperature), with a substantial impact on influenza seasonality (Lowen 
and Steel, 2014), were not considered in models. Poisson regression modelling 
and negative binomial regression modelling are more accurate if they exclude 
proxy parameters of weekly or monthly virus fluctuations which are independent 
of the influenza virus (Newall and Scuffham, 2008). The accuracy of models is 
still under debate and requires validation (Gilca et al., 2009, Yang et al., 2011).   
 
2.5.3 Limitations 
This review, inevitably, has some limitations. First, the selection criteria were set 
to include only papers published in peer-reviewed literature. They excluded the 
large amount of information contained in routine influenza surveillance reports 
produced by many countries. This restriction was based on the need to restrict the 




Second, it was difficult to conduct meta-analysis for several outcomes because of 
large study heterogeneity which was not checked before pooling. The WHO has 
recommended the following standard age groups be used for influenza 
surveillance: under 2 years; 2-4 years; 5-14 years; 15-49 years; 50-64 years; and ≥ 
65 years (WHO, 2015). Heterogeneity of age strata in the studies prevented the 
author from estimating pooled rates of influenza by age group in this review. 
However, random effects models used in this chapter “allowed for heterogeneity 
within studies” (Borenstein, 2009). 
There was insufficient data on influenza-associated health outcomes (P&I, 
respiratory illness, circulatory illness, cardiopulmonary illness and all causes) and 
the variety of methodologies used in the many papers in this review means our 
analysis of the population health results remain incomplete. 
 
Third, two thirds of the papers in this review did not provide either number of 
influenza cases (used for numerator) or total population (used for denominator), 
hence, the pooled rates of influenza mortality and hospitalisations were not fully 
calculated. 
 
Fourth, although all studies with no restrictions on language, geography or 
national socio-economic status were included in this review, there were limited 
numbers of studies from Africa, Asia (only articles from South Asia, South East 
Asia and North East Asia were retrieved) and the Pacific region (only papers from 
Australia and New Zealand were found).  
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2.5.4 Further research  
Influenza hospitalisations and deaths reported by prospective studies are markedly 
lower than those estimated with modelling techniques. Further studies are 
necessary to refine and validate modelling for estimating the incidence and 
distribution of these influenza outcomes. 
 
The association between respiratory virus infections and the appearance of clinical 
symptoms is still sparsely studied. PCR has been recognized as more precise and 
rapid than conventional methods of detecting viruses in non-symptomatic 
infections (Jartti et al., 2008). A combination of PCR and serology tests can 
provide more accurate results for diagnosis (Zhang et al., 2011). In recent years 
new molecular testing techniques have become increasingly popular for detecting 
respiratory viruses in asymptomatic people (Advani et al., 2012). 
 
2.6 Conclusion 
Influenza has a large impact on population health, including deaths and hospital 
admissions. Its contribution to both mortality and hospitalisation has been 
described frequently. Modelling appears to be a potential method to estimate the 
impact of influenza on hospitalisation and mortality. 
 
2.7 Summary of this chapter’s contribution to the thesis as a whole  
The literature review shows that the burden of influenza has been poorly 
measured because of a lack of indicative signs or laboratory tests. Influenza 
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burden is often estimated by observational studies and modelling techniques. The 
majority of research summarised here (over 80%) was conducted in high income 
countries and focused on exploring the contribution of influenza to deaths and 
hospitalisations. The pooled rate of influenza-associated mortality was 13.9 per 
100,000 for seasonal influenza and 12.1 per 100,000 for pandemic influenza. 
Because of a large heterogeneity of age strata, the pooled rate of influenza-
associated hospitalisation was not calculated. This literature review provided 
evidence for the use of modelling techniques to estimate the health burden of 
influenza throughout the thesis and the need to validate modelling with direct 
measurement/observation. 
 




Chapter Three: Hospitalisation data 
selection 
 
3.1 Chapter goal 
This study used weekly hospitalisations obtained from the National Minimum 
Dataset of New Zealand and weekly counts of isolates of influenza A (H1N1, 
H3N2 and A not- subtyped) and influenza B and respiratory syncytial virus (RSV) 
from the virology weekly report of the Institute of Environmental Science & 
Research (ESR). 
 
This chapter focuses on describing various sources of hospitalisation data and 
how they were selected for model inputs. This project used a 50 week-year dataset 
for modelling instead of a range of 52 to 53 weeks per annum like some studies. It 
also removed years dominated by the recent H1N1 influenza pandemic (2009 and 
2010). After the pandemic (2011) and the start of the SHIVERS project started in 
2012, the number of influenza virus tests increased dramatically. These changes 
had the potential to affect the model’s output in unexpected ways (see details in 






3.2 Hospitalisation data selection 
3.2.1 Observed hospitalisations 
Observed hospitalisations (modelling input data) in New Zealand were extracted 
from the National Minimum Dataset (NMDS), a national data collection managed 
by the New Zealand Ministry of Health. The dataset includes information on all 
publicly funded hospital discharges in New Zealand, as well as most private 
hospital discharges (which include very few acute admissions and which are 
routinely excluded from studies of acute illnesses such as those caused by 
influenza) (MOH, 2015). 
 
Data were obtained based on the admission date of patients. Private hospital 
admissions, transfers, waiting list cases, day cases, overseas visitors, and 
readmissions were filtered out from the selected hospitalisations. 
 
Extracted information consisted of weekly numbers of hospitalisations by sex 
(male, female), ethnicity (Māori, Pacific and European/Others) and age group (all 
ages; under 1; 1-4; 5-19; 20-34; 35-49; 50-64; 65-79; 80+).  
 
This modelling used principal diagnosis to allocate the events into the diagnostic 
categories listed below. The NMDS uses the Australian Coding Standards (ACS)  
to assign the principal diagnosis, which is defined as the diagnosis determined 
after discharge to be chiefly responsible for occasioning an episode of admitted 
patient care, an episode of residential care or attendance at the healthcare 




Codes for principal diagnosis were based on the International Classification of 
Diseases (ICD) 9
th
 Revision (ICD-9) (to July 1999) and 10
th
 Revision (ICD-10).  
In New Zealand, clinical coders who undergo some training and obtain 
qualications of clinical coding are responsible for coding discharge diagnosis. The 
major diagnostic categories used were: influenza and pneumonia (J09-J18, 480-
488); respiratory illness (J00-J99, 460-519); circulatory illness (I00-I99,380-459); 
medical illness (A00-N99, R00-R99, 001-629, 680-739, 780-799); and all causes 
(including childbirth, perinatal, congenital, injury) (A00-Y99, 001-999) (see 
Figure 8 below). “Pneumonia and influenza” (P&I) hospitalisation is a subset of 
respiratory illness. Both respiratory illness and circulatory illness are a subset of 










Figure 8. Illness categories of hospitalisations  





hospitalisations in each 
category  
Medical illness 
 (A00-N99, R00-R99, 001-






 (J00-J99, 460-519) 
 Circulatory  
(I00-I99, 380-
459) 
All causes  
(including childbirth, 




3.2.2 Data selection process 
Recorded hospitalisations for the period 1989-2013 were included. A selection 
procedure was used to identify the optimal input dataset for modelling, as 
described below. 
 
Removal of the first five years 
Weekly hospitalisations (for respiratory illness) in the first five years (1989-1994) 
were removed as hospitalisations were much less frequent than in the period 
1995-2013. 
 
Figure 9 shows coded respiratory illness and influenza hospitalisation from the 
NMDS, and the number of influenza virus isolates by year in New Zealand over 
the 20 years from 1994-2013. The number of respiratory illness (including 
influenza) and influenza virus isolates increased dramatically following the 
pandemic in 2009. These numbers were still within a peak when the SHIVERS 




Figure 9. Observed respiratory illness and influenza 
hospitalisations, and influenza virus isolates by year, New Zealand 
1994-2013 
Note: SHIVERS stands for Southern Hemisphere Influenza and Vaccine Effectiveness Research and Surveillance  
 
Model approaches for selecting data 
A Poisson regression model was applied to weekly hospitalisations in the period 
1994-2003 to test the eligibility of the dataset. A dispersion parameter was used as 
a measure of model fit. For Poisson models this is equivalent to the Akaike 
information criterion (Goldstein, 2017). 
 
When the model was applied to the whole data for the period 1994-2013 (52 
weeks per annum) the annual mean estimated number of influenza-associated 
hospitalisations for respiratory illness was 509.5, with a dispersion parameter of 
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of consecutive years. These troughs are week 1 and week 52 of the year (Figure 
10 below). 
Figure 10 also shows that while week 1 and week 52 (Christmas and New Year 
time and summer time in New Zealand) had the lowest hospitalisations, weeks 27-
34 (winter time in New Zealand) had the highest respiratory hospitalisation across 
all years. Minimum numbers of observed respiratory admissions correspond with 
the troughs in the graph. To prevent outliers the hospitalisation modelling 
removed the two lowest points of data, the two week period covering Christmas 
and New Year. 
 Note: w stands for week 
Dataset Mean Dispersion parameter 
Whole dataset 1994-2013 
- 52 weeks/year 
- 20 years 
509.5332 12.70919 
Figure 10. Observed hospitalisations and modelled hospitalisation 
(with and without virus) by year, New Zealand, 1994-2013 
 
This model, was then applied to 50 week years of hospitalisation data. The 



















































































































































Estimated hospitalisations with virus counts set to zero
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shows that the numbers of influenza hospitalisations estimated by the model (red 
line) were extraordinarily high after 2009. This was a pandemic year (Figure 11). 
Thus, the outlying period of 2009 onwards was excluded. 
Note: w stands for week 
Dataset Mean Dispersion parameter 
Whole dataset 1994-2013 
- 50 weeks/year 
- 20 years 
504.076 10.24428 
Figure 11. Observed hospitalisations and modelled hospitalisation 
(with and without virus) by year, New Zealand, 1994-2013 with 
removal of Christmas and New Year weeks 
 
The new dataset consisted of 15 years from 1994-2008. A model for a 50-week 
year dataset was applied for the period 1994- 2008. This model analysis found the 
highest average estimate of influenza-associated hospitalisation for respiratory 
illness (845 per year) and the lowest dispersion parameter (8.2). Estimated 
numbers fit to observed hospitalisations graphed across all years (Figure 12). 
Consequently, the 50-week year of observed hospitalisations over the 15 years 





















































































































































Estimated hospitalisations with virus counts set to zero
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Note: w stands for week 
Dataset Mean Dispersion parameter 
Whole dataset 1994-2008 
- 50 weeks/year 
- 15 years 
1390.23 8.202001 
Figure 12. Observed hospitalisations and modelled hospitalisation 
(with and without virus) by year, New Zealand, 1994-2008 with 
Christmas and New Year weeks removed 
 
3.2.3 Time lag  
As in other infectious diseases, influenza has an incubation period between virus 
infection and disease appearance (CDC, 2016). The incubation period lasts from 
one to four days for influenza A, up to six days for influenza B, and over four 
days for RSV (Lessler et al., 2009); and may affect influenza-associated 
hospitalisations (Upshur et al., 1999). A study in three English districts also 
indicated a lag of 1-2 weeks in influenza associated deaths and hospitalisations 



















































































































































Estimated hospitalisations with virus counts set to zero
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Kong-based study, lag time was taken into account by estimating influenza at 
different times from week 0-3 preceding the health outcome (Wong et al., 2006). 
 
The time lag was tested to explore if there was any relation between influenza 
virus circulation and hospital admission. 
 
Table 4 below describes modelled hospitalisations of influenza-associated 
respiratory illness by different time lags including no lag, lag from one week, two 
weeks, three weeks and four weeks. The estimated annual average number of 
respiratory hospitalisations attributable to influenza was highest at the admission 
time (without lag) and gradually decreased when the time lag increased (from one 
week to four weeks). The best dispersion parameter was for the model with no 
time lag.  
Table 4. Estimates of number of influenza-associated respiratory illness 
hospitalisations by time lag 
 No lag Lag 1 week Lag 2 weeks Lag 3 weeks Lag 4 weeks 
Mean 1861.3 1835.3 1801.1 1789.4 1768.5 
Dispersion 
parameter 





3.3 Summary of this chapter’s contribution to the thesis as a whole 
This chapter introduced a procedure for selecting hospitalisation data as inputs for 
our model. It provided a rationale for using a model with a 50-week year dataset 
in New Zealand where Christmas and New Year weeks coincide with summer 
time instead of using a 52 or 53 week year (the average number of weeks per 
annum) dataset like other studies. This approach also gave the best fitting models 
described in Chapter Four. 
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Chapter Four: Impact of influenza 
on hospitalisations in New Zealand 
 
4.1 Chapter goal 
The goal of this chapter is to introduce in detail how influenza contributes to 
hospitalisations in New Zealand. The findings in this chapter were presented in 
the paper “Estimating the contribution of influenza to hospitalisations in New 
Zealand from 1994-2008” published in the journal Vaccine (Khieu et al., 2015).  
 
The full paper can be found in the Appendix Two and on the website 
http://www.sciencedirect.com/science/article/pii/S0264410X15008956 and forms 
the bulk of this chapter. 
 
Building on the data described in Chapter Three, in this paper, a negative 
binomial regression model was used for the first time to estimate the total impact 
of influenza on hospitalisations for all ages and ethnic groups in New Zealand 
over the pre-pandemic period of 1994- 2008. The paper was prepared to address 
the research question “What are the impacts of influenza on hospitalisation?”  
 
The study found that the contribution of influenza to hospitalisations in New 
Zealand was 2,419.9 per year (95%CI: 2356.4, 2483.4), which is much higher 
than indicated by coded discharge data. Respiratory illness was the major 
contributor to influenza hospitalisations. Estimated influenza hospitalisation rates 
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(per 100,000) were markedly highest among Māori and Pacific people, elderly 
and infants under one year. The findings could provide useful input into decisions 
about vaccination policy and would increase the estimated cost-effectiveness of 
interventions for the most vulnerable groups. 
 
4.2 Introduction 
Influenza virus is responsible for an important proportion of the global burden of 
diseases (Wu et al., 2012, Mullooly et al., 2007). In New Zealand, respiratory 
infections (including influenza) are the largest component of infectious disease 
hospitalisations, accounting for 38.5% of acute infectious disease hospitalisations 
and 9.5% of all acute admissions over the 1989-2008 period (Baker et al., 2012). 
Although influenza is a common respiratory infection, it is not systemically tested 
for when patients are hospitalised, even for respiratory illnesses. The lack of 
laboratory results, indicative signs or supporting symptoms and ambiguous 
aetiology (Zambon, 2011, Shubin et al., 2013, Galante et al., 2012, Yang et al., 
2012b) mean many cases are not identified. 
 
Much of the disease burden is thought to come from triggering respiratory or 
circulatory events (notably myocardial infarctions and strokes) (Warren-Gash et 
al., 2009) or other medical events (Toovey, 2008) where an influenza diagnosis is 
not suspected or investigated. Consequently, the recorded contribution of 
influenza to hospitalisations is likely to greatly underestimate the true burden of 




In a number of international studies, statistical methods such as Poisson or 
negative binomial regression modelling have been applied to fill in the anticipated 
gaps and estimate hospitalisation attributable to influenza (Nicoll et al., 2012, 
Yang et al., 2012b, Thompson et al., 2004). The reported rates vary by population, 
place and year of study. For example in Australia, from 1997-2004 the average 
annual rate of admission for influenza associated respiratory illness was highest 
with 444.1 per 100,000 in those 85 years of age and older and lowest in children 
5-14 years old at -1.2 per 100,000 (Newall and Scuffham, 2008). This present 
study thus seeks to estimate the total impact of influenza on hospitalisations for all 




4.3.1 Data sources 
As described in Chapter Three, weekly counts of hospitalisations were obtained 
from the national hospitalisation dataset for the 15 year period from 1994-2008. 
Influenza hospitalisations were broadly categorised based on the International 
Classification of Diseases (ICD) 9
th
 Revision (ICD-9) (until July 1999) and the 
10
th
 Revision (ICD-10) as P&I (J09-J18, 480-488); respiratory (J00-J99, 460-
519); circulatory (I00-I99,380-459); medical illness (A00-N99, R00-R99, 001-
629,   680-739, 780-799); and all causes (all ICD codes) (A00-Y99, 001-999). 
Thus, “P&I” hospitalisation is a subset of respiratory illness and both respiratory 
and circulatory illnesses are subsets of medical illness. The analysis was limited to 
principal causes of hospitalisation which were defined as the diagnosis code 
assigned after discharge as chiefly responsible for occasioning an episode of 
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admitted patient care, an episode of residential care or attendance at the healthcare 
establishment. Hospitalisation age was disaggregated into nine groups (all ages; 
under 1; 1-4; 5-19; 20-34; 35-49; 50- 64; 65-79; 80+). Ethnicity was classified 
into three groups (Māori, Pacific and European/Others) using prioritised ethnicity. 
Statistics New Zealand explains that “Prioritisation is a classification which 
assigns the ethnicity of a person who has given multiple responses to just one 
ethnicity” (Statistics New Zealand, 2006).  
 
This analysis interpolated and extrapolated population counts for every week in 
the study period from the New Zealand Census of Population and Dwellings 
(Statistics New Zealand) population data for 1996, 2001, 2006 and 2013. 
 
Weekly counts of isolates of influenza A (H1N1, H3N2 and A not- subtyped) and 
influenza B and respiratory syncytial virus (RSV) from the virology weekly report 
of the Institute of Environmental Science & Research (ESR) for the period 1994-
2008 were used. The four regional laboratories (Auckland, Waikato, Wellington 
and Christchurch) and the WHO National Influenza Centre at ESR virology 
laboratory conduct influenza and other virus surveillance in New Zealand. These 
laboratories report nationwide inpatient and outpatient virus diagnoses (including 
influenza A and B, and RSV) to ESR. Like influenza, RSV infections are hard to 
detect due to a lack of specific symptoms and insufficient information in the 
medical record (Zhou et al., 2012, Newall et al., 2008). The Southern Hemisphere 
Influenza and Vaccine Effectiveness Research and Surveillance (SHIVERS) has 
found that RSV contributes up to about one third of influenza-like illnesses in 
75 
 
New Zealand (ESR, 2017). RSV was added as a model input to prevent 
confounding with influenza hospitalisations (Newall and Scuffham, 2008).  
 
4.3.2 Statistical methods 
For each cause of hospitalisation category (influenza and pneumonia, respiratory, 
circulatory; all medical and all causes), age grouping (all ages; under 1; 1-4; 5-19; 
20-34; 35-49; 50-64; 65-79; 80+) and ethnic grouping (Māori, Pacific, 
European/Others), negative regression models were applied to estimate influenza 
related hospitalisations. All statistical analysis was carried out with R software 
version 3.1.0. 
 
The hospital dataset has annual outlying low points during Christmas and New 
Year which coincide with New Zealand summer holidays. Hence, the two weeks 
around Christmas and New Year were excluded and the models were run on a 50-
week year. 
 
A simple initial model was run based on that used in the USA and Australia 
(Newall and Scuffham, 2008, Thompson et al., 2004) with the predicted number 
of hospitalisations per week estimated as: 
 
The simple model 









As the data contains only positive tests for influenza and RSV this study 
developed a comprehensive model which allowed for the possibility of increased 
testing by adding an interaction term for year separately with each virus type.  
 
The comprehensive model: 




) + β4[sin(2tiπ/50)] +β5[cos(2tiπ/50)]+ 
β6[A] + β7[B]+ β8[RSV] + β9[A]*year + β10[B]* year+ β11[RSV]* year 
 
In this subscript i is the week number; Yi is the output of the modelling process for 
that week (predicted hospitalisations count); and ti represents the number of weeks 
since the start of the modelling period. For the estimated regression parameters, 




) represents for the nonlinear time 
trends. β4[sin(2tiπ/50)] and β5[cos(2tiπ/50)] are proxy parameters of weekly 
fluctuations of the virus. β6[A] and β7[B] are the weekly influenza A and B counts, 
respectively; and β8[RSV] is the weekly RSV counts. β9[A]*year,  β10[B]* year 
and β11[RSV]* year allow for changes in the number of virus tests by year. 
 
The estimated number of influenza-related hospital admissions was calculated as 
the discrepancy between the number estimated by the model and the number 
estimated by the model if virus counts were set to zero. The results were expressed 
as hospitalisation numbers or hospitalisation rates per 100,000 populations. The 
annual mean numbers of influenza related hospitalisations and rates per 100,000 





The estimated annual average number of hospitalisations attributable to influenza 
for pneumonia and influenza (P&I) and respiratory illness were 743.8 (95% CI: 
737.8, 749.8) and 1679.2 (95% CI: 1663.1, 1695.3), and 822.1(95% CI: 815.3, 
828.9) and 1861.3 (95% CI: 1842.9, 1879.7) for the simple and the 
comprehensive model, respectively. The estimated average rates per 100,000 
people for P&I and respiratory illness respectively were 19.2 and 43.3 for the 
simple model and 21.2 and 48.0 for the comprehensive model. The numbers and 
rates estimated with the comprehensive model were consistently higher than for 
the simple one (Table 5).  
 
Hospitalisations varied by study year. 1996 had the highest estimated number of 
influenza-associated hospitalisations, followed by 1997 and 2003. These estimates 
of P&I and respiratory influenza-related hospital admissions in the period 1994-
2008 were 2.8 and 6.6 (for the comprehensive model) times higher than the 





Table 5. Comparison of observed influenza hospitalisations and negative 
binomial regression model (simple and comprehensive) estimates of influenza 
associated hospitalisations for pneumonia and influenza, and respiratory 






Simple model Comprehensive model 
No. of  
estimated 
P&I hosps. 





No. of  
estimated P&I 
hosps. 




1994 195 517.4 1216.8 884.0 2094.0 
1995 195 495.7 1026.6 1085.4 2192.7 
1996 410 860.9 2026.5 1321.2 3137.9 
1997 201 723.6 1566.6 1270.0 2692.0 
1998 220 548.9 1292.6 748.9 1782.2 
1999 421 862.9 1979.6 1167.9 2674.9 
2000 164 262.4 594.3 337.2 760.3 
2001 251 658.0 1461.6 801.8 1766.0 
2002 328 736.5 1673.0 793.2 1803.4 
2003 400 1164.9 2744.4 1097.1 2627.4 
2004 297 1000.7 2325.1 864.6 2037.3 
2005 247 714.5 1415.6 552.1 1070.8 
2006 311 852.7 2006.9 587.2 1414.1 
2007 246 784.9 1792.6 451.8 1059.8 
















7.2 19.2 43.3 21.2 48.0 
P&I: Pneumonia and influenza 
95% CI: 95% confidence interval 
Hosps.: Hospitalisations 
 
Figure 13 illustrates the yearly influenza virus isolates (influenza A and influenza 
B) from virology weekly reports by the Institute of Environmental Science & 
Research Limited (ESR); the weekly number of respiratory admissions; and 
estimates of influenza-related respiratory illness hospitalisation (by simple and 




Influenza A virus was dominant in 12 seasons 1994, 1996, 1998, 1999, 2000, 
2001, 2002, 2003, 2004, 2006 and 2007. In contrast, influenza B was a minor 
component in the period 1994-2008, except in 1995, 2005 and 2008. 
 
Hospitalisations (both observed and estimated numbers) and virus isolates 
differed by week and reached a peak in winter each year (for the 15 years 
modelled, peaks were in July in 9 years, in August in 5 years and in June in 1 
year). The estimated number of influenza-associated respiratory hospitalisations 
was relatively high (for both simple and comprehensive models) in 1996, 1999, 
2003 and 2004. These years also recorded greater numbers of influenza isolates 







Figure 13. Yearly counts of influenza isolates and weekly number 
of observed respiratory illness hospitalisations and estimated 
number of influenza associated respiratory illness hospitalisations, 
New Zealand 1994-2008  
 
Based on other major disease categories, the estimated annual mean numbers of 
hospitalisations attributable to influenza (by comprehensive model) were 12.1 
(95%CI: 2.6, 21.6); 2260 (95% CI: 2212.2, 2307.8); and 2419.9 (95% CI: 2356.4, 

















































































































1994 1995  1996  1997  1998  1999  2000  2001   2002    2003   2004  2005  2006  2007 2008  
Number of observed of respiratory illness hospitalisations
Estimated number of influenza associated respiratory illness hospitalisations by simple model

































No. of Influenza A isolates
No. of Influenza B isolates
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Table 6. Negative binomial regression model estimates for circulatory, all 
medical illness and all causes for all ages, annual averages, New Zealand 
1994-2008 
Illness categories  Simple model Comprehensive model 
Influenza associated P&I hospitalisations 743.8 (737.8, 749.8) 822.1 (815.3,  828.5) 
Influenza associated respiratory 
hospitalisations 
1679.2 (1663.1, 1695.3) 1861.3 (1842.9, 1879.7) 
Influenza associated circulatory 
hospitalisations 
-44.6  (-52.7,-36.5) 12.1 (2.6, 21.6) 
Influenza associated all medical 
hospitalisations 
1645.2 (1612.3,1678.1) 2260.0 (2212.2, 2307.8) 
Influenza associated all causes 
hospitalisations 
1398.2 (1340.8,1455.6) 2419.9 (2356.4, 2483.4) 
P&I: Pneumonia and influenza 
 
Table 7 summarises hospitalisation numbers and rates per 100,000 people by age 
group and disease category, using the comprehensive model. The estimated rate of 
influenza-associated hospitalisations for all causes and all ages was 62.4 per 
100,000. For respiratory illness the estimate was 48.0 per 100,000 people and for 
P&I, 21.2 per 100,000 people. The estimated contribution of influenza to 
circulatory illness hospitalisations was negligible. 
 
New Zealanders 80 years of age and older had the highest rates of influenza-
related hospital admissions across all disease categories, with a rate of 327.8 per 
100,000 people for the all-cause category. Rates were also relatively high for 
infants under 1 year, children aged from 1 to 4 years and those 65 to 79 years of 
age (Table 7). The greatest absolute number of estimated hospitalisations was in 




Table 7. Negative binomial regression model (comprehensive) estimates for 
average annual number and rate (per 100,000 people) of hospitalisations 
attributable to influenza by age group and disease categories, New Zealand 
1994-2008 
Categories Age group 
<1 1-4 5-19 20-34 35-49 50- 64 65-79 ≥80 All ages 
P&I                   
       Number 67.0 147.8 88.7 71.0 63.1 92.6 147.1 144.8 822.1 
       Rate 122.7 69.5 10.3 9.0 7.4 15.1 40.6 121.8 21.2 
Respiratory 
illness 
                  
       Number 90.9 169.7 126.0 173.4 153.8 289.4 532.6 325.4 1861.3 
       Rate 166.4 79.8 14.7 21.8 18.0 47.1 147.2 273.7 48.0 
Circulatory 
illness 
                  
       Number 1.0 -1.0 -3.4 -7.7 7.5 -1.7 -3.5 20.9 12.1 
       Rate 1.9 -0.5 -0.4 -1.0 0.9 -0.3 -1.0 17.6 0.3 
All medical 
illness 
                  
      Number 116.4 355.6 211.7 194.7 139.0 318.9 542.0 381.8 2260.0 
      Rate 213.1 167.3 24.7 24.5 16.3 51.9 149.8 321.2 58.3 
All causes                   
      Number 133.6 342.6 135.3 415.4 134.0 326.9 542.5 389.7 2419.9 
      Rate 244.5 161.1 15.8 52.3 15.7 53.2 149.9 327.8 62.4 
P&I: Pneumonia and influenza 
 
When analysed by major ethnic group (Table 8), Māori and Pacific people had 
markedly higher estimated hospitalisation rates across all disease categories 
(excluding circulatory illness where rates were negligible across all groups). The 
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estimated average annual rate per 100,000 people was 80.0 for Māori, 83.3 for 
Pacific and 58.1 for European/Others in the all cause category. 
 
Table 8. Negative binomial regression model estimates for average annual 
number and rate (per 100,000 people) of hospitalisations attributable to 




Māori Pacific European/Others 
P&I        
       Number 174.4 98.5 549.2 
       Rate 32.9 47.0 17.5 
Respiratory illness     
       Number 333.1 156.5 1371.0 
       Rate 62.9 74.6 43.7 
Circulatory illness     
       Number 2.5 -0.3 9.8 
       Rate 0.5 -0.1 0.3 
All medical illness     
      Number 378.6 147.8 1733.6 
      Rate 71.5 70.5 55.3 
All causes     
      Number 423.7 174.8 1821.4 
      Rate 80.0 83.3 58.1 





This study presents the first modelled estimate of the contribution of influenza to 
hospitalisation in New Zealand. It is also the first published estimate we are aware 
of that presents estimates for specific ethnic groups. Like other modelling studies 
from Australia, Canada and the USA (Menec et al., 2003, Newall and Scuffham, 
2008, Thompson et al., 2004), this research shows that influenza makes an 
important contribution to hospitalisations that is much larger than is apparent from 
routinely reported discharge data. This study found annual mean numbers of 
influenza-associated admissions of 1861.3 for respiratory illness, 2260 for all 
medical illness and 2419.9 for all causes compared with 278.9 observed. Based on 
these results, influenza was associated with 5.2% of all acute respiratory 
hospitalisations, 1.1% of all medical illness hospitalisations and 0.8% of all causes 
hospitalisations. Influenza associated respiratory admissions accounted for 77% of 
all causes admissions. 
 
The estimated annual average admission rates per 100,000 for P&I and all causes 
in this study were generally smaller than those reported for Australia, the USA 
and Hong Kong (Zhou et al., 2012, Thompson et al., 2004, Newall and Scuffham, 
2008, Yap et al., 2004).  For example, in Australia, using a similar model, the 
estimated hospitalisation rates per 100,000 people for all ages were 42.1 and 94.2 
for P&I and all causes, respectively (Newall and Scuffham, 2008) (compared with 
21.2 and 62.4 for the same categories in New Zealand). Similarly, studies in the 
USA and Hong Kong found higher rates (52/100,000 people and 85/100,000 
people for P&I in the USA and Hong Kong, respectively) compared with New 
Zealand (21.2/100.000 people) (Zhou et al., 2012, Thompson et al., 2004). These 
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differences may be partly explained by variations in modelling approaches. This 
study used weekly data instead of monthly data as inputs for the models (Newall 
and Scuffham, 2008, Thompson et al., 2004). Moreover, some countries excluded 
a term for RSV which has been found to significantly contribute to influenza-like 
illness in New Zealand in the models (Thompson et al., 2004) or applied different 
ICD-9 codes for respiratory and circulatory hospitalisations (i.e. for this category 
of illness the US studies used ICD-9 codes 390-519 compared with ICD-9 codes 
380-519 in this study) (Zhou et al., 2012, Thompson et al., 2004), or used small 
datasets for the modelling (Yap et al., 2004). However, the estimated admission 
rate for influenza-related all causes (62.4/100,000) in this study is similar to the 
USA (63.5/100,000) that also used a negative binomial regression model for a 
similar time period (1993-2008) (Zhou et al., 2012). 
 
This New Zealand study found influenza made a negligible contribution to 
circulatory hospitalizations, with a rate of 12.1/100,000 people for the 
comprehensive model. Studies in the Netherlands and the USA reached similar 
conclusions (Mullooly et al., 2007, Baltussen et al., 1998). However, these 
findings differed from Hong Kong where they estimated influenza associated 
admission for heart failure to be about 65/100,000 people over 65 years old in 4 
years (Yap et al., 2004). This divergence might be because the Hong Kong study 
was carried out in a single hospital over a short time period, and findings might 
therefore not reflect the real or long-term association between influenza and 




As expected, these modelled estimates of influenza hospitalisation varied 
markedly by age group. In New Zealand, the estimated yearly average rate per 
100,000 people of influenza- associated admissions was highest in the elderly, 
especially in those 80 years of age and older. Studies from Australia, the USA, 
Canada, Switzerland and England had the same findings (Thompson et al., 2004, 
Scuffham, 2004, Nguyen-Van-Tam et al., 2001, Newall and Scuffham, 2008, 
Menec et al., 2003). Furthermore, this study also showed substantial rates of 
influenza hospitalisations in children under 5 years old (244.5 per 100,000 for 
infants and 161.1 per 100,000 for children from 1 to 4 years old). This finding 
(178.1 per 100,000 for children when combining the two above age group) is 
again consistent with the Australian analysis (105.8 per 100,000 for children 
below 5 years of age which had the second highest rate of influenza-related 
hospitalisations in Australia, just behind the elderly) (Newall and Scuffham, 
2008).  
 
The findings of high hospitalisation rates in Māori and Pacific people compared 
with the European/Others population are novel for the field of influenza 
modelling, but not unexpected. Other research in New Zealand has found similar 
disparities for influenza hospitalisation and mortality (Baker et al., 2012). Māori 
and Pacific people experience higher rates of hospitalisation for serious infectious 
diseases generally as well as respiratory illness (including influenza) in particular 
(Baker et al., 2012b, Verrall et al., 2010). This finding is consistent with patterns 
seen for influenza internationally where rates are typically higher for indigenous 
peoples (Groom et al., 2014, La Ruche et al., 2009). For instance, in the USA, the 
Arizona and other indigenous American people had an influenza hospitalisation 
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rate 4.1 times higher than non-indigenous people. In Australia, Aborigines and 
Torres Straits Islanders’ rates were 7.7 times higher than the non-aboriginal 
population for hospital admission due to pandemic H1N1 influenza. Similarly, 
Canadian indigenous people had influenza hospitalisation and death rates that 
were 5.7 and 3.4 times respectively higher than non-indigenous people (La Ruche 
et al., 2009). 
 
This first estimate of the contribution of influenza to hospitalisation in New 
Zealand provides additional evidence on the burden of influenza in New Zealand 
and its health and economic impact. Moreover, it implies a need for greater 
prevention efforts for population groups where rates and impact are particularly 
high: young children, the elderly, Māori and Pacific peoples. The findings will 
also be useful for future studies on the cost-effectiveness of vaccination for 
vulnerable groups.  
 
These modelled estimates for hospitalisation have important similarities and 
differences to New Zealand estimates for influenza mortality (Kessaram et al., 
2014). Influenza mortality is obviously a rarer event than hospitalisation, with an 
estimated 401 influenza deaths a year over the 1990-2008 period. As with 
hospitalisations, mortality records markedly underestimate the contribution of 
influenza to mortality (by a factor of 17). Unlike hospitalisations, influenza 
fatalities are uncommon in younger people with 86% of deaths occurring in those 
65 years and over. Influenza mortality peaked in similar years to hospitalisations 
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(1996, 1999, 2003, 2004, 2006), which were all years where influenza A(H3N2) 
was the dominant circulating subtype (Kessaram et al., 2014) .  
 
A strength of this study is that it can draw on complete national datasets for model 
inputs. Virtually all acute illnesses and injuries are treated in public hospitals and 
therefore covered by national hospitalisation data. Also, unlike some previous 
studies applying the same modelling this research used weekly hospitalisation 
data and has therefore been able to provide more reliable and accurate estimates. 
This study included both simple and comprehensive negative regression models. 
The comprehensive model had a higher estimated value, smaller dispersion 
parameters and a more significant p-value indicating it was the best fit to estimate 
the hospitalisation burden in New Zealand. 
 
However, this study had several limitations. The biggest gap was the lack of 
information on total specimens tested and the number of laboratory tests with 
negative results. Besides that, using positive specimens has also prevented us 
from fully assessing the impact of increased testing rates and sensitivity when the 
testing method changed from viral isolation to molecular detection in a given 
period or overtime.  
 
Second, sub-types of influenza A (H1N1, H3N2 and A not-subtyped) were not 
used in the modelling. Therefore, we cannot estimate which virus contributes 
most to influenza hospitalisation. A Hong Kong study found that sub-type 
influenza A (H3N2) made the largest contribution to influenza hospitalisation, 
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four times more than influenza B and 10 times more than seasonal influenza A 
(H1N1) (Yang et al., 2012b).   
 
Third, like other studies using Poisson or negative regression models, 
β4[sin(2tiπ/50)] and β5[cos(2tiπ/50)] - the proxy parameters of weekly virus 
fluctuations - are independent from the influenza virus. The estimates would be 
higher if the model did not use these input parameters. 
 
Lastly, this modelling approach for an indirect estimation of hospitalisations 
attributable to influenza requires further validation regarding its accuracy and 
validity. 
 
Future steps will include validating the model by comparison with direct 
measurements of hospital admission for influenza from the SHIVERS study being 
run in the Auckland region, New Zealand.  
 
This modelling provides, for the first time, a robust estimate of the impact of 
influenza on hospitalisation in New Zealand, in total and for major disease 
categories. It shows that the contribution of influenza to hospitalisations is much 
higher (approximately nine times) than indicated by discharge data. The impact is 
predominantly on respiratory illness admissions. The impact is concentrated in the 
elderly and infants, consistent with the observation data. This modelling also 
confirms the higher influenza hospitalisation rates for Māori and Pacific people 
compared with other ethnic groups, which is a novel finding in the area of 
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influenza modelling. These results suggest opportunities for greater prevention 
efforts, particularly for young children, the elderly, Māori, and Pacific peoples, 
whose disease burden is highest. These data could provide a useful input into 
decisions about vaccination policy and would increase the estimated cost-
effectiveness of such interventions. 
 
4.6 Summary of this chapter’s contribution to the thesis as a whole 
This chapter has shown how negative binomial regression models are used to 
estimate the contribution of influenza to hospitalisations in New Zealand over 15 
years from 1994-2008 with a breakdown by age, ethnicity and illness categories. 
Indeed, influenza hospitalisations rates (per 100,000) were markedly higher in 
Māori and Pacific people, the elderly and infants. The modelled number of 
influenza-associated hospitalisations was nine times larger than that coded in 
routine hospital discharge data.  
 
The next chapter will explore how influenza mortality affects population health by 





Chapter Five: Sociodemographic  
characteristics of modelled 
seasonal influenza mortality  
5.1 Chapter goal  
The goal of this chapter is to explore thoroughly the number of estimated 
influenza deaths by age, sex, ethnicity and socioeconomic status. Results of this 
chapter are described in a paper “Modelled seasonal influenza mortality shows 
marked differences in risk by age, sex, ethnicity and socioeconomic position in 
New Zealand” which has been accepted for publication in the Journal of Infection 
(see Appendix Three for Acceptance letter from the Editorial Board). 
 
According to the systematic review in Chapter Two, the average annual rate of 
influenza-related deaths for all causes ranged from 10.6 to 26.4 per 100,000. 
Influenza mortality seems to increase in the elderly aged 65 years and above. This 
review found no studies that had applied modelling techniques to estimate 
influenza mortality difference by socioeconomic status and ethnicity. 
 
Using a quasi Poisson regression model, this study, for the first time, estimated 
influenza mortality disparities by socioeconomic status and ethnicity as well as by 
age and sex. The study used weekly deaths obtained from the national mortality 
data and a similar dataset of weekly counts of isolates of influenza A (H1N1, 
H3N2 and A not-subtyped) and influenza B and respiratory syncytial virus (RSV) 
from the virology weekly report of the Institute of Environmental Science & 
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Research (ESR) as described in Chapter Three and used in Chapter Four for 
hospitalisation. 
 
This study showed that influenza deaths were markedly associated with males 
aged 65 to 79 years, Māori and Pacific peoples and those living in the most 
deprived areas. Moreover, estimated annual overall influenza-associated mortality 
was about 23 times higher than measured influenza mortality. In contrast to 
hospitalisations, circulatory illness was responsible for a large number of deaths 
attributable to influenza. These findings raise a need to further understand the 
principal admission diagnosis of people dying in hospital, especially for those 
who die from circulatory illness. 
 
This research reinforces that using modelling techniques provides more plausible 
estimates of the burden of influenza mortality than can be extracted from 
observational studies. Results from this study suggest that interventions (notably 
immunisation programmes) should prioritise vulnerable groups (indigenous 
people, elderly, males aged 65 to 79 years and individuals living in the most 




Influenza causes a large number of deaths and hospitalisations worldwide (Wu et 
al., 2012). Its impact on respiratory, circulatory, other medical mortality and 
hospital admission is substantial in many countries (Warren-Gash et al., 2009, 
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Toovey, 2008). Disease modelling has been used to assess the risk of influenza 
according to underlying conditions, age and sex (Quandelacy et al., 2014). They 
show that influenza mortality is associated with increasing age and male sex 
(Quandelacy et al., 2014, Hardelid et al., 2013).  
 
Despite many studies of influenza mortality there appear to be none that have 
used modelling techniques to estimate disparities by ethnicity and socioeconomic 
position. International studies have found evidence of variation between 
indigenous and non-indigenous people in observed disease mortality (including 
pneumonia and influenza) (Bramley et al., 2004). In New Zealand, mortality rates 
for Māori (indigenous people) in three influenza pandemics (1918, 1958 and 
2009) were 7.3, 6.2 and 2.6 higher, respectively than those reported for European 
people (Wilson et al., 2012a). The Southern Hemisphere Influenza and Vaccine 
Effectiveness Research and Surveillance (SHIVERS) project reported that Māori 
and Pacific peoples experienced influenza-associated hospitalisation about 1.5 and 
3 times higher, respectively than European/Others. Low socioeconomic status is 
associated with increased hospital admission rates for the diseases (Lopez L, 
2015). Baker et al. have found that those living in the most deprived areas have a 
significantly higher rate of infectious disease hospitalisation than people in the 
least deprived areas with a rate ratio from 2.4 to 2.8 over the 1989-2008 period. 
Māori and Pacific populations had a higher hospital admission rate for infections 
in general and influenza in particular when compared with European/Others 
(Baker et al., 2012). During the 2009 influenza pandemic, hospitalisation rates for 
Māori and Pacific peoples were 3 and 7 times higher respectively than those 




This paper, therefore, used modelling techniques to assess the distribution of 
seasonal influenza-attributable mortality in New Zealand according to a broad set 




5.3.1 Data sources 
Weekly counts of deaths were obtained from the New Zealand mortality dataset 
for the 15-year period from 1994-2008. These records included a field for 
underlying causes of death which is defined as “events leading directly to death” 
(WHO, 2017). Causes of deaths were coded according to the International 
Classification of Diseases (ICD) 9
th
 Revision (ICD-9) (before 2000) and the 10
th
 
Revision (ICD-10-AM) (AM:Australian Modification) from January 2000 
onwards.  
 
Influenza deaths were classified according to broad illness categories, as used in 
previous analysis of influenza-associated hospitalisation (Chapter Four): 
 Influenza (487-488, J09-J11), 
 Influenza and pneumonia (480-488, J09-J18),  
 Respiratory illness (460-519, J00-J99),  
 Circulatory illness (380-459, I00-I99),  
 Medical illness (001-629, 680-739, 780-799, A00-N99, R00-R99); and 




As in the previous analysis, ethnicity was classified into three prioritised groups: 
Māori, Pacific, and European/Others. New Zealand Census of Population and 
Dwellings (Statistics New Zealand) population data for 1991, 1996, 2001, 2006 
and 2013 were used as the denominator (Chapter Four). Age was classified into 
four groups (under 20; 20-64; 65-79; 80 years of age and older). Age 
standardisation used the age distribution of the population at the time of the 2013 
census except for the ethnic comparison where the Māori population was used as 
the reference (because of the very small number of Māori in the 80 years of age 
and older stratum). The New Zealand Deprivation Index (NZDep) was used to 
describe socioeconomic status. NZDep quintile was stratified by 5 groups, 1&2, 
3&4, 5&6, 7&8 and 9&10 (from the least to the most deprived) (Salmond and 
Crampton, 2002). A multivariate stratification was applied for ethnicity, sex and 
socioeconomic status to minimise confounding in analysis. 
 
The same weekly counts of isolates of influenza A (H1N1, H3N2 and A not- 
subtyped combined) and influenza B and respiratory syncytial virus (RSV) as 
inputs for modelling were used as in the previous analysis of influenza-related 
hospitalisations in Chapter Four. Approximately one third of influenza-like 
illnesses in New Zealand test positive for RSV. Consequently, RSV was included 
in the model to decrease confounding with influenza deaths. A research week 





5.3.2 Statistical methods 
This chapter used the same statistical approach as in the previous analysis of 
hospitalisations (Chapter Four). For every health component in the study including 
each cause of death category (influenza and pneumonia, respiratory, circulatory, 
all medical, and all causes), age grouping (under 20; 20- 64; 65-79; 80 years of 
age and older), sex (male, female), socioeconomic status (NZDep 1&2, NZDep 
3&4, NZDep 5&6, NZDep 7&8, and NZDep 9&10) and ethnic grouping (Māori, 
Pacific, European/Others), a stratified quasi-Poisson regression model was 
applied to estimate influenza attributable deaths. All statistical analysis was 
implemented in R software version 3.2.1. 
 
There was evidence of overdispersion and a small residual deviance, so, a quasi-
Poisson regression model was used. When testing correlation, influenza A, 
influenza B and RSV had very little correlation with each other, with a correlation 
r
2 
below 0.25 for each pairing (0.003 between influenza A and influenza B; 0.24 
between influenza A and RSV; and 0.09 between influenza B and RSV). The 
modelled week was the annual average number of weeks calculated by dividing 
the total weeks in the period 1994-2008 by 15 (years). 
 
The full model was based on one previously used in the USA (Thompson et al., 
2003) with the predicted number of deaths per week estimated as: 
Yi =  α exp{β0 + β1(ti) + β2(ti
2
) + β3[sin(2tiπ/52.07)] + β4[cos(2tiπ/52.07)] 




In this model, i is the week number; Yi is the output of the modelling process for 
that week (predicted mortality count); α is the population offset (accounts for 
population size changes over time); and ti represents number of weeks since the 
start of the modelling period. For the estimated regression parameters, β0 is the 
intercept (number of deaths predicted at t0, in the hypothetical absence of any 
influenza virus); β1(ti) models the linear trend and β2(ti
2
) models the non-linear 
trend in mortality over time. Seasonal changes in deaths are modelled with the 
cyclical parameters β3[sin(2tiπ/52.07)] and β4[cos(2tiπ/52.07)]. The final three 
parameters represent virus counts in the population: β5[A] and β6[B] are the 
weekly influenza A and B counts, respectively; and β7[RSV] is the weekly RSV 
counts.  
 
The estimated number of influenza related deaths was calculated as the 
discrepancy between the number estimated by the model and the number 
estimated by the model if virus counts were set to zero. The results were 
expressed as death numbers and mortality rates per 100,000 people. The 
denominator population was the mean population over the study period. The 
annual mean number of measured influenza deaths and rates per 100,000 were 
also calculated. Age specific and age standardised mortality rates were reported.  
 
5.4 Results 
5.4.1 Mortality by year 
Influenza-attributable deaths differed markedly by year, ranging from 166.4 in 
2000 (4.6/100,000) to a peak of 971.5 in 2003 (26.0/100,000). This peak year also 
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reported the highest number of influenza isolates, which were predominantly 
influenza A (Figure 14). 
 
Figure 14. Poisson regression model estimates for influenza-
attributable deaths and counts of influenza isolates by year, New 
Zealand 1994-2008 
 
5.4.2 Mortality by underlying causes 
The estimated annual average number of deaths from influenza-attributable 
pneumonia and influenza (P&I), respiratory illness, circulatory illness, all medical 
illness and all causes were 63.6 (95% CI: 61.8, 65,4); 173.6 (95% CI: 171.7, 
175.5); 186.2 (95% CI: 184.7, 187.7); 491.0 (95% CI: 488.9, 493.1) and 498.8 
(95% CI:496.6, 501.0), respectively. The estimated average mortality rate per 
100,000 people for all ages was 1.7 for P&I, 4.7 for respiratory illness, 5.0 for 
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Influenza deaths included a 35.6% (4.7 out of 13.5 per 100,000) contribution from 
respiratory illness and 37.0% (5.0 out of 13.5 per 100,000) contribution from 
circulatory illness. Influenza and pneumonia deaths accounted for 12.7% of total 
influenza deaths. 
 
Influenza deaths accounted for 10.2%, 6.9%, 1.7%, 1.9% and 1.8 % of total 
measured mean annual deaths in P&I, respiratory, circulatory, all medical illness 
and all causes, respectively. 
 
Table 9. Poisson regression model estimates of annual averages for influenza-
attributable deaths, New Zealand 1994-2008 
Underlying cause of 
death categories  
Estimated average annual 
influenza- associated deaths 
(95% CI) 
Estimated rate of influenza-
associated deaths per 











P&I  63.6  (61.8, 65.4) 1.7  (1.6, 1.8) 623 10.2 
Respiratory illness 173.6  (171.7, 175.5) 4.7  (4.6, 4.8) 2529 6.9 
Circulatory illness 186.2  (184.7, 187.7) 5.0  (5.0, 5.1) 11168 1.7 
All  medical illness 491.0  (488.9, 493.1) 13.3  (13.2, 13.4) 25863 1.9 
All causes  498.8  (496.6, 501.0) 13.5  (13.4, 13.6) 27928 1.8 
Note that Pneumonia and influenza (P&I) are  a subset of Respiratory illness.   
Both Respiratory and Circulatory illness are subsets of Medical illness.  
95% CI: 95% confidence interval. 
 
5.4.3 Mortality by age  
When analysed by age group (Figure 15 below and Table 10), the elderly aged 80 
plus years had the highest rate of influenza-attributable mortality across all 
disease categories, with a rate of 214.0 per 100,000 (95% CI: 211.0, 217.0) for all 
100 
 
causes, followed by those in age group 65 to 79 with 49.7 per 100,000 (95% CI: 
49.4, 51.1) and people from 20 to 64 years of age with 2.5 per 100,000 (95% CI: 
2.4, 2.6). Overall, slightly over half (254.4/498.8) of influenza-attributable deaths 
each year were in those aged 80 years and over. Influenza-attributable mortality 
was low in those below 65 years of age. 
 
 
Figure 15. Poisson regression model estimates for average annual 
influenza-attributable mortality rates (per 100,000 people) by age 
group and illness category, New Zealand 1994-2008 
Note: Age standardised rates per 100,000 calculated using the structure of the total NZ population at the 2013 Census. 
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Table 10. Poisson regression model estimates for average annual number and rate (per 100,000 people) of influenza-
attributable deaths by age group and disease categories, New Zealand 1994-2008 
Categories Age group (95%CI) 
























































































































































































































































Note that Pneumonia and influenza (P&I) are a subset of Respiratory illness.   
Both Respiratory and Circulatory illness are subsets of Medical illness.  
95% CI: 95% confidence interval. 




5.4.3 Mortality by sex 
Overall, the crude rate per 100,000 people of deaths for all ages attributable to 
influenza was slightly lower in males than females across all illness categories. 
After age standardisation, however, mortality rates per 100,000 people were 
higher in males in all disease categories, except for P&I (Figure 16 and Table 11).  
 
 
Figure 16. Poisson regression model estimates  for influenza-
attributable age-standardised mortality rate (per 100,000 people) 
by sex and illness categories, New Zealand 1994-2008 
Note : Age standardised rates per 100,000 calculated using the structure of the total NZ population at the 2013 Census. 


































































Table 11. Poisson regression model estimates for average annual rate (per 100,000 people) of influenza-attributable deaths by 




Rate per 100,000 (95%CI) Age standa-rdised rate  





P&I 0.0 (0.0, 0.0) 0.2 (0.2, 0.2) 4.0 (3.9, 4.1) 44.0 (42.9, 45.1) 1.3 (1.3, 1.3) 2.1 (2.0, 2.2) 
Respiratory illness -0.1 (0.0, 0.0) 0.6 (0.6, 0.6) 19.7 (19.3, 20.1) 104.3 (102.1, 106.5)  4.0 (3.9, 4.1) 6.2 (6.0, 6.4) 
Circulatory illness 0.1 (0.1, 0.1) 0.8 (0.7, 0.9) 30.4 (29.6, 31.2) 66.2 (61.6, 70.8) 4.8 (4.7, 4.9) 6.1 (5.7, 6.5) 
All  medical illness 0.0 (-0.1, 0.1) 2.5 (2.4, 2.6) 72.0 (70.6, 73.4) 243.4 (237.4, 249.4) 12.5  (12.3, 12.7) 18.0 (17.5, 18.5) 
All causes 0.3 (0.2, 0.4) 2.4 (2.2, 2.6) 71.8 (70.4, 73.2) 250.4 (244.4, 256.4) 12.7     (12.5, 12.9) 18.3 (17.8, 18.8) 







P&I 0.0 (0.0, 0.0) 0.1 (0.1, 0.1) 1.5 (1.4, 1.6) 54.0 (53.1, 54.9) 2.1 (2.1, 2.1) 2.2 (2.0, 2.2) 
Respiratory illness 0.0  (0.0, 0.0) 0.9 (0.9, 0.9) 15.9 (15.6, 16.2) 94.2 (92.9, 95.5) 5.4 (5.3, 5.5) 5.6 (5.5, 5.7) 
Circulatory illness 0.0  (0.0, 0.0) 0.6 (0.5, 0.7) 13.9 (13.3, 14.5) 101.7 (99.0, 104.4) 5.3 (5.2, 5.4) 5.5 (5.2, 5.8) 
All  medical illness 0.6  (0.6.0.6) 2.6 (2.5,2.7) 38.0 (37.0, 39.0) 245.1 (241.1, 249.1) 14.1 (13.9, 14.3) 14.7 (14.4, 15.0) 













             
P&I NA  NA  2.6 (2.6, 2.6) 0.8 (0.8, 0.8) 0.6 (0.6, 0.6) 1.0 (1.0, 1.0) 
Respiratory illness NA  0.7 (0.7, 0.7) 1.2 (1.2, 1.2) 1.1 (1.1, 1.1) 0.7 (0.7, 0.8) 1.1 (1.1, 1.1) 
Circulatory illness NA  1.3 (1.3, 1.3) 2.2 (2.2, 2.2) 0.7 (0.7, 0.7) 0.9 (0.9, 0.9) 1.1 (1.1, 1.1) 
All  medical illness NA  1.0 (1.0, 1.0) 1.9 (1.9, 1.9) 1.0 (1.0, 1.0) 0.9 (0.9, 0.9) 1.2 (1.2, 1.2) 
All causes NA  0.9 (0.9, 0.9) 1.9 (1.9, 1.9) 1.0 (1.0, 1.0) 1.0 (1.0, 1.0) 1.2 (1.2, 1.2) 
Note that Pneumonia and influenza (P&I) are a subset of Respiratory illness.   
Both Respiratory and Circulatory illness are subsets of Medical illness.  
RR: Rate ratio; 95% CI: 95% confidence interval. 
NA: Not applicable/able to calculate. 




5.4.4 Mortality by ethnicity  
Figure 17 and Table 12 summarise the number and rate per 100,000 people of 
death attributable to influenza by disease category and ethnic group stratified by 
age. European/Others experienced the highest crude rate of influenza-attributable 
mortality across all illness categories, with a rate of 14.2 per 100,000 people for 
all causes, followed by Māori (8.3/100,000) and Pacific people (4.3/100,000). 
However, the age standardised mortality rate for all causes was markedly higher 
in Māori (12.1/100,000) and Pacific peoples (6.8/100,000) compared to that 
estimated in European/Others (4.5/100,000). 
 
The distribution of influenza-attributable mortality also varied by disease category 
across ethnic groups. In general, influenza mortality rates by respiratory and 
circulatory disease were similar for European/Others. By contrast, circulatory 
disease deaths from influenza predominated in Māori and respiratory disease 







Figure 17. Poisson regression model estimates for influenza-
attributable mortality rate (per 100,000 people) by ethnicity and 
illness categories, 1994-2008 
Note : Age standardised rates per 100,000 calculated using the structure of the total NZ population at the 2013 Census. 
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Table 12. Poisson regression model estimates for average annual number and rate (per 100,000 people) of influenza-
attributable deaths by ethnic group, age group and disease category, New Zealand 1994-2008 
 Categories 
 
Rate per 100,000 (95% CI) Age standardised rate 







) P&I -0.3 (-0.3, -0.3) 0.2 (0.2, 0.2) 0.0 (-0.4, 0.4) 37.8 (34.1, 41.5) 0.2 (0.2, 0.2) 0.3 (0.3, 0.3) 
Respiratory illness -0.3 (-0.3, -0.3) 2.1 (2.0, 2.2) 11.3 (9.7, 12.9) 138.6 (131.2, 146.0) 1.8 (1.7, 1.9) 2.6 (2.4, 2.8) 
Circulatory illness 0.0 (0.0, 0.0) 1.2 (1.0, 1.4) 69.2 (66.2, 72.2) 24.7 (11.5, 37.9) 3.0 (2.9, 3.1) 4.2 (3.9, 4.5) 
All medical illness 1.0 (0.9, 1.1) 4.9 (4.6, 5.2) 139.0 (134.2, 143.8) 210.2 (190.1, 230.2) 7.6 (7.4, 7.8) 11.4 (10.8, 12.0) 
All causes 1.6 (1.4, 1.8) 5.4 (5.1, 5.7) 141.8 (137.0, 146.6) 214.9 (194.8,235.0) 8.3 (8.0, 8.6) 12.1 (11.5, 12.7) 









P&I 0.0 (0.0, 0.0) 0.3 (0.3, 0.3) 5.2 (4.5, 5.9) 105.5 (99.6, 111.4) 0.9 (0.9, 0.9) 1.3 (1.2, 1.4) 
Respiratory illness 0.1 (0.0, 0.2) 0.3 (0.2, 0.4) 45.4 (43.3, 47.5) 223.2 (210.9, 235.5) 2.5 (2.4, 2.6) 4.2 (3.9, 4.5) 
Circulatory illness 0.6 (0.6, 0.6) 2.0 (1.7, 2.3) 15.1 (10.5, 19.7) -257.9 (-279.1, -236.7) 0.8 (0.6, 1.0) -0.1 (-0.6, 0.4) 
All medical illness -0.1 (-0.2, 0.0) 4.3 (3.8, 4.8) 89.5 (82.0, 97.0) 44.1 (12.5, 75.7) 4.8 (4.5, 5.1) 6.8 (5.8, 7.8) 
All causes 0.0 (-0.2, 0.2) 3.7 (3.2, 4.2) 92.4 (84.8, 100.0) 68.8 (36.9, 100.7) 4.7 (4.3, 5.1) 6.9 (5.9, 7.9) 

















P&I 0.0 (0.0, 0.0) 0.1 (0.1, 0.1) 2.2 (2.1, 2.3) 39.5 (38.9, 40.1) 1.9 (1.9, 1.9) 0.5 (0.5, 0.5) 
Respiratory illness 0.0 (0.0, 0.0) 0.6 (0.6, 0.6) 13.9 (13.7, 14.1) 75.2 (74.2, 76.2) 5.1 (5.0, 5.2) 1.6 (1.6, 1.6) 
Circulatory illness 0.0 (0.0, 0.0) 0.5 (0.5, 0.5) 15.2 (14.8, 15.6) 78.7 (76.8, 80.6) 5.4 (5.3, 5.5) 1.6 (1.5, 1.7) 
All medical illness 0.1 (0.1, 0.1) 2.1 (2.0, 2.2) 39.1 (38.4, 39.8) 194.7 (191.8, 197.7) 14.1 (13.9, 14.3) 4.5 (4.4, 4.6) 
All causes -0.2 (-0.3, -0.1) 2.0 (1.9, 2.1) 38.9 (38.2, 39.6) 199.9 (196.9, 202.9) 14.2 (14.0, 14.4) 4.6 (4.5, 4.7) 







P&I NA  2.0 (2, 2) NA  1.0 (0.9, 1.0) 0.1 (0.1, 0.1) 0.6 (0.6, 0.6) 
Respiratory illness NA  3.5 (3.3, 3.7) 0.8 (0.7, 0.9) 1.8 (1.8, 1.9) 0.4 (0.3, 0.4) 1.6  (1.4, 1.8) 
Circulatory illness NA  2.4 (2, 2.8) 4.6 (4.5, 4.6) 0.3 (0.1, 0.5) 0.6 (0.5, 0.6) 2.6 (2.4, 2.6) 
All medical illness NA  2.3 (2.0, 2.4) 3.6 (3.5, 3.6) 1.1 (1.0, 1.2) 0.5 (0.5, 0.6) 2.5 (2.4, 2.6) 
All causes NA  2.7 (2.7,2.7) 3.6 (3.6, 3.7) 1.1 (1.1, 1.1) 0.6 (0.6, 0.6) 2.7 (2.6, 2.8) 







P&I NA  3.0 (3, 3) 2.4 (2.1, 2.6) 2.7 (2.6, 2.8) 0.5 (0.5, 0.5) 2.6 (2.4, 2.8) 
Respiratory illness NA  0.5 (0.3, 0.7) 3.3 (3.2, 3.4) 3.0 (2.8, 3.1) 0.5 (0.5, 0.5) 2.6 (2.4, 2.8) 
Circulatory illness NA  4.0 (3.4, 4.6) 1.0 (0.7, 1.3) -3.2 (-3.6, -2.9) 0.1 (0.1, 0.2) -0.1 (-0.3, 0.1) 
All medical illness NA  2.0 (1.9, 2.2) 2.3 (2.1, 2.4) 0.2 (0.1, 0.4) 0.3 (0.3, 0.4) 1.5 (1.3, 1.7) 
All causes NA  1.8 (1.8, 1.8) 2.4 (2.4, 2.4) 0.4 (0.4, 0.4) 0.3 (0.3, 0.3) 1.5 (1.3, 1.7) 
Note that Pneumonia and influenza (P&I) are a subset of Respiratory illness.   
Both Respiratory and Circulatory illness are subsets of Medical illness.  
M/E : Māori /European and Others; P/E;: Pacific/European and Others; RR: Rate ratio; 95% CI: 95% confidence interval; NA: Not applicable/able to calculate. 




5.4.5 Mortality by New Zealand deprivation (NZDep) 
The influenza-attributable death rate per 100,000 people was higher for the most 
deprived quintile (NZDep 9&10) than the least deprived quintile (NZDep 1&2) 
across all illness categories. The influenza-attributable mortality rate ratio for 
NZDep 9&10/NZDep 1&2 areas was 1.7 (95% CI: 0.7, 4.3) for P&I, 2.2 (95% CI: 
1.3, 3.9) for respiratory illness, 0.8 (95% CI: 0.5, 1.3) for circulatory illness, 1.7 
(95% CI: 1.2, 2.3) for all medical illness and 1.8 (95% CI: 1.3, 2.4) for all causes 
(Figure 18 and Table 13). 
 
 
Figure 18. Poisson regression model estimates for influenza-
attributable mortality rate (per 100,000 people) by New Zealand 
deprivation (NZDep) and illness categories, 1994-2008 
Note : NZDep1&2: the least deprived; NZDep9&10: the most deprived. 
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Table 13. Poisson regression model estimates for average annual number and rate per 100,000 people of influenza-
attributable mortality by New Zealand deprivation (NZDep) quintile and illness categories, New Zealand 1994-2008 
Categories NZDep (95% CI) NZDep9&10/NZDep1&2 









































































































































































































































Note that Pneumonia and influenza (P&I) are a subset of Respiratory illness.   
Both Respiratory and Circulatory illness are subsets of Medical illness.  
RR: Rate ratio; 95% CI: 95% confidence interval. 





Table 14. Poisson regression model estimates for average annual number and rate (per 100,000 people) of influenza-
attributable deaths by ethnic group, New Zealand deprivation (NZDep) and disease category, New Zealand 1994-2008 
 Categories 
 
Rate per 100,000 (95% CI) 







) P&I -0.3 (-0.4, -0.2) 0.5 (0.4, 0.6) -1.0 (-1.1, -0.9) 0.2 (0.1, 0.3) 0.4 (0.4, 0.4) 
Respiratory illness 2.1 (1.9, 2.3) 2.5 (2.3, 2.7) 1.0 (0.8, 1.2) 2.9 (2.8, 3.0) 1.6 (1.5, 1.7) 
Circulatory illness -1.2 (-1.7, -0.7) 3.4 (3.0, 3.8) 4.9 (4.5, 5.3) 2.6 (2.3, 2.9) 3.7 (3.5, 3.9) 
All medical illness 5.3 (4.5, 6.1) 3.8 (3.2, 4.4) 9.1 (8.5, 9.7) 7.2 (6.7, 7.7) 10.2 (9.8, 10.6) 
All causes 6.5 (5.7, 7.3) 3.9 (3.2, 4.6) 10.5 (9.9, 11.1) 7.4 (6.9, 7.9) 11.5 (11.1, 11.9) 









P&I -0.2 (-0.4, 0.0) 1.9 (1.8, 2.0) 1.4 (1.2, 1.6) 0.4 (0.3, 0.5) 1.1 (1.0, 1.2) 
Respiratory illness 0.9 (0.4, 1.4) 3.3 (2.9, 3.7) 3.7 (3.4, 4.1) 4.7 (4.5, 4.9) 2.3 (2.1, 2.5) 
Circulatory illness -0.3 (-1.7, 1.1) 5.6 (4.5, 6.7) 8.5 (7.7, 9.3) -1.4 (-1.9, -0.9) -0.5 (-0.8, -0.2) 
All medical illness -1.6 (-3.8, 0.6) 17.0 (15.2, 18.8) 5.8 (4.5, 7.1) 7.2 (6.3, 8.1) 4.2 (3.6, 4.8) 
All causes 4.6 (2.5, 6.7) 17.1 (15.4, 18.8) 6.2 (6.0, 7.4) 8.0 (7.1, 8.9) 4.9 (4.3, 5.5) 

















P&I 1.4 (1.4, 1.4) 2.2 (2.1, 2.3) 2.4 (2.3, 2.5) 2.3 (2.2, 2.4) 3.7 (3.6, 3.8) 
Respiratory illness 3.0 (2.9, 3.1) 13.9 (13.7, 14.1) 6.4 (6.3, 6.5) 6.1 (6.0, 6.2) 10.4 (10.2, 10.6) 
Circulatory illness 5.6 (5.4, 5.8) 4.1 (3.9, 4.3) 7.9 (7.7, 8.1) 6.8 (6.5, 7.1) 5.6 (5.3, 5.9) 
All medical illness 9.9 (9.6, 10.2) 12.6 (12.3, 12.9) 19.1 (18.7, 19.5) 17.2 (16.7, 17.7) 22.5 (22.0, 23.0) 
All causes 9.9 (9.6, 10.2) 13.4 (13.1, 13.7) 19.2 (18.8, 19.6) 17.9 (17.4, 18.4) 23.4 (22.8, 24.0) 







P&I NA  0.2 (0.2, 0.3) NA  0.1 (0.1, 0.1) 0.1 (0.1, 0.1) 
Respiratory illness 0.7 (0.0, 0.7) 0.2 (0.2, 0.3) 0.2 (0.2, 0.2) 0.5 (0.5, 0.5) 0.2 (0.1, 0.2) 
Circulatory illness NA  0.8 (0.8, 0.9) 0.6 (0.6, 0.6) 0.4 (0.4, 0.4) 0.7 (0.7, 0.7) 
All medical illness 0.5 (0.0, 0.6) 0.3 (0.3, 0.3) 0.5 (0.5, 0.5) 0.4 (0.4, 0.4) 0.5 (0.4, 0.5) 
All causes 0.7 (0.1, 0.7) 0.3 (0.2, 0.3) 0.6 (0.6, 0.6) 0.4 (0.4, 0.4) 0.5 (0.5, 0.5) 







P&I NA  0.9 (0.9, 0.9) 0.6 (0.5, 0.6) 0.2 (0.2, 0.2) 0.3 (0.3, 0.3) 
Respiratory illness 0.5 (0.0, 0.5) 0.2 (0.2, 0.3) 0.6 (0.5, 0.6) 0.8 (0.8, 0.8) 0.2 (0.2, 0.2) 
Circulatory illness NA  1.4 (1.2, 1.6) 1.1 (1.0, 1.1) NA  NA  
All medical illness NA  1.3 (1.2, 1.4) 0.3 (0.2, 0.4) 0.4 (0.4, 0.4) 0.2 (0.2, 0.2) 
All causes 0.5 (0.3, 0.7) 1.3 (1.2, 1.4) 0.3 (0.2, 0.4) 0.5 (0.4, 0.5) 0.2 (0.2, 0.2) 
Note that Pneumonia and influenza (P&I) are a subset of Respiratory illness.   
Both Respiratory and Circulatory illness are subsets of Medical illness.  
M/E : Māori /European and Others; P/E;: Pacific/European and Others; RR: Rate ratio; 95% CI: 95% confidence interval. 
NZDep1&2: the least deprived; NZDep9&10: the most deprived. 




When stratifying NZDep by ethnicity, European/Others peoples had the highest crude 
rate (per 100,000) of influenza-attributable mortality for all causes across all 
quintiles, except for NZDep 3&4 with a higher crude death rate in Pacific peoples 
(Table 14). 
 
5.4.6 Mortality by sex and ethnicity when stratified by age 
The pattern was more mixed when looking at specific age strata. For people below 65 
years, influenza-attributable mortality rates were low in both sexes and were 
moderately higher in females than males, except for people aged 20 to 64 years with 
circulatory illness. Estimated influenza-attributable mortality rates were significantly 
higher in males aged 65 to 79 years across all disease categories. In the elderly aged 
80 years and above, the average annual rate of influenza related deaths was higher in 
females except for respiratory illness (including P&I) (Figure 19). 
 
Similarly, when stratifying ethnicity by age, the estimated average annual mortality 
rates per 100,000 people were significantly higher among Māori and Pacific 
compared with European/Others for all age strata, except for Pacific people aged 80 
years and above where numbers were very small. For example, in the 65-79 year age 
stratum where most Māori and Pacific influenza-attributable deaths are estimated to 
occur, the all cause, rate ratio (RR) compared to European and Others was 3.6 (95% 





a. Mortality by sex when stratified by age 
 
b. Mortality by ethnicity when stratified by age 
Figure 19. Poisson regression model estimates for influenza-
attributable mortality rate (per 100,000 people) for all causes by sex 
and ethnicity when stratified by age, New Zealand 1994 -2008 
Note : Age standardised rates per 100,000 calculated using the structure of the total NZ population at the 2013 Census. 
Error bar represents for one standard error above and below estimate. 
 
5.4.7 Comparison between modelled and measured influenza mortality 
Table 15 compares estimated all-cause influenza mortality with measured influenza 
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that annual overall estimated influenza-attributable mortality is about 23 times higher 
than measured influenza mortality.  These ratios vary according to demography 
position with higher ratios for those aged 20 years and above, males, Māori and those 
living in the most deprived areas (NZDep 9&10).  
 
This analysis shows that the estimated gradients across age, ethnic and socio-
economic status groups are broadly similar for measured and modelled influenza 
mortality. However, the measured numbers are so much lower that it is hard to 
compare these gradients in an exact manner. 
 
Table 15. Comparison of the average annual number of modelled all cause 
influenza mortality with measured influenza mortality according to age group, 
sex, ethnicity and deprivation, New Zealand 1994-2008 
 
Characteristics Average annual modelled 
influenza-attributable all causes 
mortality 
(Modelled) 





Total influenza deaths 498.8 22 22.7 
By year    
                  1994 402.0 43 9.3 
                  1995 209.4 30 7.0 
                  1996 694.0 95 7.3 
                  1997 390.0 15 26.0 
                  1998 425.0 7 60.7 
                  1999 604.6 27 22.4 
                  2000 166.4 2 83.2 
                  2001 399.4 9 44.4 
                  2002 490.8 9 54.5 
                  2003 971.5 12 81.0 
                  2004 762.8 28 27.2 
                  2005 229.9 14 16.4 
                  2006 691.6 17 40.7 
                  2007 561.0 10 56.1 
                  2008 496.0 9 55.1 
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Characteristics Average annual modelled 
influenza-attributable all causes 
mortality 
(Modelled) 





Age group    
<20 6.0 0 NA 
20-64 55.8 1 52.9 
65-79 182.0 5 36 
≥80 254.4 16 16 
Sex    
Male 228.9 8 28 
Female 269.3 14 19 
Ethnicity    
Māori 43.8 1 44 
Pacific 9.8 0 NA 
European/Others 446.4 21 22 
New Zealand deprivation 
(NZDep) 
   
NZDep1&2 69.8 3 23 
NZDep3&4 87.7 4 22 
NZDep5&6 119.8 5 24 
NZDep7&8 104.9 5 20 
NZDep9&10 116.0 4 28 
 
5.5 Discussion 
This study is the first to use modelling methods to estimate influenza mortality 
according to socioeconomic status and ethnic group. Combined with estimates 
according to disease category, age and gender, it provides a comprehensive analysis 
of the socio-demographic distribution of influenza mortality estimated for a single 
country. 
 
The chapter’s estimate of the crude influenza mortality rate was 13.5 per 100,000 for 
all causes which is similar to the rate of 10.6 per 100,000 previously estimated for 
New Zealand (Kessaram et al., 2014). The estimated rate is considerably lower than 
those obtained for the USA, Germany, Singapore, Norway, Spain and Denmark 
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(Thompson et al., 2003, Gran et al., 2010, Nielsen et al., 2011, Zucs et al., 2005, 
Chow et al., 2006, Lopez-Cuadrado et al., 2012), but similar to those found in 
Portugal (Nunes et al., 2011). Interestingly, this study’s estimate for influenza-
attributable all causes deaths is almost the same as that in a Canadian study 
(11.3/100,000) which also applied a Poisson regression model with weekly mortality 
data for a similar period of time (1992-2009) (Schanzer et al., 2013b).  
 
Unlike hospitalisations, influenza-attributable mortality includes a large contribution 
from circulatory illness (37.0%) and from respiratory illness (35.6%). These findings 
raise the need to further investigate the large numbers of influenza deaths from 
circulatory illness to see if they are taking place outside hospital, or whether they are 
occurring in patients with a principle discharge diagnosis of respiratory illness that are 
coded as circulatory system deaths based on their underlying cause. This estimated 
mortality rate of influenza-attributable circulatory illness was higher than those 
reported for Portugal, Canada and Hong Kong (Nunes et al., 2011, Schanzer et al., 
2013b, Wu et al., 2012).  
 
In contrast to influenza hospital admissions (Chapter Four) or other hospitalised 
serious infectious diseases (Baker et al., 2012), these estimates of crude influenza-
attributable mortality rates were higher among European/Others compared to Māori 
and Pacific people across all illness categories. However, when stratified by age 
group, there is a remarkable disparity of influenza-attributable mortality among ethnic 
groups. Mortality rates were significantly higher for Māori and Pacific populations in 
New Zealand compared with the European/Others majority for age groups up to 80 
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years of age. For people aged 80 years and above, influenza deaths varied by ethnicity 
and illness category. These findings are not unexpected. In New Zealand, the 
population of Māori and Pacific people 80 years of age and older is small (accounted 
for approximately 3% of total populations in this age group). When mortality rates 
were age-standardised using the Māori age distribution, this study found that the risk 
of influenza deaths was significantly higher for Māori and Pacific peoples (with rates 
of 2.7 and 1.5 times, respectively greater than that reported for European/Others). 
There are no comparable modelled influenza mortality data available for other 
countries. However, observational data from Australia, Canada and the USA found a 
significant mortality rate from pneumonia and influenza (rate ratio of 2.1, 1.4 and 1.1, 
respectively) for indigenous people compared to non-indigenous people (Bramley et 
al., 2004).  
 
Socioeconomic disparities markedly affect influenza deaths. This analysis found that 
people living in the most deprived areas experienced the highest estimated influenza-
attributable mortality rate for all causes, which was 1.8 times greater than that found 
for the least deprived areas. Baker et al. reported the infectious disease hospitalisation 
rate increased with NZDep quintile. Those in the most deprived areas had a 
hospitalisation rate 2.8 times higher than those in the least deprived areas in New 
Zealand over the period 2004-2008 (Baker et al., 2012a). In England, males and 
females in manual (partly skilled and unskilled) occupations had substantially higher 
respiratory disease (including influenza and pneumonia) mortality than those in non-
manual (professional and intermediate) occupations, with rate ratios of 5.6 and 2.6, 




Crude all cause influenza-attributable death rates (per 100,000) were consistently 
higher in European/Others across most NZDep quintiles, when stratified deprivation 
by ethnicity. These findings were consistent with a result of a higher overall crude 
influenza-attributable mortality rates in European/Others compared to other ethnic 
groups (Table 14). This analysis shows that the two factors “ethnicity” and 
“socioeconomic status” had largely independent effects without any significant 
interaction.  
 
This study found that influenza mortality differed markedly by sex when stratified by 
age group. While in general influenza-attributable death rates were significantly 
higher in males than females in people under 80 years old, especially in the 65 to 79 
years age group, rates were moderately lower in males compared with females in 
those over 80 years old. To some extent this divergence might be explained by the 
fact that New Zealand’s female population is twice as large as the male population in 
the elderly aged 80 years and above and includes more of the very elderly (Statistics 
NZ, 2017). With life expectancy for females higher than for males (Bramley et al., 
2004), women over 80 years are on average older than men over 80 years, making 
them particularly vulnerable to influenza. A similar pattern of higher influenza-
associated mortality in males under 75 years old has also been reported for the USA 
(Quandelacy et al., 2014). 
 
Unlike hospital admissions (Chapter Four), influenza-attributable mortality rates 
among young people under 20 years old were negligible, with less than 1 per 100,000 
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for all causes. This finding is consistent with results from many countries, including 
Hong Kong (Wu et al., 2012) and Denmark (Nielsen et al., 2011). In this study, more 
than 86% of influenza-attributable deaths for all causes (average annual rate of 90.3 
per 100,000) were estimated to occur in those 65 years of age and older. Australia, 
Denmark, Hong Kong, Norway and the USA also found the highest influenza 
mortality rate per 100,000 people for the same age population (Newall et al., 2008, 
Nielsen et al., 2011, Wu et al., 2012, Thompson et al., 2003, Gran et al., 2010). The 
large number of influenza deaths in those aged 65-79 years reinforces the need to 
maximize vaccination coverage in the population 65 years of age and older, where 
annual influenza immunisation is already recommended (Sue Huang et al., 2008). The 
relatively high mortality risk for Māori and Pacific peoples and males also strengthens 
the essential prerequisite for immunisation in this group.  
 
This study, inevitably, has some limitations. Like previous studies on mortality and 
hospitalisations in New Zealand, this study did not have data on total specimens 
tested or the number of laboratory tests with negative results (Kessaram et al., 2014). 
Second, although RSV contributes up to about one third of influenza like illnesses in 
New Zealand (Chapter Four), other viruses such as Rhinovirus or Adenovirus, which 
can result in respiratory infection, were not included as inputs for modelling. 
Furthermore, other confounders (for example, humidity and ambient temperature), 
with substantial impact on influenza seasonality (Nicoll et al., 2012, Lowen and Steel, 
2014), were not considered in this paper’s modelling. Hence, influenza-attributable 
deaths may be overestimated. Third, like other studies using Poisson regression 
models, the estimates would be more accurate if the model excluded some inputs, 
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such as proxy parameters of weekly virus fluctuations (β4[sin(2tiπ/52.07)] and 
β5[cos(2tiπ/52.07)]) which are independent of the influenza virus. Fourth, the 
influenza-attributable mortality rate among Pacific peoples can be overweighed 
because of a small proportion of Pacific peoples in the New Zealand population in 
comparison with European and Māori. Fifth, vaccine coverage, a strong determinant 
for influenza mortality in different strata (Gessner et al., 2013), was not accounted for 
in this study. Sixth, this study was restricted to underlying causes of deaths which are 
“the events leading directly to deaths” (WHO, 2017), therefore, this study was unable 
to assess the contribution of respiratory illness to influenza-attributable circulatory 
illness deaths. Finally, about 1% of deaths were missing the information necessary to 
classify by NZDep quintile. More fundamentally, I hope to further investigate 
validation of estimates obtained from disease modelling with observational data or 
other sources. 
 
These results provide strong evidence for applying modelling techniques to obtain 
more valid estimates of the impact of influenza on mortality than can be obtained 
from observational data. They demonstrate that influenza makes a substantial 
contribution to annual mortality accounting for 1.8% of deaths, which is 23 times 
more than indicated by coded influenza deaths. Unlike hospitalisation, influenza-
attributable mortality is greatly affected by circulatory illness and concentrated in the 
elderly. The research also shows, for the first time, that the modelled influenza 
burden shows marked ethnic, and socioeconomic inequalities in addition to those 
estimated for age and gender. In New Zealand groups with relatively high influenza 
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mortality are Māori and Pacific peoples, males aged 65-79 years old, and individuals 
living in the most deprived areas. These findings support prioritised interventions 
(notably vaccination) for these vulnerable groups and further research to identify 
ways of reducing these inequalities. 
 
5.6 Summary of this chapter’s contribution to the thesis as a whole 
This chapter concludes that influenza-associated mortality is markedly influenced by 
ethnicity, age, gender and socioeconomic status. Relatively vulnerable groups were 
males aged 65-79 years (RR=1.9, 95% CI: 1.9, 1.9 compared with females), Māori 
(RR=3.6, 95% CI: 3.6, 3.7 compared with European and Others aged 65-79 years), 
Pacific (RR=2.4, 95% CI: 2.4, 2.4 relative to European and Others aged 65-79 years) 
and those living in the most deprived quintile of neighbourhoods (RR=1.5, 95% CI: 
1.1, 2.1) for NZDep 9&10 relative to NZDep 1&2. Similar to the previous chapter, 
findings of this chapter show that modelling approaches are a plausible method to 
estimate burden of influenza on population health. 
 
The next chapter will validate statistical methods for estimating influenza incidence 
and contribution by using prospective study (from the SHIVERS Project) of influenza 




Chapter Six: Validation of modelling 
and direct measurement in 
estimating influenza burden in New 
Zealand 
 
6.1 Chapter goal 
The goal of this chapter is to validate the models used in the previous chapters and 
see if this method could be a valid way to estimate contribution of influenza to 
hospitalisation. Modelled incidence and distribution of influenza hospitalisation was 
also compared with findings from direct measurement. This was done at both an 
overall level and across demographic and socioeconomic status characteristics (time, 
place, age, sex, ethnicity, and New Zealand Deprivation quintile). This is the first 
study to make a comprehensive comparison of results obtained from both methods in 
the total population of adults as well as children. 
 
6.2 Introduction 
Each year influenza causes about 250,000 to 500,000 deaths and approximately 3 to 5 
million severe cases worldwide (WHO, 2016). Two approaches commonly used to 
estimate the influenza burden are direct measurement and modelling (Yang et al., 




Direct surveillance of influenza requires virological confirmation. Some influenza 
cases, especially those in children, present with ambiguous symptoms and may not 
have samples sent for laboratory testing (Jartti et al., 2008, Advani et al., 2012). 
Often, influenza is not listed as the principal diagnosis or underlying cause of death in 
hospital discharge documents or death certificates, because of its non-specific clinical 
features (Muscatello et al., 2008, Ang et al., 2014, Redlberger-Fritz et al., 2012). 
Observational studies are recognised as having high specificity but low sensitivity 
(Nicoll et al., 2012), and are costly because a large number of subjects need to be 
recruited and tested (Gilca et al., 2009). 
 
Modelling has been used in many countries to estimate influenza-related illness. 
Serfling first used a rate-difference method to estimate influenza-related pneumonia 
deaths in 1963 (Serfling, 1963). More recently, Poisson regression models have 
commonly been used to provide annual average rates (per 100,000) of influenza-
associated deaths. Poisson regression generated estimates of 19.6 deaths per 100,000 
in the USA; 13.1 in Canada, and 10.6 in New Zealand (Kessaram et al., 2014, 
Schanzer et al., 2007a, Thompson et al., 2003). Multiple linear regression models 
produced annual mean rates per 100,000 of influenza-attributable deaths estimates of 
approximately 11.0 in both the USA and Hong Kong for the same study period 
(Quandelacy et al., 2014, Wu et al., 2012). Negative binomial regression models 
provided similar estimates of yearly influenza hospitalisations rates per 100,000, at 
63.5 in the USA (Zhou et al., 2012) and 62.4 in New Zealand (Chapter Four) over 15-
year periods. Modelling has also been useful for estimating the large health impact of 
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influenza, across influenza-associated respiratory illness, circulatory illness, 
cardiopulmonary illness, and all cause illness (Nicoll et al., 2012). Modelled 
estimates of influenza hospitalisations and deaths are inevitably much higher than 
those recorded in routine discharge and mortality data (Thompson et al., 2003, Khieu 
et al., 2015, Kessaram et al., 2014), but may be overestimates (Nicoll et al., 2012).  
 
In New Zealand, a hospital-based severe acute respiratory illness (SARI) surveillance 
system was implemented in 2012 under the Southern Hemisphere Influenza and 
Vaccine Effectiveness Research and Surveillance (SHIVERS) project. It provided a 
comprehensive picture of influenza-attributable SARI for much of the Auckland 
Region (in the north of the country) (Huang et al., 2015, Huang et al., 2014). 
 
Recently two studies by Gilca et al. in Canada (Gilca et al., 2009) and Yang et al. in 
Hong Kong (Yang et al., 2011) used prospective studies to validate statistically 
modelled estimates of the contribution of influenza to hospitalisation in children aged 
under 3 years, and  aged 18 years and under, respectively. Both studies concluded that 
modelling was an effective method for estimating influenza hospitalisations (Yang et 
al., 2011, Gilca et al., 2009). As both studies were restricted to child admissions, they 
could not validate modelling for the total population.  
 
This study used negative binomial regression models to estimate influenza-associated 
respiratory hospitalisations, then compared results (modelled estimates) with findings 
123 
 
based on observational data from a large prospective study of SARI hospitalisations 
that had been directly tested for influenza (Huang et al., 2015) (direct measurement). 
This chapter aimed to compare results from each source for both the total incidence 
of influenza and its distribution by major sociodemographic characteristics (time, 
place, age, sex, ethnicity, and socioeconomic status). The goal was to assess whether 




6.3.1 Data sources 
This study was limited to the population aged one year and over. Figure 20 describes 
the numbers and proportions of respiratory admissions in Auckland District Health 
Board (ADHB) and Counties Manukau District Health Board (CMDHB) hospitals 
during the influenza season. Respiratory hospitalisations were categorised into two 
groups: captured by SHIVERS (about 65.8%); and non-captured by SHIVERS 
(approximately 34.2%).  
 
SHIVERS dataset 
The SHIVERS project was a large prospective study of patients hospitalised with 
respiratory infections. It operated in four public hospitals which admitted all acutely 
ill adults and children in the ADHB and CMDHB districts, covering approximately 




Those captured by SHIVERS included SARI and non-SARI respiratory cases as 
defined in the SHIVERS study (Huang et al., 2014). Systematic tests for influenza 
positives were carried out with the goal of testing most consented SARI and a 
proportion of non-SARI respiratory patients. Only a small proportion of non-
consented cases were otherwise tested for clinical management purposes (Huang et 
al., 2014). Figure 20 shows there was low testing and low flu positivity in non-
captured SHIVERS respiratory admissions (8 influenza positives out of 75 visits, 
equivalent to 10.6% of total admissions).                                      
 
SHIVERS aimed to recruit all patients admitted overnight to ADHB and CMDHB 
with SARI. Measured influenza-associated SARI comprised total influenza positives 
returned from laboratory results for consented SARI (a) and non-consented SARI (b) 
(Figure 20).  
 
Hospital dataset   
To measure ADHB and CMDHB respiratory infection admissions, this study used 
principal hospital discharge diagnoses for people aged one year and over, extracted 
from New Zealand’s national hospitalisation dataset which includes all publicly 
funded hospitalisations in New Zealand. These data are routinely collected by the 





There was a total of 18,510 respiratory illness hospitalisations (codes 460-519, J00-
J99) over the study period in the study region. This research excluded 1399 (about 
7.6%) respiratory hospitalisations covering codes J30-39, J60-70, J80-84, J90-94, 
J95, J97-99, as these were unlikely to be infectious respiratory diseases and were 
similarly excluded from SHIVERS (Huang et al., 2014). There was no respiratory 
illness with codes J97-J99 over the study period. The remaining 17,111 respiratory 
infection hospitalisations were included in this study. Measured influenza-associated 
respiratory hospitalisations were divided into three groups (Figure 20, Figure 21): 
influenza-associated SARI (consented and non-consented sub-groups); influenza-
associated non-SARI (consented and non-consented sub-groups); and non-SHIVERS 
respiratory influenza.  
 
Seasonal coverage 
SHIVERS influenza hospitalisation data collection began in week 18 of 2012. As 
New Zealand is in the southern hemisphere, the influenza and respiratory 
hospitalisation season, roughly 22 weeks long, falls between week 18 and week 39 
each year. According to SHIVERS data, only 10% of influenza positives were 
reported outside the influenza season in the years 2012-2015. Therefore, 
hospitalisation data from week 18 to 39 for the four years 2012-2015 were selected 
for this study. 
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Figure 20. Measured respiratory infection hospitalisations at ADHB and CMDHB during the influenza season (week 18 -39), 2012-
2015 (Excluding infants under 1 year)  
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6.3.3 Measured SARI and respiratory influenza hospitalisations 
Measured SARI and respiratory influenza hospitalisations were derived from 
observed numbers, following three assumptions: 
 For measured influenza-associated SARI: The proportion of influenza 
positives among SARI cases tested for influenza was assumed to be the same 
for consented and non-consented SARI (see formulas a and b). 
 For measured influenza-associated non-SARI respiratory: the proportion of 
influenza positives found by systematic testing of consented non-SARI 
respiratory cases was applied to all non-consented non-SARI respiratory 
hospitalisations (see formulas c and d). 
 For measured non-SHIVERS respiratory influenza:  as shown in Figure 20, 
the observed rate of influenza positives in non-captured SHIVERS cases was 
low, but the testing was non-systematic. Therefore, the proportion of 
influenza positives for non-captured SHIVERS was assumed to be 
approximately equivalent to that for consented non-SARI cases (see formula 
e). 
      (a)                                
Number of consented 
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 Total measured influenza-associated SARI hospitalisations = Number of 
consented SARI influenza cases + Number of non-consented SARI influenza 
cases. 
 Total measured influenza-associated respiratory hospitalisations = Number 
of consented SARI influenza cases + Number of non-consented SARI 
influenza cases + Number of consented non-SARI influenza cases + Number 
of non-consented non-SARI influenza cases + Number of non-SHIVERS 
respiratory influenza cases = Measured influenza-associated SARI cases + 




As with measured influenza-associated SARI and influenza-associated 
respiratory hospitalisations, the percentage of influenza positives in each group 
followed the three given assumptions across all demographic and socioeconomic 
characteristics. In this study, we derived the number, proportion and rate per 
100,000 of measured influenza-associated SARI and measured influenza-
associated respiratory admissions by key demographic and socioeconomic 
characteristics including: time (week, year); place (ADHB, CMDHB); age group 
at hospitalisation (1-4, 5-19, 20-34, 35-49, 50- 64, 65-79, and 80+ years); sex 
(male, female); prioritised ethnicity (Māori, Pacific, Asian, and 
European/Others); and socioeconomic status using the New Zealand Deprivation 
Index (NZDep) quintile (NZDep 1&2, NZDep 3&4, NZDep 5&6, NZDep 7&8, 
and NZDep 9&10, from the least to the most deprived) (Salmond and Crampton, 
2002) (see estimation formulas below).  
H (%) = 
p 
x 100 
p + n 
 
I = 
p x P 
t 
Where: 
H: Percentage of influenza positives in each group 
p: Number of influenza positive from systematic testing in each group 
n: Number of influenza negative from systematic testing in each group 
t: Number of tests for influenza (including consented SARI, non-consented SARI, consented non-SARI, non-
consented non-SARI, non-captured SHIVERS) 
I: Number of estimated influenza positives in each group (including consented SARI, non-consented SARI, 
consented non-SARI, non-consented non-SARI, non-captured SHIVERS) 
P: Number of respiratory illness cases (including consented SARI, non-consented SARI, consented non-SARI, 





6.3.4 Sensitivity analyses 
A sensitivity analysis was performed to test the effect of changes in the 
proportion of flu positives among non-SARI influenza cases.  
 
A high value of measured influenza-associated respiratory hospitalisations was 
estimated assuming the proportion of non-SARI influenza to be equal to the real 
proportion of SARI influenza (24.9%). The low value of measured influenza-
associated respiratory hospitalisations was derived by assuming the percentage 
of non-SARI influenza to be half the real percentage of non-captured SHIVERS 
influenza (5.3%) (see the below formulas). 
The high value of measured respiratory influenza = (
a
Number of consented SARI influenza + 
b
Number of non-consented SARI influenza + 
c
Number of consented non-SARI influenza + 
d
Number of non-consented non-SARI influenza + 
e
Number of non-captured SHIVERS 
influenza) x 0.249 
 
The low value of measured respiratory influenza = (
a
Number of consented SARI influenza + 
b
Number of non-consented SARI influenza + 
c
Number of consented non-SARI influenza + 
d
Number of non-consented non-SARI influenza + 
e
Number of non-captured SHIVERS 
influenza) x 0.053 
 
6.3.5 Modelled influenza 
Hospitalisation dataset 
As in Chapter Four, this modelling included all hospitalisations with a principal 
diagnosis of respiratory illness (codes 460-519, J00-J99) in the ADHB and 
CMDHB areas. This analysis excluded the two weeks of each year which 
contained Christmas and New Year (which fall in the New Zealand summer) so 
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as to prevent outliers, as these weeks have abnormally low hospitalisations in 
general and the lowest number of respiratory hospitalisations. Models were 
applied to a 50-week year dataset. Data were recorded for the 20 years from 
1994-2015 excluding 2009 and 2010 (pandemic influenza years). As in the Hong 
Kong study, negative binomial regression models estimated an insignificant 
contribution of influenza to hospitalisations for infants under 12 months old 
(Yang et al., 2011), so this infant age group was unlikely to follow the same 
pattern of hospitalisations as the general population  and was  excluded from the 
study population. 
 
As in Chapter Four, the analysis was limited to hospital admissions with a 
respiratory cause as principal diagnosis. Sociodemographic categories used the 
categories previously noted.  
 
Virological data 
Weekly counts of isolates of influenza A (H1N1, H3N2, and A not-subtyped), 
influenza B, and respiratory syncytial virus (RSV) from virology weekly reports 
of the Institute of Environmental Science & Research (ESR) for the period 1994-
2015 (excluding 2009 and 2010) were used. As in the previous chapters, RSV 
was included in modelling to minimise confounding, as it makes up a third of 





As in Chapter Four, negative binomial regression models were applied to 
estimate influenza-associated respiratory hospitalisations in the ADHB and 
CMDHB. Many previous studies have used negative binomial regression models 
to address over-dispersion (Zhou et al., 2012, Newall and Scuffham, 2008, Jacks 
et al., 2012, Ang et al., 2014).  
 
The formula for the full model used to estimate the number of influenza-
associated respiratory illness hospitalisations per week was as follows: 
Yi = offset (population) + β1(ti) + β2(ti
2
) +  
β3[sin(2tiπ/50)] +β4[cos(2tiπ/50)]+ β5[A] + β6[B]+ β7[RSV] 
 
Subscript i is the week number; Yi is the output of the modelling process for that 
week (predicted influenza-associated respiratory illness hospitalisation count); 
and ti represents the number of weeks since the start of the modelling period. For 
the estimated regression parameters, β1(ti) models linear trend and β2(ti
2
) 
represents nonlinear time trends. Β3[sin(2tiπ/50)] and β4[cos(2tiπ/50)] are proxy 
parameters of weekly virus fluctuations. Β5[A] and β6[B] are the weekly 
influenza A and B counts, respectively; and β7[RSV] is the weekly RSV count. 
The estimated number of influenza related hospital admission was calculated as 
the discrepancy between the number estimated by the model and the number 
estimated by the model if the virus counts were set to zero. 
 
For each characteristic, i.e. age (1-4, 5-19, 20-34, 35-49, 50- 64, 65-79, and 80+), 
sex (Male, Female), ethnicity (Māori, Pacific, Asian, and European/Others), 
district (ADHB, CMDHB) and socioeconomic status (NZDep 1&2, NZDep 3&4, 
NZDep 5&6, NZDep 7&8, and NZDep 9&10), negative binomial regression 
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models were applied to estimate influenza-associated respiratory illness 
hospitalisations.  
 
6.3.6 Comparison of measured and modelled influenza 
The number and rate (per 100,000) of modelled influenza cases estimated by 
negative binomial regression models to the number and rate (per 100,000) of 
measured SARI influenza were compared with measured respiratory influenza 
cases from the observation study, across the major sociodemographic 
characteristics (time, age, sex, ethnicity, socioeconomic status and place). 
Weekly estimates of modelled influenza were also compared with those for 
measured SARI influenza and measured respiratory influenza over the period 
2012-2015. 
 
A SHIVERS source population stratified by age, sex, ethnicity, socioeconomic 
status and registered hospital (Huang et al., 2014) was used to calculate the rate 





6.4.1 Incidence of measured and modelled influenza hospitalisations 
Measured  influenza hospitalisations by major categories 
The categories of measured influenza-associated respiratory infections shown in 
Figure 20 are shown in aggregate in Figure 21. Consented SARI influenza 
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(11.0%) and non-consented SARI influenza (33.5%) are subsets of measured 
influenza-associated SARI (44.5%). Consented non-SARI influenza (4.3%) and 
non-consented non-SARI influenza (23.9%) are subsets of measured influenza-
associated non-SARI (28.2%). The remaining group is measured non-SHIVERS 
respiratory influenza (27.3%). 
 
 
Figure 21. Contribution (%) of major categories of measured 
influenza-associated respiratory hospital isations, ADHB and 
CMDHB, during the influenza season (week 18 to week 39), 2012 -
2015 
 
Comparison of total measured and modelled influenza hospitalisation  
The yearly average number of measured influenza-associated respiratory 
hospitalisations for the period 2012-2015 (Table 16) was 726.9, which was 
similar to the modelled estimate of 780.1 (95% confidence interval (CI): 773.8, 
786.4).  Annual admission rates per 100,000 were also similar, being 81.5 for 
measured influenza-associated respiratory hospitalisations and 87.4 (95% CI: 



















Measured influenza-associated SARI accounted for an average of 323.5 
hospitalisations per year, a rate of 36.3 per 100,000, which was only 44.5% of 
total influenza-associated respiratory hospitalisations. 
Influenza hospitalisation by year 
The number of influenza hospitalisations differed markedly from year to year 
(Table 16, Figure 22). Modelling showed the highest number of influenza-
associated admissions in 2015, whereas measured SARI influenza was highest in 
2012, and measured influenza-associated respiratory hospitalisations were 
highest in 2014. 
 
Table 16. Comparison of number and rate per 100,000 of measured 
influenza-associated SARI, measured influenza-associated respiratory and 
modelled influenza, ADHB and CMDHB, during the influenza season (week 









2012 393.5 541.7 628.5 (622.2, 634.8) 
2013 245.1 590.1 356.3 (351.7, 360.9) 
2014 383.7 1008.9 986.6 (979.9, 993.3) 
2015 271.7 816.8 1148.7 (1139.5, 1157.9) 
Annual average number 323.5 726.9 780.1 (773.8, 786.4) 
Annual average rate  
(per 100,000) 
36.3 81.5 87.4 (86.7, 88.2) 





The trend for influenza hospitalisation was consistent across all methods. 
However, the curve for modelled influenza fluctuated more smoothly than that 
for observations. Weekly measured influenza-associated respiratory admissions 
were somewhat higher than modelled influenza across all weeks in 2013 and 
2014 (Figure 22). 
 
 
Figure 22. Comparison of weekly hospitalisations of measured 
influenza-associated SARI, measured influenza-associated 
respiratory admissions, and modelled influenza, ADHB and 
CMDHB, during the influenza season (week 18 to week 39), 2012-
2015 







































































































































Comparison of measured and modelled influenza hospitalisations by socio-
demographic characteristics  
Age group 
The age group distribution of measured and modelled respiratory influenza both 
followed a U-shaped age distribution, though there were important differences. 
Among children aged 1 to 4 years, the admission rate was highest for measured 
respiratory influenza, with a rate of 262.9 per 100,000. This incidence was 3.5 
times higher than modelled influenza (76.0 per 100,000). By contrast, for those 
aged 80 years and above, the highest rate of influenza-associated respiratory 
hospitalisations came from modelling (538.2 per 100,000) compared with 
measured influenza-associated respiratory admissions (343.3 per 100,000) 
(Figure 23 below, Table 21 and Table 22 in the Appendix One). 
 
Figure 23. Comparison of rate per 100,000 of measured influenza -
associated SARI, measured influenza-associated respiratory 
admissions, and modelled influenza, by age group, for ADHB and 


























































































All measurement methods found Pacific peoples to have the highest rate and 
number of influenza hospitalisations, followed by Māori, and European and 
Others. Asian people had the lowest rate. The rates of measured influenza-
associated respiratory admissions and modelled influenza were fairly similar 





Figure 24. Comparison of rate per 100,000 of measured influenza-
associated SARI, measured influenza-associated respiratory 
admissions, and modelled influenza, by ethnic group, for ADHB 




































































































Those living in the most deprived areas (NZDep 9&10) had the highest rate of 
influenza hospitalisation regardless of the measurement method. Both direct 
measurement and modelling yielded similar rates (per 100,000) of influenza 
hospitalisation across all NZDep quintiles (Figure 25 below, Table 2 and Table 
22 in the Appendix One). 
 
 
Figure 25. Comparison of rate per 100,000 of measured influenza-
associated SARI, measured influenza-associated respiratory 
admissions, and modelled influenza by New Zealand Deprivation 
Index (NZDep), for ADHB and CMDHB during influenza season 
(week 18 to week 39), 2012-2015 
NZDep1&2: the least deprived; NZDep9&10: the most deprived. 
 
Sex and hospital 
All methods also showed a higher rate of influenza hospitalisations in females 
compared with males. Modelling returned a larger rate of influenza-associated 
respiratory illness hospitalisations in CMDHB, while observation reported a 
higher rate of measured SARI influenza and measured respiratory influenza 
























































































New Zealand Deprivation quintile 




6.5.1 Main findings and relationship to what is known 
This study compared estimates of influenza-associated respiratory illness 
hospitalisations derived from modelling, with direct observations of influenza 
hospitalisations obtained from a prospective study (SHIVERS). It appears to be 
the first study to make such a comparison in a total population of adults as well 
as children. 
 
This study found that the average annual number and rate of influenza-
associated respiratory hospitalisations estimated from modelling was very close 
to that found from direct measurement of respiratory hospitalisations. Influenza-
associated SARI, which is a defined respiratory syndrome used for surveillance 
purposes, accounted for only 44.5% of total influenza-associated respiratory 
admissions. 
 
There have been two validation studies in children hospitalised with respiratory 
illness. Gilca et al. found the same contribution of influenza to weekly 
hospitalisations in a prospective study and in statistical estimates restricted to 
children less than 3 years of age during the winters of 2001-2002 and 2002-2003 
in Canada. That study found that different statistical methods (including the 
Serfling method, Periseason II, Poisson regression, negative binomial regression 
and Box-Jenkins method) produced estimated proportions of admissions 
attributable to pneumonia and influenza similar to those observed in the 
prospective data (Gilca et al., 2009). Yang et al. in Hong Kong validated two 
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statistical modelling approaches (Poisson regression and a rate difference model) 
using hospitalisation data to estimate the contribution of each respiratory virus 
(including influenza) to hospitalisation in children aged 18 years and under.  
 
A novel aspect of this present study was to compare influenza hospitalisations 
estimated across major sociodemographic characteristics, including time, place 
and personal characteristics (age, sex, ethnicity, socioeconomic status). These 
comparisons showed that modelled estimates were generally very similar across 
these groups providing a further validation of modelling. Weekly influenza 
admission curves over the four years from 2012-2015 were also similar for 
modelling and direct measurement.  
 
The main area of difference between modelling and direct observation was in 
age distribution. Modelled results for influenza hospitalisations were highest in 
older age groups. This was especially so in those 80 years and older whose rate 
was 538.2 per 100,000, which was 1.6 times higher than the measured influenza-
associated respiratory rate observed for the same age group. To my knowledge, 
no studies have compared modelled and observed influenza-associated 
respiratory illness hospitalisations for this age group. There are several potential 
reasons why direct measurement may not have fully captured influenza 
admissions in the older population. Laboratory test consent rates were relatively 
low for the elderly in the SHIVERS Study, due in part to greater cognitive 
impairment and comorbidities in this age group. International studies have also 
found influenza tests to have lower sensitivity in older populations (Talbot et al., 




Unlike modelling, the prospective study showed a markedly higher rate of 
influenza hospitalisations among children aged from 1 to 4 years (262.9 for 
measured influenza-associated respiratory), about 3.5 times higher than that 
estimated with modelling. This result was consistent with Yang et al.’s Hong 
Kong study, which found a negligible rate of influenza hospitalisation in the 
infant and 5-10 year age groups using a negative binomial regression model 
(Yang et al., 2011). Again, there are several potential reasons for the markedly 
high rate of influenza positives among children aged from 1 to 4 years. The 
finding could have been influenced by a high background rate of asymptomatic 
influenza infection and a higher likelihood of hospitalisation in children than in 
adult age groups with influenza. 
 
As well as reporting results by age group, this paper also reported influenza-
associated respiratory admissions across ethnicity, socioeconomic status (New 
Zealand Deprivation) and sex. Both modelling and direct observation showed 
higher rates of influenza hospitalisations in Pacific peoples and Māori, in those 
living in the most deprived areas, and in females. Numbers and rates per 100,000 
of influenza hospitalisations were similar for modelled and directly measured 
respiratory hospitalisations. This study is the first to use direct measurement to 
show that modelled estimates of influenza appear valid across these socio-




6.5.2 Strengths and limitations 
A major strength of this study is its use of a large representative hospitalised 
population which had intensive surveillance of respiratory hospitalisations over a 
four year period. The ADHB and CMDHB cover about 20% of the New Zealand 
population. Prospective data from SHIVERS also captured two thirds of all 
respiratory illness hospitalisations in these two hospitals over the four year 
observation period. Previous studies were restricted to children under 18 years 
(about 246 influenza positives per year over period 2003-2006) (Yang et al., 
2011) or children younger than three years of age in a single hospital (39 
influenza positives in total over period 2001-2003) (Gilca et al., 2009). As 
influenza is markedly affected by age (Zhou et al., 2012, Thompson et al., 2004, 
Quandelacy et al., 2014, Newall and Scuffham, 2008, Baltussen et al., 1998), 
comparison of influenza-associated respiratory hospitalisation numbers and rates 
across different age groups is crucial in validating modelling with direct 
measurement. 
 
Influenza hospitalisation trends were very similar when modelling and direct 
measurement were compared. Consistent with a study from Canada (Gilca et al., 
2009), this study’s chosen negative binomial regression models estimated a 
number of influenza hospitalisations close to that obtained from direct 
measurement. 
 
This validation has several limitations. First, weekly counts of isolates of 
influenza A (H1N1, H3N2 and A not-subtyped), influenza B and RSV were not 
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available for ADHB and CMDHB. Instead, this modelling relied on virological 
data for all New Zealand. Variation in the length and frequency of virus 
circulation across geographical areas and time (Mullins et al., 2003) can mean 
that trends within a district (ADHB and/or CMDHB) may be somewhat different 
from those within the whole country. For this reason, the annual influenza-
associated respiratory hospitalisations by major subtypes could not be estimated.  
Modelled influenza-associated respiratory hospitalisations may not reflect the 
real influenza burden in the region.  
 
Second, SHIVERS obtained specimens from only 73.2% of SARI cases. 17.9% 
of non-SARI respiratory cases and a further 34.2% of respiratory illness 
hospitalisations were not captured by SHIVERS. This study was, therefore, 
unable to access laboratory results for these cases. Although this research took 
into account this under-captured number by multiplying the proportion of 
influenza positives among non-SARI cases, the directly measured number in this 
study may over- or under-represent the true burden of influenza hospital 
admissions. 
 
Third, this study was restricted to the main influenza season (22 weeks between 
week 18 to week 39 of each year) covering 90% of influenza positives over the 4 
year-period. The number of measured influenza-associated respiratory 
hospitalisations would be approximately 10% higher, and the validation could be 
more accurate, if whole year data were available. This is a limitation that I hope 




Finally, this study excluded infants. As in the Hong Kong study, negative 
binomial regression models estimated an insignificant contribution of influenza 
to hospitalisations in infants aged under 12 months (Yang et al., 2011). Over the 
four years of SHIVERS, the proportion of influenza positives in total 
hospitalisations in children aged under one year was approximately 20%. This 
means direct measurement suggests a high incidence of influenza among 
hospitalised children in this age group, while the modelling implies that there are 
very few influenza-associated hospitalisation at this age group. It is conceivable 
that the modelling is particularly poor in this age group as the threshold for 
hospitalisation is very different to that for the general population; and it is also 
possible that in many of the observed cases the positive influenza test was 
incidental to the hospitalisation.  
 
A sensitivity analysis was done to check how much the final estimate was 
changed when the proportion of non-SARI assumed to have influenza was 
changed. This analysis gave a range from 481.4 to 1065.2 for total measured 
influenza-associated respiratory admissions, which is ± 33% of the measured 
respiratory influenza shown in Table 16. It appears that measured influenza-
associated respiratory admissions are markedly affected by the number of 
influenza positives obtained from laboratory tests. High coverage of testing for 
influenza in all potentially infectious respiratory admissions could possibly 





6.5.3 Implications and further research 
Despite these limitations, this study provides a basis for validating the use of 
modelling for estimating the influenza burden in a single geographic area. It 
enables comparison of influenza hospitalisation numbers and rates for modelling 
and measurement across demographic characteristics. Further study could 
investigate the difference between modelled and directly measured influenza 
hospitalisations in specific age groups, notably infants, children, and the elderly. 
 
Modelling methods appear to provide a valid way of estimating the contribution 
of influenza to respiratory hospitalisations. Consequently, these methods are 
likely to be valid for estimating the contribution of influenza to non-respiratory 
hospitalisations and influenza mortality – important outcomes that are otherwise 
difficult to measure directly. 
 
Modelling methods also appear to produce valid estimates of the distribution of 
influenza by major sociodemographic group, particularly for sex, ethnicity and 
deprivation, though their validity across all age groups needs further 
investigation.  
 
Intensified surveillance for influenza in settings such as hospitals can use a 
syndromic approach (e.g. SARI). If these data are to be used to estimate the total 
burden of influenza, then validation studies are necessary to assess the 
sensitivity of such surveillance case definitions (e.g. through large systematic 
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studies of patient groups who are systematically under-sampled, notably the 
elderly). If such validation studies are carried out, their findings could be used to 
adjust estimates derived from ongoing syndromic surveillance of conditions such 
as SARI. 
 
6.6 Summary of this chapter’s contribution to the thesis as a whole 
Modelling methods appear to provide a valid way of estimating the contribution 
of influenza to respiratory hospitalisations. The numbers produced by modelling 
are comparable with the high quality observation data provided by the SHIVERS 
study. This is a very important consideration given the heavy emphasis placed 
on models in this thesis. Further study should focus on the marked difference 
between modelled and directly measured influenza hospitalisation among 
children and the elderly. It is unclear if these differences are due to inadequate 
models or the difficulties in data collection and interpretation in these groups. 
 
The next chapter will explore and estimate the proportion of influenza deaths 
occurring inside and outside hospital, and the proportions with respiratory causes 
compared with cardiovascular disease and other medical illnesses. Such 




Chapter Seven: How and where 
influenza kills?  Using modelling 
and linked data to partition 
influenza deaths into useful 
categories 
 
7.1 Chapter goal 
Influenza causes a large number of deaths each year that can only be estimated 
using modelling methods. Surprisingly little is known about where and how 
these deaths occur. This chapter aims to estimate the proportion of influenza 
deaths occurring inside and outside hospital, and the proportions with respiratory 
causes compared with cardiovascular disease and other medical illnesses. Such 
information could help to identify and prioritise broad prevention strategies.  
 
7.2 Introduction 
Influenza causes a substantial burden of diseases with an annual average of 
250,000-500,000 deaths and about three to five million severe illnesses 
worldwide. It has an annual attack rate of 5-10% in adults and 20-30% children 
(WHO, 2016). Influenza makes a huge contribution to hospitalisations in many 
countries (Newall and Scuffham, 2008, Wu et al., 2012). In the USA, over 
200,000 hospitalised respiratory and circulatory illnesses are attributable to 
influenza every year (Thompson et al., 2004). The estimated yearly average 
influenza-associated hospitalisation rates (per 100,000) for all causes in 
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Australia and New Zealand were 94.2 and 62.4, respectively (Newall and 
Scuffham, 2008, Khieu et al., 2015). 
 
Furthermore, influenza is under-recognised because of limited laboratory results 
and ambiguous symptoms/signs (Zambon, 2011, Galante et al., 2012). In the 
Netherlands, for every detected influenza case there were 2.6 influenza cases 
which were coded under another illness (Sprenger et al., 1993). In England it is 
estimated that only 39% of deaths from the pandemic were recorded as influenza 
in the death certificates of deceased people with positive pandemic A/H1N1 
results (Donaldson et al., 2009). In New Zealand, the contribution of influenza to 
total hospitalisations and mortality was about 9 and 23 times, respectively, larger 
than indicated by routine coded data (Chapter Four and Chapter Five). 
 
Modelling techniques have been widely used to estimate influenza 
hospitalisations and deaths in many countries (Nicoll et al., 2012, Thompson et 
al., 2004, Thompson et al., 2009). Chapter Six validated the use of regression 
modelling in New Zealand using influenza data from a large observation study 
of hospitalised respiratory illness. These influenza outcomes are frequently 
divided into respiratory, circulatory and other medical illness categories 
(Thompson et al., 2003, Chow et al., 2006, Khieu et al., 2015, Nunes et al., 
2011, Wu et al., 2012, Yap et al., 2004, Baltussen et al., 1998, Menec et al., 
2003). However, none of these studies have explored how the impact of 
influenza changed across different settings (and when stratified by age groups 




This study, for the first time, used statistical models to estimate influenza 
hospitalisations and deaths by major settings and components to see how and 
where they were occurring in a high income country setting (New Zealand). It 
also aimed to estimate the proportions with respiratory causes compared with 
cardiovascular disease and other medical illnesses. Such information could help 
to identify and prioritise broad prevention strategies.  
 
7.3 Method 
7.3.1 Data sources 
This study aimed to partition estimated (modelled) influenza deaths into useful 
categories that indicate opportunities for effective interventions. In practice, this 
meant relating these deaths to various forms of contact with the hospital system. 
Two national datasets, covering hospital discharges and mortality for the 15 
year-period from 1994-2008 were used in this research. All patients have a 
unique health number that allows health events to be linked, including 
hospitalisations, readmissions and deaths. 
 
Hospitalisations 
The hospitalisations dataset contains records of all publicly funded 
hospitalisations in New Zealand, including those discharged alive and those 
dying in hospital. Influenza hospitalisations were identified as described in 





Deaths were extracted from the mortality dataset that contains coded data on all 
deaths occurring in New Zealand and deaths occurring in hospital. In this study, 
the place of deaths was classified into two settings; in hospital and outside 
hospital based on the facility type/code where the deaths occurred.  
 
Classification of diagnostic categories 
As in Chapter Four on hospitalisations and Chapter Five on mortality, influenza 
hospitalisations and deaths were coded according to the International 
Classification of Diseases (ICD) 9
th
 Revision (ICD-9) (before 2000) and 10
th
 
Revision (ICD-10-AM) (AM: Australian Modification). This study used the 
following broad diagnostic categories: 
 Respiratory illness (460-519, J00-J99), including Influenza (487-488, J09-
J11) and Pneumonia and Influenza (P&I) (480-488, J09-J18);  
 Circulatory illness (380-459, I00-I99); 
 Other medical illness (A00-N99, R00-R99, 001-629, 680-739, 780-799) 
excluding J00-J99, 460-519 and I00-I99, 380-459; 
 All medical illness (001-629, 680-739, 780-799, A00-N99, R00-R99);  
 All causes (all ICD codes) (001-999, A00-Y99).  





Classification of hospitalisations status and place of death 
In this study, place of deaths was classified into two settings; in hospital and 
outside hospital based on the facility type/code where the deaths occurred.  
 
In hospital deaths covered acute overnight public hospital admissions which 
represented the main population of interest being people who became acutely ill, 
sometimes because of recent influenza infection, and were admitted overnight to 
hospital, or for longer, and where some would die; re-admissions within 30 days 
with the same diagnosis; and deaths on the date of discharge.Outside hospital 
deaths included non-hospitalised cases who died in the community without 
recent contact with the hospital; day cases who were admitted and then 
discharged or died on the same day; public hospital waiting list admissions and 
private hospital admissions; recent discharged people who died within 30 days 
of hospitalisation; deaths occurring in residential care (rest home) (although rest 
home have inpatients most of their care and treatments are performed at home); 
and deaths occurring in hospice (hospice clients include approximately 85% of 
deaths occurring outside hospital). According to the Ministry of Health, “rest 
home is intended for residents with the lowest level of dependency in residential 
care” while “hospices are the main providers of specialist palliative care services 





Table 17. Summary of data sources and models used 
 






1 National mortality 
dataset and linked 
hospitalisations 




cause of death 
To estimate influenza-
attributable deaths by 
diagnostic category and 

























In this study, there were four major outcomes for an influenza-infected case: 
hospitalised and discharged alive; hospitalised and discharged dead; alive 
without hospital admission; or death without hospitalisation (outside hospital).  
 
Isolates of virus 
As in previous chapters, the same weekly counts of isolates of influenza A 
(H1N1, H3N2 and A not- subtyped combined) and influenza B and respiratory 
syncytial virus (RSV) were used as inputs for modelling regression. 
 
Similar to previous chapters, New Zealand Census of Population and Dwellings 
(Statistics New Zealand, 2017) population data for 1991, 1996, 2001, 2006 and 
2013 for denominator to calculate rate per 100,000 were used. Age was stratified 
into four groups (<20; 20-64; 65-79; ≥80 years).   
 
7.3.2 Statistical methods 
As for Chapter Four and Five, the same statistical methods as in our previous 
paper on hospitalisations and mortality were used. An independent model was 
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applied for each disease category by facility type and age group. A total of 75 
quasi Poisson and negative binomial regression models were used. All statistical 
analysis was implemented in R software version 3.2.3.  
 
Quasi Poisson regression models (mortality model) were applied to estimate 
influenza-attributable deaths by facility type of deaths.  
Yi =  α exp{β0 + β1(ti) + β2(ti
2
) + β3[sin(2tiπ/52.07)] + β4[cos(2tiπ/52.07)] 
+ β5[A] + β6[B]+ β7[RSV]} 
 
As in Chapter Four, negative binomial regression models (hospitalisation model) 
were used to estimate influenza-associated hospitalisation who were discharged 
alive. Two weeks around Christmas and New Year which had the smallest 
number of hospitalisations and deaths were excluded to prevent outliers. 




) + β4[sin(2tiπ/50)] +β5[cos(2tiπ/50)]+ 
β6[A] + β7[B]+ β8[RSV] + β9[A]*year + β10[B]* year+ β11[RSV]* year 
 
In the mortality and hospitalisation models, i is the week number; Yi is the 
output of the modelling process for that week (predicted mortality count for 
mortality model or predicted hospitalisation count for hospitalisation model); α 
is the population offset (accounts for population size changes over time); and ti 
represents number of weeks since the start of the modelling period.  
 
For the estimated regression parameters, β0 is the intercept (number of deaths 
predicted at t0, in the hypothetical absence of any influenza virus); β1(ti) models 




) represent nonlinear time trends are proxy 




Seasonal changes in deaths and hospitalisations are modelled with the cyclical 
parameters β3[sin(2tiπ/52.07)] and β4[cos(2tiπ/52.07)], β3[sin(2tiπ/50)] and 
β4[cos(2tiπ/50)], respectively. β5[A] and β6[B] (model (1)) or β6[A] and β7[B] 
(model (2))  are the weekly influenza A and B counts, respectively; and β7[RSV] 
in model (1) or β8[RSV] model (2) is the weekly RSV counts. In the 
hospitalisation model β9[A]*year,  β10[B]* year and β11[RSV]* year allow for 
the possible changes in the number of virus tests by year because the dataset 
only used positive tests for influenza A, B and RSV as previous chapters. 
 
The estimated number of influenza related deaths or hospital admissions was 
calculated as the discrepancy between the number estimated by the model and 
the number estimated by the model if virus counts were set to zero. Results were 
expressed as death numbers and mortality rates per 100,000 population. 
Denominator populations were the mean population over the study period.  
 
Based on this estimate, the study also calculated in-hospital case fatality risks 
(CRF) for the hospitalised cases using hospitalised cases as the denominator and 
modelled deaths as the numerator. To validate these modelled findings this 






7.4.1 Influenza deaths by setting and diagnostic category  
Table 18 describes the estimated influenza-related mortality over 15 years from 
1994-2008 in New Zealand by place of death. Overall 58.1% of influenza deaths 
occurred in hospital. This was also true for respiratory illness (66.4%) and 
pneumonia and influenza coded deaths (63.3%). By contrast, for circulatory 
illness those dying outside hospital predominated (52.2%).  
 
Table 18. Estimated annual number of influenza-attributable deaths 
occurring in and outside hospital, New Zealand, 1994-2008 
Illness categories Deaths in hospital Deaths outside hospital Influenza-
associated deaths, 
in total, all ages * 
P&I  40.3 (63.3%) 23.6 (37.1%) 63.6 
Respiratory illness 115.2 (66.4%) 57.6 (33.2%) 173.6 
Circulatory illness 85.6 (46.0%) 97.2 (52.2%) 186.2 
All medical illness 283.4(57.7%) 202.4 (41.2%) 491.0 
All causes  289.6 (58.1%) 220.7 (44.2%) 498.8 
Note that Pneumonia and influenza (P&I) is a subset of Respiratory illness.   
Both Respiratory and Circulatory illness are subsets of Medical illness.  
A quasi-Poisson model was applied independently for each illness in each dataset (In-hospital, outside 
hospital. This means that the sums from estimated respiratory +cardiovascular causes often exceed all causes. 







Influenza deaths in hospital and outside hospital varied by year and reached a 
peak in 2003 where the total number of death was the highest. The modelled 
number of influenza deaths in hospital were higher than outside hospital across 





Figure 26. Number of influenza-attributable deaths occurring in 
hospital and outside hospital by type of influenza virus and year, 
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7.4.2 Influenza infected cases by setting 
The majority of influenza associated hospitalisations were diagnosed as 
respiratory illness (76.9%) with a negligible contribution from circulatory 
illness. Respiratory illness was the major contributor to influenza deaths in 
hospital. Similar to all influenza hospitalisations, those hospitalised with 
influenza and discharged alive were mostly diagnosed with respiratory illness. 
 
By contrast, circulatory illness was strongly associated with influenza deaths 
outside hospital. Circulatory illness was not a contributor to influenza-









Figure 27. Modelled influenza hospitalisations and deaths by illness 
category and setting, average annual numbers and proportions, all 
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7.4.3 Influenza hospitalisations and deaths by setting and age group 
 
The annual average modelled rate (per 100,000) of influenza-attributable 
mortality for all causes was 7.9 (95% CI: 7.8, 8.0) for death in hospital and 6.0 
(95% CI: 5.9, 6.1) for death outside hospital. 
 
The rate (per 100,000) of influenza-attributable deaths for respiratory illness in 
hospital was double those estimated for outside hospital (3.1 (95% CI: 3.1, 3.1) 
compared with 1.6 (95% CI: 1.6, 1.6), respectively). Influenza-attributable 
deaths for circulatory illness were similar in hospital and outside hospital. 
 
For both influenza deaths in and outside hospital, those aged 80 years and above 
had the highest mortality rate per 100,000 across all illness categories, followed 
by the 65 to 79 years age group and people aged 20 to 64 years. Influenza deaths 




Table 19. Estimated annual average number and rate (per 100,000) of influenza-attributable deaths by illness categories, age group and 
facility type of death, New Zealand, 1994-2008 
Age group Illness categories 
P&I Respiratory illness Circulatory illness All medical illness All causes 
Number (95%CI) Rate (95%CI) Number (95%CI) Rate (95%CI) Number 
(95%CI) 




<20 -0.2 (-0.2,-0.2) 0.0 (0.0, 0.0) -0.1 (-0.2, 0.0) 0.0 (0.0, 0.0) 0.2 (0.1,0.3) 0.0 (0.0, 0.0) 3.0 (2.8,3.2) 0.3 (0.3, 0.3) 3.2 (2.8,3.6) 0.3 (0.3,0.3) 
20-64 1.4(1.3,1.5) 0.1 (0.1, 0.1) 10.1(9.7,10.4) 0.5 (0.5,0.5) 0.1(-0.5,0.7) 0.0 (0.0, 0.0) 24.6(23.3,25.9) 1.2 (1.1,1.3) 24.9(23.6, 26.2) 1.2(1.1,1.3) 
65-79 6.1(5.9, 6.3) 1.8 (1.7, 1.9) 38.3(37.6, 39.0) 11.5 (11.3, 11.7) 37.6 (36.4, 38.8) 11.3 (11.0, 11.6) 99.7(97.5, 101.9) 30.0 (29.3, 30.7) 100.7(98.5,102.9) 30.3(29.6,31.0) 
≥80 33 (32.4, 33.6) 32.8 (32.2, 33.4) 66.9(65.9, 67.9) 66.5 (65.5, 67.5) 47.5(1.8) 47.2 (45.4,49.0) 153.4(150.4,153.4) 152.5 (149.5, 155.5) 157.6(154.6, 160.6) 156.7 (153.7,159.7) 
All ages 40.3(39.6,41.0) 1.1 (1.1,1.1) 115.2(113.8,116.6) 3.1 (3.1, 3.1) 85.6(2.5) 2.3 (2.2, 2.4) 283.4(278.8,288.0) 7.7 (6.9,7.1) 289.6 (284.9,294.3) 7.9 (7.8, 8.0) 
 Age 
standardised 
 1.4 (1.4,1.5)  3.9 (3.9,4.0)  2.9 (2.8,3.0)  9.5 (9.3, 9.8)  9.7 (9.5, 10.0) 




<20 0.2(0.1,0.3) 0.0 (0.0, 0.0) -0.3(-0.4,-0.2) 0.0 (0.0, 0.0) 0.3(0.2,0.4) 0.0 (0.0, 0.0) -0.4(-0.7,-0.1) 0.0 (0.0, 0.0) 2.6(2.0,3.2) 0.2 (0.1,0.3) 
20-64 1.8 (1.7,1.9) 0.1 (0.1,0.1) 5.5 (5.2,5.8) 0.3 (0.3,0.3) 14.2 (13.4, 15.0) 0.7 (0.7,0.7) 29.2 (27.8,30.6) 1.4 (1.3,1.5) 37.9 (36.1, 39.7) 1.8 (1.7, 1.9) 
65-79 2.9 (2.8,3.0) 0.9 (0.9,0.9) 20.6 (20.1, 21.1) 6.2 (6.1,6.3) 33.5 (32.3,34.7) 10.1(9.7,10.5) 78.9 (77.0,80.8) 23.7 (23.1, 24.3) 80.6 (78.7,82.5) 24.2 (23.6, 24.8) 
≥80 18.4 (18.0,18.8) 18.3 (17.9,18.7) 31.5 (30.9,32.1) 31.3 (30.7, 31.9) 48.3 (46.8,49.8) 48.0 (46.6,49.4) 92.4 (90.2,94.6) 91.9 (89.7,94.1) 95.7 (93.5, 97.9) 95.2 (93.0, 97.4) 
All ages 23.6(23.2, 24.0) 0.6 (0.6,0.6) 57.6(56.7,58.5) 1.6 (1.6,1.6) 97.2(95.0,99.4) 2.7 (2.6.2.8) 202.4(198.7,206.1) 5.5 (5.4,5.6) 220.7(216.3, 225.1) 6.0(5.9,6.1) 
 Age 
standardised 
 0.8 (0.8,0.8)  2.0(1.9,2.0)  3.2(3.1,3.3)  6.7(6.5,6.9)  7.2(6.9,7.4) 
            
Note that Pneumonia and influenza (P&I) is a subset of Respiratory illness.   
Both Respiratory and Circulatory illness are subsets of Medical illness.  
95% CI: 95% confidence interval. 
Age standardised rates per 100,000 calculated using the structure of the total NZ population at the 2013 Census. 
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7.4.4 Case fatality risk (CFR) 
Using modelled mortality (numerator) and modelled hospitalisations (denominator), 
the in-hospital case fatality risk (CFR) of influenza for all causes was 12.0%. In-
hospital CFR was strongly influenced by age, ranging from 3.8% for those 20-64 
years of age to 41.3% for those aged 80 years and above. The same pattern was seen 
for the respiratory illness component (Figure 28 and Table 20 below). As circulatory 
illness only made a negligible contribution to influenza hospitalisation, it was not 




Figure 28. In-hospital case fatality risk (CFR) by age group and 
illness category for people hospitalised with influenza using modelled 
mortality (numerator) and modelled hospitalisations (denominator), 












Total <20 20-64 65-79 ≥80 
CFR% 
Age group (years) 
Respiratory illness All causes
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7.4.5 Validation of influenza mortality in hospital 
To validate these modelled estimates, the in-hospital CFR was calculated for patients 
using coded influenza hospitalisations (Table 20). These results are compared with 
the modelled estimates for influenza-attributable respiratory hospitalisations. This 
group was used (rather than total modelled estimates for influenza-attributable 
hospitalisations) as they are likely to be more comparable as the observed (diagnosed 
and coded) influenza hospitalisations will almost certainly have presented as 
respiratory infections. 
 
This analysis shows that modelled estimates of the influenza CFR are broadly similar 
to observed results. This similarity is particular strong for those aged 65 to 79 years 
and 80 years of age and older. For those 65 years of age and above, the CFR for 
modelled respiratory influenza in hospital was 12.3%, which was broadly similar to 
the CFR of 16.8% observed for those with diagnosed influenza in hospital. 
 
Table 20. In-hospital case fatality risk (CRF) by age group for modelled 
influenza-attributable respiratory mortality compared with coded influenza, 
New Zealand, 1994-2008 
Age group Modelled influenza attributable respiratory 
hospitalisations 
Observed (diagnosed and coded) influenza 
hospitalisations 
Hospitalisations (*) Deaths CRF (%) Hospitalisations Deaths CRF (%) 
        <20 5,805 NA NA 1,742 3 0 
       20-64 9,255 151.5 1.6 1,578 6 0 
       65-79 7,995 574.5 7.2 538 37 6.8 
       ≥80 4,875 1,003.5 20.6 356 113 31.7 
      All ages 27,915 1,728 6.2 4,214 159 3.8 






7.5.1 Main findings 
Despite the huge burden of hospitalisation and death caused by influenza, there have 
been few attempts to divide this burden into discrete components that might highlight 
opportunities for effective interventions. This study is the first to used modelling 
techniques to estimate influenza-attributable hospitalisations and deaths by major 
setting and illness categories. It not only assessed influenza deaths in hospital but also 
included those that occurred outside hospitals. 
 
Among influenza-attributable all causes deaths, we estimated the percentage of in-
hospital mortality as 58.1%, which was slightly lower than that reported for Canada 
(65%) (Schanzer et al., 2007a). The proportion of influenza-attributable deaths 
outside hospital in Canada (2.6%) was higher than that estimated in this study (1.8%). 
However, the proportions of in-hospital deaths attributable to influenza out of all 
observed deaths for all causes were similar in both countries (2.0% in New Zealand 
compared to 1.7% in Canada) (Schanzer et al., 2007a). 
 
This study found that estimated influenza deaths in hospital were more common than 
influenza deaths outside hospital. This trend has obviously increased and become 
more stable since 2000 although the proportions of deaths in hospital slightly 




Influenza hospitalisations and deaths were markedly affected by age. This analysis 
estimated that more than 50% of influenza hospitalisations but only 13% of influenza 
deaths in-hospital happened in those under 65 years (who account for 90% of the New 
Zealand population). A study in England found a similar trend with over 70% of 
admissions in those 65 years of age and below, but less than 10% of influenza-
attributable deaths in hospital in this age group (Cromer et al., 2014).  
 
The current influenza vaccine coverage in New Zealand is about 25%. Although the 
annual influenza vaccine has been subsidised in New Zealand for those aged 65 years 
and over in 1997 and then for other defined risk groups in 1999, 80% of influenza 
deaths in hospital are in the elderly. These findings suggest the need for a more 
efficient vaccination strategy for those aged 65 years and above, especially for those 
at risks of cardiovascular death. In this study, the proportion of influenza 
hospitalisations among young people under 20 years of age was the largest (nearly 
30% of all influenza admissions), but these accounted for only 1% of in hospital 
deaths.  
 
In this study, the in-hospital CFR of influenza was largely associated with age. In-
hospital CFR was greatest in people aged 80 years and above (41.3%), followed by 
those aged from 65 to 79 years (18.6%) and least among the age group below 65 
years old. A similar pattern was seen when restricted to respiratory hospitalisations. 
To validate these findings, this analysis was repeated for admitted patients with coded 
influenza. The results were consistent with the modelled estimates for respiratory 
hospitalisations which are likely to be highly comparable. Similarly, a higher CFR in 
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hospital was also found for those aged 65 years and above with acute respiratory 
illness in England (Cromer et al., 2014). Interestingly, the estimated in-hospital CFR 
for respiratory admissions to hospital (6.2%) is much higher than that found for the 
2009 influenza pandemic in New Zealand in the first wave with a range from 1.6-
3.1% (Baker et al., 2009, Bandaranayake et al., 2010). 
 
This study showed that all three components (respiratory, cardiovascular and other 
medical diseases) contributed to influenza deaths (in total, in hospital and in other 
places). Respiratory illness dominated for deaths in hospital (39.9%) whereas 
circulatory diseases were predominant in the community (44%).  
 
7.5.2 Strengths and limitations of this study 
First, this study has the limitations inherent in using modelling to estimate an illness 
event that is difficult to measure (hospitalisations and mortality from influenza). A 
major strength is that it is using modelling methods that have now been validated for 
estimating hospitalisations (used in Chapter Six). A further form of validation 
reported in this chapter is the use of observational data to calculate the CFR for 
influenza hospitalisation and show that it is broadly similar to that obtained from 
modelled influenza hospitalisation and mortality data. This finding provides support 
for the validity of regression models to estimate influenza mortality, which has not 
previously been shown. There are also some weaknesses in the modelling approach 
that could be improved in the future work. For example, as in the previous study 
(Kessaram et al., 2014) and chapters (Chapter Four, Five and Six), this study was 
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restricted to the number of laboratory tests with positive tests. Second, this study 
assumed that all deaths in other places occurred outside hospital. A proportion of 
these deaths would have been associated with health care facilities of various sorts. It 
is known that some (8.3%) have occurred within 30 days of hospital discharge for 
example. Therefore, influenza mortality by facility type might be underestimated.  
 
7.5.3 Implications for influenza management, prevention and future research 
These findings, for the first time, partition estimated influenza mortality into major 
setting and illness categories. Influenza deaths from diagnosed respiratory illness in 
hospital are theoretically the group most likely to present opportunities for specific 
therapeutic interventions, such as anti-viral treatment. By contrast, deaths from 
circulatory illness in the community (e.g. myocardial infarction, stroke) triggered by 
an influenza infection will be far more challenging to treat, so represent a goal for 
prevention actions such as vaccination.  This finding is also in line with a conclusion 
from a study in the USA that one death was prevented for every 4,000 elderly 
vaccinated against influenza (Fireman, 2009). 
 
People with a history or at risk of cardiovascular diseases should have a more 
effective influenza vaccine and follow-up programme. In England, the CFR for 
influenza hospitalisation was 6.5 times higher in clinical risk groups than that 
reported for non-clinical risk groups (Cromer et al., 2014). Some countries have also 
informed specific policies on influenza vaccination for target groups. For example, 
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influenza vaccine is recommended for high risk people under 65 years of age in Italy 
and those with circulatory illness or chronic pulmonary disease among member states 
of the European Centre for Disease Prevention and Control (Barberis et al., 2016). It 
appears that influenza vaccination could help to decrease circulatory illness 
hospitalisation during the influenza season (Nichol, 2003) 
 
Over one third of influenza-attributable P&I deaths in New Zealand did not occur in 
hospital. This suggests that people with P&I in the community or community-
acquired pneumonia should receive follow-up and an early treatment programme once 
symptoms appear. Moreover, influenza-associated circulatory illness predominated in 
those dying outside hospital (52.2%).  
 
Future works should be conducted to explore and fill the gap between the number of 
influenza hospitalisation and in hospital deaths associated with circulatory illness. 
Hospital testing or autopsies can be used for certifying influenza in those within 
certain groups such as circulatory illness or respiratory illness which contribute to 
37% or 34%, respectively of influenza deaths. A study from the USA investigated 
influenza from respiratory autopsy tissues and found that 50% of suspected influenza 
cases were positive for the influenza virus (including seasonal influenza A (H1N1, 
H3N2 and A not-subtyped combined), pandemic influenza H1N1pdm09 and 




To conclude, there is considerable potential to refine and further validate this method 
for partitioning influenza deaths into functional categories. This approach could be 
used to monitor the effectiveness of public health and clinical interventions over time.  
 
7.6 Summary of this chapter’s contribution to the thesis as a whole 
This chapter concludes that overall 58.1% of influenza deaths occurred in hospital. 
The majority of these influenza deaths (66.4%) were associated with respiratory 
illness. By contrast, circulatory illness predominated in those dying in other places 
(57%). The CFR of influenza for all causes in hospital was 12.0%. The CFR was 
strongly influenced by age, ranging from 3.8% for those 20-64 years of age to 41.3% 
for those aged 80 years and above. Findings from this chapter could help to reinforce 
the need for influenza vaccination in the community especially for those who are at 
risk of cardiovascular diseases. Further, the findings of this chapter could be a 
stimulus for further research to identify that could address specific components of 
influenza mortality. 
 
The next chapter will be a general discussion. It will discuss key findings, strengths 
and limitations of this research. It will also compare the findings of this thesis with 




Chapter Eight: General discussion  
 
8.1 Chapter goal 
This chapter combines and summarises the discussions from the preceding chapters. I 
compare the results to the international literature, and outline the strengths and 
limitations of this thesis. 
 
8.2 Summary of key findings  
The thesis has addressed its overall goal and all of the specific aims set out in the 
introduction. 
 
In particular, it has used modelling to estimate influenza hospitalisations and 
mortality in New Zealand (Chapters Four and Five). The annual rates are 13.5 deaths 
per 100,000 and 62.4 hospitalisations per 100,000 associated with influenza. 
 
This study is the first to use modelling methods to estimate influenza hospitalisation 
and mortality across demographic characteristics including age, sex, ethnicity and/or 




Further, it appears to be the first study to compare measured and modelled estimates 
of influenza hospitalisation in a total population of adults as well as children. Chapter 
Six indicated that regression modelling appears to provide valid estimates of the 
contribution of influenza to hospitalisation.  
 
Despite a large number of influenza deaths, little is known about where and how 
these deaths occur. Chapter Seven used modelling to estimate the number and 
proportion of influenza deaths by illness categories (respiratory illness, circulatory 
illness and other medical illnesses) and major settings (inside and outside hospital).  
 
This work has demonstrated that it is plausible to use modelling to measure the 
burden of influenza in a population. Modelling appears to produce valid influenza 
burden estimates that can provide insight for policy and strategies for improved 
health outcomes. 
 
8.2.1 Influenza hospitalisations 
One of the most important aspects of this study was to use modelling, for the first 
time in New Zealand, to estimate the contribution of influenza to hospitalisation. 
Findings from Chapter Four showed a large contribution of influenza to 
hospitalisations in New Zealand. This result is consistent with other modelling studies 
from Australia, Canada and the USA (Menec et al., 2003, Newall and Scuffham, 
2008, Thompson et al., 2004). The annual average number of influenza 
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hospitalisations for all causes was 2419.9 per year (95%CI: 2356.4, 2483.4), which is 
about nine times higher than indicated by coded discharged data. 
 
Respiratory illness was responsible for 76.9% of influenza hospitalisations. By 
contrast, circulatory illness made negligible contributions to influenza hospitalisation. 
This result is in keeping with other countries, which also found a small contribution 
of influenza-associated circulatory disease to hospitalisations (Mullooly et al., 2007, 
Baltussen et al., 1998) and a large contribution of respiratory illness to influenza 
hospitalisation (Thompson et al., 2004, Zhou et al., 2012). 
 
Estimated influenza hospitalisations rates (per 100,000) were markedly highest 
among Māori and Pacific people, elderly and infants under one year. This finding is 
similar to patterns reported in the international literature, especially in countries with 
temperate climates where rates are typically higher for vulnerable groups (elderly or 
children) and/or indigenous peoples (Groom et al., 2014, La Ruche et al., 2009, 
Newall and Scuffham, 2008, Thompson et al., 2004, Baltussen et al., 1998, Nguyen-
Van-Tam et al., 2001). It also implies a need for greater prevention efforts for these 
populations. 
  
8.2.2 Influenza mortality 
The influenza mortality rate was 13.5 per 100,000 for all causes in New Zealand. This 
rate was similar to the average mortality rate found through the systematic review of 
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modelled estimates from other countries of 13.9 per 100,000 (Chapter Two). The 
estimated average annual number of influenza-attributable deaths was 498.8 (95% CI: 
496.6, 501.0). Influenza is responsible for 1.8% of total deaths in New Zealand, 
which is 23 times more than indicated by coded mortality data.  
 
As described in Chapter Five, no published studies have applied modelling 
techniques to estimate influenza mortality differences by socioeconomic status and 
ethnicity in addition to age and sex. 
 
In contrast to hospital admission, influenza-attributable mortality has a strong 
contribution from circulatory diseases, accounting for 37.0% of influenza deaths. This 
study found a higher rate of influenza-associated deaths for circulatory illness than 
those reported in other countries, notably Portugal, Canada and Hong Kong (Nunes et 
al., 2011, Schanzer et al., 2013b, Wu et al., 2012). Although infants had high rates of 
influenza hospitalisation their mortality was negligible. The majority of influenza 
deaths (86%) occurred in those 65 years of age and older. Influenza mortality also 
varied markedly by sex. Relatively vulnerable groups were males aged 65 to 79 years 
(RR=1.9, 95% CI: 1.9, 1.9 compared with females). These findings are consistent 
with international literature (Newall et al., 2008, Nielsen et al., 2011, Wu et al., 2012, 




A novel finding drawn from Chapter Five was to explore the role of socioeconomic 
and ethnic characteristics. Both social deprivation and ethnicity were found to be 
strongly associated with influenza mortality. The influenza-attributable mortality rate 
for all causes among those living in the most deprived areas was 1.8 times greater 
than that found for those in the least deprived areas. Similarly, death rates were 
markedly higher for Māori and Pacific people compared with the European/Others for 
age groups up to 80 years of age.  Relatively vulnerable groups were Māori (RR=3.6, 
95% CI: 3.6, 3.7 compared with European and Others aged 65 to 79 years), Pacific 
(RR=2.4, 95% CI: 2.4, 2.4 relative to European and Others aged 65 to 79 years) and 
those living in the most deprived areas (RR=1.5, 95% CI: 1.1, 2.1). A similar pattern 
of higher influenza-associated mortality in those with low socioeconomic status and 
indigenous peoples has also been reported for other countries, based on measured 
rather than modelled rates (White et al., 2003, Bramley et al., 2004).  
 
The disparity of influenza mortality rates across age, sex, ethnicity and 
socioeconomic status suggests the need to enhance vaccination coverage in the 
identified vulnerable population in New Zealand (Māori and Pacific peoples, males 
aged 65-79 years old, and individuals living in the most deprived areas). 
 
8.2.3 Validation of modelling in estimating influenza incidence and distribution  
The influenza hospitalisation burden has been estimated by using two approaches: 
observational studies (direct measurement) and modelling techniques that extrapolate 
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from a range of data (indirect measurement). Because influenza symptoms are 
sometimes ambiguous and laboratory testing has limitations, influenza is under-
detected by direct observation. Consequently, modelling techniques have been widely 
applied to estimate the influenza contribution to hospitalisation. To date, there has 
been little use of prospective data (direct measurement) to validate results obtained 
from modelling techniques (indirect measurement). No studies appear to have 
compared results obtained from both methods across the total population of adults 
and children and by major sociodemographic characteristics.  
 
Chapter Six compared, for the first time, influenza estimates from modelling with 
measured incidents across major sociodemographic characteristics, including time, 
place and person characteristics (age, sex, ethnicity, socioeconomic status). In 
general, modelled estimates were similar to those observed from direct measurement 
across these groups. 
 
However, modelling and direct measurement showed different patterns of influenza 
incidence and distribution by age group. The rate of influenza hospitalisation in those 
aged 65 years and over, especially in those 80 years plus (538.2 per 100,000) was 
highest for modelling. This figure was 1.4 times higher than the measured respiratory 
influenza rate found from a prospective study for the same age group. This study is 
the first to compare modelled influenza hospitalisations with direct measurement for 
this age group. It is likely that direct measurement does not capture influenza 
hospitalisation in the elderly. This finding could be in large part due to difficulty in 
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gaining consent from the elderly. International studies also found a low sensitivity of 
influenza tests, especially in culture and rapid antigen testing in the older population 
(Talbot et al., 2010, Steininger et al., 2009). However, a modern molecular method 
like polymerase chain reaction (PCR) testing appears to provide better sensitivity in 
the elderly because it is able to discover viral nucleic acids within a short amount of 
time.  
 
In contrast to modelling, direct measurement showed a significantly higher rate of 
influenza hospitalisations among children aged from 1 to 4 years (282.5 per 100,000 
for measured respiratory influenza). This rate is about 3.8 times higher than that 
estimated with modelling. A low estimate of influenza hospitalisation in young 
children was also reported by a study in Hong Kong when using a negative binomial 
regression model (Yang et al., 2011).  
 
It appears that modelling is a valid method to estimate overall influenza associated 
hospitalisation for respiratory illness.  
 
8.2.4 Place of influenza deaths 
As noted in Chapter Seven, little is currently known about how and where influenza 
kills people despite the huge mortality burden from this disease. This study used New 
Zealand’s linked mortality and hospitalisation data to distinguish deaths occurring 
inside and outside hospital. A total of 75 quasi-Poisson and negative binomial 
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regression models with weekly counts of hospitalisations or deaths along with data on 
isolates of influenza A, influenza B, and respiratory syncytial virus for the period 
1994-2008 were used. 
 
The study found that there was a marked difference in influenza outcomes 
(hospitalisations and deaths) by health settings and illness. 58.1% of influenza-
associated deaths for all causes occurred in hospital. The majority of in-hospital 
influenza deaths (66.4%) were associated with respiratory illness. By contrast, 
circulatory illness predominated in those dying outside hospital (57.0%). No previous 
studies have reported on the proportion of influenza deaths occurring inside and 
outside hospital along with the proportions with respiratory causes compared with 
circulatory disease and other medical illnesses. 
 
One novel aspect of this analysis (Chapter Seven) is to calculate the modelled CFR 
for influenza-associated hospitalisation using influenza-associated deaths in hospital 
as the numerator and influenza admission as the denominator. The CFR of influenza 
for all causes in hospital was 12.0%. It was strongly influenced by age, ranging from 
3.8% for those 20-64 years of age to 41.3% for those aged 80 years and above. To 
validate these findings, a similar analysis was repeated using observational data 
(coded hospitalisations from the national hospitalisation dataset) for those admitted to 
hospital and diagnosed as having influenza. Similar to modelled estimates, the coded 
CFR was particular high for those aged 65 to 79 years and 80 years of age and older. 
For those 65 years of age and over, the CFR for modelled respiratory influenza in 
178 
 
hospital was 12.3% which was broadly similar to the CFR of 16.8% observed for 
those with diagnosed influenza in hospital. People under 65 years of age, especially 
those under 20 years had negligible CFR. The finding is in keeping with an English 
study, which found a higher CFR for acute respiratory illness in hospital in the 
elderly from 65 years of age and older (Cromer et al., 2014). 
 
8.3 Strength and limitations of the project 
8.3.1 Strengths 
This thesis used three broad approaches for estimating the incidence and distribution 
of influenza hospitalisations and deaths: published literature (which aimed to review 
available research and find plausible estimates of influenza burden in New Zealand); 
direct measurements (coded hospitalisation and mortality data from the national 
hospitalisation and mortality dataset, and observations from the SHIVERS Project) 
and modelling (multiple approaches, including modeling events within outcome 
category and extrapolation of other categories). 
 
The biggest strength of this project was its use of various forms of regression models 
to provide estimates of the health burden of influenza in a single country across a set 
of sociodemographic characteristics including age, sex, ethnicity and deprivation. 
Modelling is novel in measuring the magnitude of influenza in New Zealand. Over 
200 quasi-Poisson regression models and negative binomial regression models were 
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used in this thesis for estimating influenza deaths and influenza hospitalisations, 
respectively.  
 
Two data sources, the national hospitalisation and mortality dataset, were used to 
identify hospitalisations and deaths in the New Zealand population. All health care 
users in New Zealand have a unique national health index (NHI) number. It became 
universal for hospital records from 1988 onwards and has been progressively rolled 
out for other health care datasets after that. It was originally established to improve 
management of patient records and health care services across the country. For health 
research, including modelling, it allows identification of linked health events such as 
readmissions and deaths associated with hospitalisations. 
 
All deaths and hospitalisations were categorised into broad groups according to the 
likely contribution of influenza. At the centre are influenza (J09-J11) and influenza 
and pneumonia (J09-J18), followed by respiratory illness J00-J99) and circulatory 
illness (I00-I99). On the periphery are medical deaths (A00-N99, R00-R99) and all 
causes deaths (including childbirth, perinatal, congenital, injury) (A00-Y99) where 
influenza is likely to make only a small contribution to the total. Unlike some 
previous studies applying the same modelling this research used weekly 
hospitalisations (from the national hospitalisation dataset) and deaths (from the 
national mortality dataset) and has therefore been able to provide more valid and 




In Chapter Seven where influenza deaths by major settings and illness catergories 
were explored, modelling input deaths were first extracted from two sources; hospital 
discharge data and linked mortality data. This extraction provided accurate numbers 
of deaths occurring inside and outside hospital. For example, deaths coded as in-
hospital in the national mortality dataset were reclassified as outside hospital where 
the national hospitalisation dataset showed their date of death to be before or on the 
same day as hospital admission.  
 
As mentioned in Chapter Six, this project is among the first studies to use 
observational data (direct measurement) to validate results obtained from modelling 
techniques (indirect measurement). Further, it is the first study to obtain prospective 
data across the total population of adults and children. Also, it used highly 
representative observational data (which covers 20% of the population of New 
Zealand tracked over a four year period from 2012-2015) to provide a robust 
validation method.  
 
Similar to other modelling papers, a further required input is virological data. In this 
study, weekly counts of influenza A (H1N1, H3N2 and pandemic influenza (pdm09) 
combined), influenza B, and RSV for New Zealand were extracted from the Weekly 
Virology reports from ESR. The four regional laboratories (Auckland, Waikato, 
Wellington and Christchurch labs) and the ESR virology laboratory are responsible 
for conducting influenza and other virus surveillance in New Zealand. These virus 
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counts integrate data on positive isolates from: i) influenza sentinel surveillance in 
general practices (collected May to September each year), and ii) regional 
laboratories (mostly hospital patients, covering the entire year). RSV isolates are 
ascertained by ESR and hospital laboratories from specimens received throughout the 
year. In this study, RSV, which contributed up to one third of influenza like illnesses 
in New Zealand each year, was also included in the model to reduce confounding. 
 
A unique strength of this research is that it has used observational data to validate the 
use of modelling to estimate hospitalisation. A further form of validation reported in 
this thesis is the use of observational data to calculate the case fatality risk for 
hospitalised influenza and show that it is broadly similar to that obtained from 
modelled influenza hospitalisation and mortality. This finding provides support for 
the validity of regression models to estimate influenza mortality, which has not 
previously been shown. 
 
8.3.2 Limitations 
The research presented in this thesis, has some limitations, as presented in previous 
chapters.  
 
Regression modelling has inherent limitations for estimating an illness event that is 
difficult to measure (hospitalisations and mortality from influenza). Partly for these 
reasons, a number of different modelling approaches have been applied to estimate 
influenza outcomes. This thesis used both quasi-Poisson regression models and 




The available virological data lacked information on total specimens tested and the 
number of laboratory tests with negative results. Besides that, using positive 
specimens has also prevented this study from fully assessing the impact of increased 
testing rates and sensitivity when testing methods changed from viral isolation to 
molecular detection over time.  
 
In this study, sub-types of influenza A (H1N1, H3N2 and A not-subtyped) were not 
used in the modelling for estimating influenza deaths and hospitalisations. A question 
as to which virus contributes most to influenza hospitalisation and deaths is 
unanswered. International literature has noted a higher rate of influenza 
hospitalisation from sub-type influenza A (H3N2) compared with influenza B and 
seasonal influenza A (H1N1) (Yang et al., 2012b). Although RSV makes a major 
contribution to influenza- like illnesses in New Zealand, other viruses such as 
Rhinovirus or Adenovirus, which can result in respiratory infection, were not 
included as inputs for modelling. 
 
Although it appears that influenza is associated with febrile convulsion, especially in 
children (Toovey, 2008) this study might underestimate the contribution of influenza 




The next chapter is the final chapter of the thesis. It will describe implications and 
future work arising from the thesis, and will also present brief conclusions from this 




Chapter Nine: Implications, future 
works and conclusion 
 
9.1 Chapter goal 
This is the final chapter of the thesis. The goal of this chapter is to highlight 
implications of this research, identify future research questions arising from it and 
briefly summarise the high-level conclusions of the research. 
 
9.2 Implications 
This is the first research to provide robust estimates of the impact of influenza on 
both hospitalisations and deaths in New Zealand. It is also the first research to 
produce such estimates for major disease categories across demographic 
characteristics including age, sex, ethnicity and socioeconomic status for a single 
country.  
 
Overall, this research estimates that an average of 2,420 hospitalisations and 499 
deaths occurred in New Zealand each year that were associated with influenza during 
the 1994-2008 period. This is a rate of 62.4 hospitalisations and 13.5 deaths per 
100,000 per year. Influenza accounts for 1.8% of total mortality and 0.8% of total 
acute hospitalisations. It may therefore represent one of the largest single infectious 




The contribution of influenza to total hospitalisations and mortality was about 9 and 
23 times, respectively, larger than indicated by routine coded data. Respiratory illness 
was the major contributor to hospitalisations attributed to influenza whereas 
circulatory illness made a negligible contribution. By contrast, influenza mortality 
included a large contribution from both circulatory and respiratory illness. Discussion 
on the public health importance of influenza needs to consider this very large 
unmeasured disease impact. 
 
Modelled influenza deaths and hospitalisation differ markedly by age pattern. The 
elderly (80 years of age and older) had the highest influenza-attributable 
hospitalisation rate and mortality. Infants also had high rates of influenza 
hospitalisation but their mortality was negligible. These impacts are consistent with 
the observation data.  
 
This modelling also confirms the higher influenza hospitalisation and death rates for 
Māori and Pacific people compared with other ethnic groups, which is a novel finding 
in the area of influenza modelling. Further, the research also indicates, for the first 
time, a marked difference in modelled influenza deaths by socioeconomic status 
additional to age, sex and ethnicity. In New Zealand groups with relatively high 
influenza mortality are Māori and Pacific peoples, males aged 65 to 79 years old, and 
individuals living in the most deprived areas. These findings highlight the importance 
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of prioritised interventions (notably achieving high vaccination coverage) for these 
vulnerable groups and further research to identify ways of reducing these inequalities. 
 
This PhD research project is the first study to make a comparison of influenza 
hospitalisation between direct measurement (observational study) and indirect 
measurement (modelling) for a full population. It was also novel to do these 
comparisons across sociodemographic characteristics including time, place, age, sex, 
ethnicity and deprivation. It appears that modelling methods provide a valid way of 
estimating the contribution of influenza to respiratory hospitalisations.  
 
9.3 Future work 
The validity of this modelling would be improved by including more robust measures 
of the contribution of influenza, and potentially other, seasonal respiratory viruses. In 
particular, data on the total number of specimens tested and the number of laboratory 
tests with negative results. It would also be useful to repeat these analyses using data 
on sub-types of influenza A (H1N1, H3N2, A-not subtyped) and influenza B. Such 
analyses would provide information on which influenza viruses contribute most to 
influenza hospitalisations and deaths. 
 
The models used in this project, Poisson or negative regression models, included the 
proxy parameters of weekly virus fluctuations. The estimates would be higher if the 
model did not use these input parameters. As mentioned in Chapter Five, although 
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humidity and ambient temperature substantially influence influenza (Nicoll et al., 
2012, Lowen and Steel, 2014), they are excluded from the study’s models. Hence, 
estimates of influenza deaths and hospitalisations might be changed if those factors 
were included. Future models that include temperature or humidity would be 
expected to provide more accurate estimates of the true burden of influenza in New 
Zealand. 
 
Future study should investigate the significant disparity between estimates and 
observations of influenza hospitalisations among children, especially infants under 12 
months old and the elderly. This research could specifically test the hypothesis that 
modelling is a plausible approach to estimate the influenza burden in the elderly 
where measurement is difficult and incomplete. It would also be useful to assess 
whether modelling is an appropriate method to estimate influenza in children. 
Additional studies should be conducted to see if modelling is valid for estimating the 
contribution of influenza to non-respiratory hospitalisations and influenza mortality. 
 
The work presented here has focused on two levels of the influenza ‘pyramid’ being 
hospitalisation and mortality. It would be useful to extend this work to include other 
levels, notably ICU admissions, medically attended illnesses, non-medically attended 




Economic evaluations of the burden of influenza and its prevention should also 
consider incorporating modelled estimates of the impact of these infections to give a 
more valid estimate of its economic cost than relying on measured disease burden. 
Such estimates are likely to provide greater economic support for investing in 
effective interventions. 
 
Ultimately, results of this research should inform interventions to lower the burden of 
influenza and associated health inequalities. One area to focus on could be raising 
influenza vaccine coverage among those at highest risk of influenza mortality. This 
area could be suitable for a controlled trial, possibly focused on defined groups such 
as those discharged from hospital with respiratory or circulatory disease. 
 
The disparity of influenza mortality rates across age, sex, ethnicity and 
socioeconomic status suggests the need to enhance vaccination coverage in the 
identified vulnerable population in New Zealand (Māori and Pacific peoples, males 
aged 65 to 79 years old, and individuals living in the most deprived areas). 
 
As mentioned in Chapter Seven, this is the first time that modelling has been used to 
partition influenza mortality into major setting and illness categories. Influenza deaths 
from diagnosed respiratory illness in hospital are theoretically the group most likely 
to present opportunities for specific therapeutic interventions and therefore represent 
a goal for prevention actions such as vaccination. Deaths from circulatory illness in 
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the community triggered by an influenza infection would be far more challenging to 
treat. There is considerable potential to further refine and validate this method for 
partitioning influenza deaths into functional categories. This approach could be used 
to monitor the effectiveness of public health and clinical interventions over time. 
 
As RSV contributes to one third of influenza-like illness in New Zealand, it would be 
helpful to explore the burden of RSV-associated hospitalisation and mortality, 
especially in children and the elderly. 
 
9.4 Conclusion 
Influenza causes a substantial number of hospitalisations and deaths worldwide. The 
health impact of this infection is underestimated because much of its disease burden 
comes from medical events (i.e. circulatory illness) where influenza is not 
investigated. Further, influenza is under-recognised because of lack of laboratory 
results, indicative signs or supporting symptoms and ambiguous aetiology. This PhD 
research project used modelling techniques to estimate the impact of influenza on 
hospitalisations and mortality in New Zealand.  
 
Modelling has been used to estimate mortality before, however, surprisingly little is 
known about where and how these deaths occur. This study provided estimates of the 
proportion of influenza deaths occurring inside and outside hospital. Further, it is the 
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first study to explore marked differences of influenza-associated deaths across 
socioeconomic status in addition to sex, age, and ethnicity. 
 
Although influenza is a common respiratory infection, it is not systemically tested for 
when patients are hospitalised, even for respiratory illnesses. This study provides, for 
the first time, a robust estimate of the impact of influenza on hospitalisation in New 
Zealand, in total and for major disease categories. Findings of this thesis could 
provide a useful input into decisions about vaccination policy and would increase the 
estimated cost effectiveness of such interventions. Modelling methods appear to 
provide a valid way of estimating the contribution of influenza to respiratory 
hospitalisations. 
 
Further investigation is needed to extend this analysis to contribution of influenza to 
other levels in the pyramid “burden of diseases”, notably ICU admissions, medically 
attended illnesses, non-medically attended illnesses and asymptomatic infections. 
Also, future studies should focus on the marked difference between modelled and 
directly measured influenza hospitalisation among children and the elderly to see 
whether modelling can be used to measure the influenza burden in the elderly and to 
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Appendix One: Supplementary materials of Chapter 
Six  
Table 21. Comparison of annual average number and rate per 100,000 of estimated influenza associated respiratory 
illness hospitalisation by demographic and socioeconomic status characteristics in ADHB and CMDHB, 2012-2015 
 
Characteristics 
Measured SARI influenza Measured respiratory influenza Modelled influenza 
Number Rate per 100,000 Number Rate per 100,000 Number (95% CI) Rate per 100,000 (95% CI) 
Total 323.5 36.3 726.9 81.5 780.1 (773.8, 786.4) 87.4 (86.7, 88.2) 
       
Age group       
1-4 49.4 93.4 139.0 262.9 40.9 (38.6, 41.8) 76.0 (72.9, 79.1) 
5-19 21.7 11.3 52.7 27.4 49.9 (48.8, 51.0) 25.9 (25.3, 26.5) 
20-34 50.1 24.0 98.3 47.2 97.4 (96.4,98.4) 46.7(46.2, 47.2) 
35-49 49.0 25.7 73.2 38.3 62.6 (61.4, 63.8) 32.8 (32.2, 33.4) 
50-64 67.9 45.1 161.0 107.0 153.3(151.6, 155.0) 101.8(100.6,103.0) 
65-79 56.7 77.6 122.2 167.2 219.6 (217.4, 221.8) 300.5(297.5, 303.5) 
80+ 28.7 122.5 80.4 343.3 126.1(124.4, 127.8) 538.2(530.8, 545.6) 
       
Ethnicity       
Maori 46.6 47.5 105.2 107.3 119.5 (118, 121) 122.0 (120.5, 123.5) 
Pacific 125.0 92.0 252.6 185.8 263.8 (261, 266.6) 194.0 (191.9, 196.1) 
Asian 35.4 17.1 69.8 33.7 79.8 (78.5, 81.1) 38.5 (37.9, 39.1) 
European and others 116.6 29.5 299.3 75.7 297.4 (294.4, 300.4) 75.2 (74.8, 76.0) 
       
Sex       
Female 183.8 40.1 407.9 89.0 401.2 (397.5,404.9) 92.2 (91.6, 93.4) 
Male 139.7 32.2 319.0 73.5 366.5(363.2, 369.8) 80.0 (79.3, 80.7) 
       
NZDep       
NZDep1&2 32.9 18.7 77.7 44.2 72.8 (71.5,74.1) 41.4 (40.7,42.1) 
NZDep3&4 33.6 20.5 109.5 66.6 92.1(91.0,93.2) 56.0 (55.3,56.7) 
NZDep5&6 52.5 36.6 111.1 77.5 113.1(111.6, 114.6) 78.9 (77.8, 80.0) 
NZDep7&8 44.1 27.0 106.2 65.1 115.4(114.0, 116.8) 70.7 (69.8, 71.6) 
NZDep9&10 160.4 65.3 322.4 131.3 356.3(352.7,359.9) 145.1 (143.6, 146.6) 
       
Hospital        
ADHB 168.1 39.1 392.2 91.2 308 (304.8, 311.2) 71.7 (71.0, 72.4) 
CMDHB 155.5 33.6 334.7 72.4 459.9 (455.7, 464.1) 99.5 (98.6, 100.4) 
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Table 22. Estimated proportion and annual average number of influenza positives (captured and non-captured by 


















annum) N % N % N % N % N % N % 
              
Population 3907   1289   926   5131   5858   17111   4277.8 
Tested for influenza 3710 94.96 1224   864 93.30 4787 93.30 5466 93.30 16051 93.81 4012.8 
 
Influenza positives 
 from systematic 
testing 
924 24.91 305 24.91 117 13.54 648 13.54 740 13.54 2734 17.03 683.6 
 
Estimated number of 
SARI influenza 
positives 
973.1   321.0   125.4   694.8   793.3   2908   726.9 
              
Age group (years)                           
1-4 148.5 16.75 49 16.75 27.9 12.62 154 12.62 176 12.62 556 13.83 139.0 
5-19 65.3 23.66 22 23.66 9.6 8.04 53 8.04 61 8.04 211 11.04 52.7 
20-34 150.6 36.29 50 36.29 15.0 20.90 83 20.90 95 20.90 393 26.65 98.3 
35-49 147.4 30.63 49 30.63 7.5 8.24 42 8.24 47 8.24 293 16.15 73.2 
50-64 204.3 29.44 67 29.44 28.9 21.95 160 21.95 183 21.95 644 24.59 161.0 
65-79 170.6 22.85 56 22.85 20.4 10.56 113 10.56 129 10.56 489 14.07 122.2 
≥80 86.4 21.19 28 21.19 16.1 16.48 89 16.48 102 16.48 322 17.90 80.4 
             
              
Ethnicity                         
 Maori 140.1 21.59 46 21.59 18.2 11.89 101 11.89 115 11.89 421 14.84 105.2 
Pacific 376.0 27.31 124 27.31 39.7 14.98 220 14.98 251 14.98 1010 19.29 252.6 
Asian 106.4 25.25 35 25.25 10.7 12.76 59 12.76 68 12.76 279 17.02 69.8 
European and Other 350.7 24.01 116 24.01 56.8 14.56 315 14.56 359 14.56 1197 17.20 299.3 
             
               





















annum) N % N % N % N % N % N % 
              
Female 552.9 26.46 182 26.46 69.7 14.44 386 14.44 441 14.44 1632 18.16 407.9 
Male 420.2 23.12 139 23.12 55.7 12.56 309 12.56 353 12.56 1276 15.70 319.0 
             
 NZ Dep                         
 NZ Dep1-2 99.0 24.16 33 24.16 13.9 13.68 77 13.68 88 13.68 311 16.76 77.7 
NZ Dep3-4 101.1 24.37 33 24.37 23.6 20.75 131 20.75 149 20.75 438 21.74 109.5 
NZ Dep5-6 158.0 27.03 52 27.03 18.2 10.43 101 10.43 115 10.43 445 14.69 111.1 
NZ Dep7-8 132.7 24.42 44 24.42 19.3 13.64 107 13.64 122 13.64 425 16.70 106.2 
NZ Dep9-10 482.3 24.68 159 24.68 50.4 12.77 279 12.77 319 12.77 1290 16.80 322.4 
             
 Hospital                           
AHDB 505.5 26.33 167 26.33 69.7 14.16 386 14.16 441 14.16 1569 17.66 392.2 




Appendix Two: Publication on 
Vaccine ‘Estimating the contribution 
of influenza to hospitalisations in 
































Appendix Three: Publication on 
Journal of Infection ‘Modelled 
seasonal influenza mortality shows 
marked differences in risk by age, 
sex, ethnicity and socioeconomic 




















































Appendix Five: How modelling can be 
used to estimate influenza 
hospitalisations and deaths 
 
Influenza causes a large number of hospital admissions and deaths, only a small 
proportion of which are recognised as caused by this virus. This under-recognition 
particularly occurs with influenza deaths outside hospital, which are seldom tested for 
influenza. Consequently, recorded influenza hospitalisations and deaths  represent 
just the tip of the influenza mortality iceberg. Modelling uses statistical method to 
investigate under-diagnosis of influenza hospitalisations and deaths.  
 
Modelling estimates influenza events by comparing predicted values and observations 
assuming minimal or no influenza activity. It has been used to predict expected (non-
epidemic) influenza mortality in future weeks. It can also capture all influenza-
attributable health outcomes (P&I, respiratory illness, circulatory illness, 
cardiopulmonary illness and all causes) and estimate excess influenza events. 
It would be difficult for a prospective or observational study to obtain laboratory 
confirmation of influenza infection in deaths which were acute or occurred without an 
associated hospitalisation. Modelling can estimate influenza deaths where testing is 




Appendix Six: Electronic search results 





flu.mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword 
heading word, protocol supplementary concept 
word, rare disease supplementary concept word, 
unique identifier] 
9054 
2 influenza.mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, 
keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept 
word, unique identifier] 
85463 
3 influenza - attributable.mp. [mp=title, abstract, 
original title, name of substance word, subject 
heading word, keyword heading word, protocol 
supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
46 
4 influenza-associated.mp. [mp=title, abstract, 
original title, name of substance word, subject 
heading word, keyword heading word, protocol 
supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
594 
5 influenza-related.mp. [mp=title, abstract, original 
title, name of substance word, subject heading 
word, keyword heading word, protocol 
supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
621 
6 mortality.mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, 
keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept 
word, unique identifier] 
530255 
7 fatality.mp. [mp=title, abstract, original title, name 
of substance word, subject heading word, keyword 
heading word, protocol supplementary concept 





8 death.mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword 
heading word, protocol supplementary concept 
word, rare disease supplementary concept word, 
unique identifier] 
576842 
9 hospitalization.mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, 
keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept 
word, unique identifier] 
140287 
10 hospital admission.mp. [mp=title, abstract, original 
title, name of substance word, subject heading 
word, keyword heading word, protocol 
supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
15581 
11 hospitalisation.mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, 
keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept 
word, unique identifier] 
9755 
12 respiratory illness.mp. [mp=title, abstract, original 
title, name of substance word, subject heading 
word, keyword heading word, protocol 
supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
3387 
13 cardiovascular disease.mp. [mp=title, abstract, 
original title, name of substance word, subject 
heading word, keyword heading word, protocol 
supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
82042 
14 circulatory illness.mp. [mp=title, abstract, original 
title, name of substance word, subject heading 
word, keyword heading word, protocol 
supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
6 
15 all causes.mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, 
keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept 
word, unique identifier] 
4666 
16 all-cause.mp. [mp=title, abstract, original title, name 




heading word, protocol supplementary concept 
word, rare disease supplementary concept word, 
unique identifier] 
17 1 or 2 or 3 or 4 or 5 89524 
18 6 or 7 or 8 1001743 
19 9 or 10 or 11 157487 
20 12 or 13 or 14 or 15 or 16 108311 
21 17 and 18 and 20 496 
22 17 and 19 and 20 269 
23 21 or 22 633 
24 limit 23 to humans 629 
25 limit 24 to yr="1994 -Current" 587 
26 from 25 keep 1-587 587 
27 remove duplicates from 26 571 
 
Cochrane 
ID Search Hits 
#1 influenza:ti,ab,kw  (Word variations have been searched) 3948 
#2 flu  1676 
#3 influenza-associated  30 
#4 influenza-related  102 
#5 influenza-attributable  4 
#6 influenza-like illness  318 
#7 hospitalization  17446 
#8 hospital admission  11927 
#9 hospitalisation  5930 
#10 respiratory illness  3883 
#11 circulatory illness  168 
#12 all causes  9361 
#13 mortality  58044 
#14 death  34029 
240 
 
#15 fatality  2043 
#16 #1 or #2 or #3 or #4 or #5 or #6  5314 
#17 #7 or #8 or #9  30739 
#18 #13 or #14 or #15  76335 
#19 #10 or #11 or #12  12471 
#20 #16 and #17 and #18  242 
#21 #16 and #18 and #19  226 
#22 #16 and #17 and #19  188 
#23 #21 or #22  269 
 
Embase 
# ▲ Searches Results 
1 
influenza.mp. [mp=title, abstract, heading word, drug trade name, 




influenza - attributable.mp. [mp=title, abstract, heading word, 
drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword] 
53 
3 
influenza-associated.mp. [mp=title, abstract, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, 
device trade name, keyword] 
766 
4 
influenza-related.mp. [mp=title, abstract, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device 
trade name, keyword] 
814 
5 
flu.mp. [mp=title, abstract, heading word, drug trade name, 









hospital admission.mp. [mp=title, abstract, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, 
device trade name, keyword] 
144329 
8 
hospitalisation.mp. [mp=title, abstract, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device 
trade name, keyword] 
19198 
9 
hospitalization.mp. [mp=title, abstract, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device 
trade name, keyword] 
316982 
10 
mortality.mp. [mp=title, abstract, heading word, drug trade name, 




fatality.mp. [mp=title, abstract, heading word, drug trade name, 







death.mp. [mp=title, abstract, heading word, drug trade name, 




respiratory illness.mp. [mp=title, abstract, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, 
device trade name, keyword] 
5133 
15 
cardiovascular disease.mp. [mp=title, abstract, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, 
device trade name, keyword] 
273170 
16 
circulatory illness.mp. [mp=title, abstract, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, 
device trade name, keyword] 
8 
17 




original title, device manufacturer, drug manufacturer, device trade 
name, keyword] 
18 
all-cause.mp. [mp=title, abstract, heading word, drug trade name, 




1 or 2 or 3 or 4 or 5 or 6 
151110 
20 
7 or 8 or 9 
448042 
21 
10 or 11 or 12 or 13 
1906156 
22 
14 or 15 or 16 or 17 or 18 
316943 
23 
19 and 20 and 22 
632 
24 
19 and 21 and 22 
1373 
25 
23 or 24 
1646 
26 
remove duplicates from 25 
1620 
27 
limit 26 to human 
1507 
28 
limit 27 to yr="1994 -Current" 
1459 
29 
remove duplicates from 28 
1459 
30 
limit 29 to cochrane library 
7 
31 
1 or 2 or 3 or 4 or 5 
151110 
32 
10 or 11 or 13 
1906156 
33 
22 and 31 and 32 
1373 
34 
20 and 22 and 31 
632 
35 
33 or 34 
1459 
 
